University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2011

The Structural Proteomics of S-Nitrosylation: From Global
Identification to Elucidating Protein Function Through Structural
Bioinformatics
Jennifer L. Greene
University of Pennsylvania, jlynn.greene@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biochemistry Commons, Bioinformatics Commons, and the Biophysics Commons

Recommended Citation
Greene, Jennifer L., "The Structural Proteomics of S-Nitrosylation: From Global Identification to
Elucidating Protein Function Through Structural Bioinformatics" (2011). Publicly Accessible Penn
Dissertations. 513.
https://repository.upenn.edu/edissertations/513

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/513
For more information, please contact repository@pobox.upenn.edu.

The Structural Proteomics of S-Nitrosylation: From Global Identification to
Elucidating Protein Function Through Structural Bioinformatics
Abstract
ABSTRACT
THE STRUCTURAL PROTEOMICS OF S-NITROSYLATION: FROM GLOBAL IDENTIFICATION TO
ELUCIDATING PROTEIN FUNCTION THROUGH STRUCTURAL BIOINFORMATICS
Jennifer L. Greene
Harry Ischiropoulos, Ph.D.
S-nitrosylation is the covalent addition of nitric oxide to reduced cysteine residues on proteins. It has been
well documented that not all proteins are S-nitrosylated and more specifically, not all cysteine residues
within an S-nitrosylated protein are modified. Therefore, it is very important to determine how this
specificity is derived. Additionally, the mechanism by which nitric oxide can modify cysteines is still
unclear. Even with the discovery of functional consequences of S-nitrosylation, there are still large deficits
in our understanding and validation that it is a newly identified means of nitric oxide signaling within the
body. These gaps in knowledge primarily exist due to a lack of tools necessary for identifying in vivo sites
of S-nitrosylation. To this end, complementary mercury-based mass spectrometric approaches were
developed for the identification of endogenous S-nitrosoproteomes. This resulted in the identification of
328 SNO-cysteines coordinated to 192 proteins in the mouse liver, 97% of which corresponded to novel
targets of S-nitrosylation. Bioinformatic analysis of these targets then revealed that multiple mechanisms
of S-nitrosylation may occur in vivo, one of which involving S-nitrosoglutathione (GSNO). To test this
hypothesis, the SNO-proteome of mice incapable of metabolizing GSNO was resolved. Quantum
mechanics/molecular mechanics calculations coupled with molecular dynamics simulations proposed a
novel GSNO-mediated mechanism of transnitrosation. Basic residues in the surrounding cysteine
microenvironment were shown to catalyze the formation of protein S-nitrosocysteine residues.
Collectively, these data suggest that the specificity of cysteines targeted for S-nitrosylation is driven by
the surrounding protein microenvironment. Additionally, with only 9 structures of S-nitrosylated proteins
our present understanding of the structural consequences of S-nitrosylation is limited. Using an in vivo
model, attempts were made to correlate changes in enzymatic activity as a function of S-nitrosylation.
Normal mode analysis revealed local motions near the site of S-nitrosylation which may alter product
release. In summary, this thesis utilized a global proteomic approach to craft a more targeted
investigation into the specificity and molecular mechanism of S-nitrosylation.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Biochemistry & Molecular Biophysics

First Advisor
Harry Ischiropoulos

Keywords
mass spectrometry, nitric oxide, proteomics, S-nitrosoglutathione, S-nitrosylation

Subject Categories
Biochemistry | Bioinformatics | Biophysics

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/513

THE STRUCTURAL PROTEOMICS OF S-NITROSYLATION: FROM GLOBAL
IDENTIFICATION TO ELUCIDATING PROTEIN FUNCTION THROUGH
STRUCTURAL BIOINFORMATICS
Jennifer L. Greene
A DISSERTATION
in
Biochemistry and Molecular Biophysics
Presented to the Faculties of the University of Pennsylvania
in Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2011

___________________________________
Supervisor of Dissertation: Harry Ischiropoulos, Ph.D., Research Professor of Pediatrics
and Pharmacology

___________________________________
Graduate Group Chairperson: Kathryn M. Ferguson, Ph.D., Associate Professor,
Physiology
Dissertation Committee
Doron C. Greenbaum, Ph.D., Assistant Professor, Department of Pharmacology
Cecilia Tommos, Ph.D., Assistant Professor, Department of Biochemistry and Biophysics
Roland L. Dunbrack, Jr, Ph.D., Adjunct Associate Professor, Department of
Biochemistry and Biophysics
Ian A. Blair, Ph.D., Professor, Department of Pharmacology
Gideon Dreyfuss, Ph.D., Professor, Department of Biochemistry and Biophysics
Andrew Gow, Ph.D., Associate Professor, Department of Pharmacology and Toxicology

THE STRUCTURAL PROTEOMICS OF S-NITROSYLATION: FROM GLOBAL
IDENTIFICATION TO ELUCIDATING PROTEIN FUNCTION THROUGH
STRUCTURAL BIOINFORMATICS

COPYRIGHT

2011

Jennifer Lynn Greene

iii

“I was leaving the South to fling myself into the unknown. I was taking a part of the
South to transplant in alien soil, to see if it could grow differently, if it could drink of new
and cool rains, bend in strange winds, respond to the warmth of other suns, and,
perhaps, to bloom.”
-Richard Wright

To my grandparents, Flenard and Jessie, who planted the seed
and my mother, Melvelyn, who relentlessly nurtured it.

iv

ACKNOWLEDGMENTS
I would first like to thank the entire Ischiropoulos Laboratory. I joined this lab at a time
when I was unsure about my own future in science. The collaborative spirit and good
nature of everyone in the lab, past and present, helped bring my scientific dreams back to
life. I would like to thank my advisor, Dr. Harry Ischiropoulos, for his constant support
and encouragement. Under his tutelage, I have become a far better scientist than I could
have imagined. I would like to thank Richard Lightfoot, Drs. Margarita Tenopoulou and
Paschalis-Thomas Doulias. Karthik Raju, Kristen Malkus, Marissa Martinez, and past
members: Drs. Elpida Tsika, Todd Greco, and Christie Bruno. I would also like to thank
the members of the Vanderkooi laboratory for being my lab home for my first 3 years
here at Penn. I would like to thank the members of my committee for their advice and
support. I’d also like to thank my friends and family, especially my mother Mel, my sister
Nikoia, and my brother Bernard. And lastly, I’d like to thank my fiancé, Ebenezer.
Without your love, I don’t think I would have made it.

Sola fide

v

ABSTRACT

THE STRUCTURAL PROTEOMICS OF S-NITROSYLATION: FROM GLOBAL
IDENTIFICATION TO ELUCIDATING PROTEIN FUNCTION THROUGH
STRUCTURAL BIOINFORMATICS
Jennifer L. Greene
Harry Ischiropoulos, Ph.D.

S-nitrosylation is the covalent addition of nitric oxide to reduced cysteine residues
on proteins. It has been well documented that not all proteins are S-nitrosylated and more
specifically, not all cysteine residues within an S-nitrosylated protein are modified.
Therefore, it is very important to determine how this specificity is derived. Additionally,
the mechanism by which nitric oxide can modify cysteines is still unclear. Even with the
discovery of functional consequences of S-nitrosylation, there are still large deficits in
our understanding and validation that it is a newly identified means of nitric oxide
signaling within the body.
These gaps in knowledge primarily exist due to a lack of tools necessary for
identifying in vivo sites of S-nitrosylation. To this end, complementary mercury-based
mass spectrometric approaches were developed for the identification of endogenous Snitrosoproteomes. This resulted in the identification of 328 SNO-cysteines coordinated to
192 proteins in the mouse liver, 97% of which corresponded to novel targets of Snitrosylation. Bioinformatic analysis of these targets then revealed that multiple
mechanisms of S-nitrosylation may occur in vivo, one of which involving S-
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nitrosoglutathione (GSNO). To test this hypothesis, the SNO-proteome of mice incapable
of metabolizing GSNO was resolved. Quantum mechanics/molecular mechanics
calculations coupled with molecular dynamics simulations proposed a novel GSNOmediated mechanism of transnitrosation. Basic residues in the surrounding cysteine
microenvironment were shown to catalyze the formation of protein S-nitrosocysteine
residues. Collectively, these data suggest that the specificity of cysteines targeted for Snitrosylation is driven by the surrounding protein microenvironment.
Additionally, with only 9 structures of S-nitrosylated proteins our present
understanding of the structural consequences of S-nitrosylation is limited. Using an in
vivo model, attempts were made to correlate changes in enzymatic activity as a function
of S-nitrosylation. Normal mode analysis revealed local motions near the site of Snitrosylation which may alter product release. In summary, this thesis utilized a global
proteomic approach to craft a more targeted investigation into the specificity and
molecular mechanism of S-nitrosylation.
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CHAPTER ONE
1.1 Introduction
Nitric oxide (•NO) received the distinction of a signaling molecule in physiology
when Furchgott, Ignarro, and Murad were awarded the 1998 Nobel Prize in Medicine &
Physiology for their combined efforts in elucidating the role of •NO in vasodilation. It
was concluded that •NO produced by endothelial cells can bind to the heme iron of
soluble guanylate cyclase (sGC) thereby converting GTP to cGMP and resulting in a
cascade of events leading to smooth muscle relaxation. Because it is well known that •NO
can react with many intracellular targets, the mechanism by which •NO selectively
reacted with sGC became of significance. Stamler et al. hypothesized that •NO could also
propagate its signal by forming stable adducts with protein thiols that would then deliver
nitric oxide to a specific target (Stamler et al. 1992). This study resulted in the first
observation that nitric oxide could react with cysteine residues in proteins to form protein
S-nitrosocysteine.
Over the past 2 decades, hundreds of proteins have been identified as being Snitrosylated. S-nitrosylation is defined as the covalent addition of nitric oxide to selective
protein cysteine residues that can regulate protein activity across a variety of organs and
cellular systems. Their cellular functions have ranged from oxidoreductases to ion
channels to histone deacetylases, suggesting that S-nitrosylation appears to be a
widespread biological mechanism of nitric oxide signaling. Nevertheless, fundamental
questions regarding this emerging posttranslational modification (PTM) still remain
unanswered. It is difficult to convince the scientific community that upon generation of
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this small highly reactive molecule, •NO selectively modifies a specific cysteine residue.
The mechanism by which •NO can modify cysteines is still unclear. For other more
characterized PTMs such as acetylation (which is of comparable relative size to •NO),
specific enzymes are necessary to catalyze its reaction with its target protein. Therefore,
with the unequivocal identification of such enzyme(s) for S-nitrosylation, it is difficult to
ascertain how specificity is achieved. Answers to these pressing questions will expand
our understanding of S-nitrosylation and offer insight as to how to better regulate this
emerging posttranslational modification.

1.2 Nitric oxide
1.2.1 Chemical properties of nitric oxide
Nitric oxide (also known as nitrogen monoxide) is a colorless, diatomic gas
composed of one nitrogen atom and one oxygen atom. It was first described as “nitrous
air” in 1774 by Joseph Priestley in his book titled Experiments and Observations on
Different Kinds of Air, Vol. 1. An uncharged free radical, nitric oxide has one unpaired
electron. With an oil/water partition coefficient ~6.5 (Kow measured at 37°C) and a low
solubility in water, •NO is capable of easily diffusing through hydrophobic environments
such as cell membranes (Balbatum et al. 2003). In aqueous solutions, nitric oxide reacts
primarily with oxygen and its half-life is proportional to its concentration.
The half-life of •NO can be altered by its interactions with different targets. Nitric
oxide can react with a wide range of molecules to form end products with various
functions. Upon its reaction with molecular oxygen (O2), nitric oxide is oxidized to form
relative stable metabolites nitrite (NO2-) and nitrate (NO3-). Nitric oxide can also react
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with free radicals such as superoxide (O2-•) to generate the strong oxidant peroxynitrite
(ONOO-). This reaction has been observed to be near diffusion limited suggesting that it
is only restricted by the ability of the molecules to come into contact with one another
(Beckman et al. 1990; Koppenol, et al. 2001). The interaction of nitric oxide with lipidderived radicals has also been characterized as being a diffusion-limited reaction
(O’Donnell et al. 1997). •NO has been most classically described by its coordination to
transition metals such as copper or iron to form M-NO (Wink et al. 1994; Wade & Castro
1990).
In general, the chemical reactivity of •NO is contingent upon its surrounding
environment. Therefore, when attempting to understand the role of nitric oxide in
biological processes, it is important to know when and where it is produced within the
body.

1.2.2 Biological synthesis of nitric oxide

In 1916, Mitchell, Shonle, and Grindley first noticed that the amount of nitrates
and nitrites excreted through urine from healthy subjects was more than the amount that
could be ingested from the diet (Mitchell, et al. 1916). Using 15N-labelled nitrate (15NO3), Tannenbaum et al. monitored nitrate metabolism and quantified an excess of excreted
nitrates in human urine compared to dietary intake, supporting this 65-year old
observation (Tannenbaum, et al. 1978; Green et al. 1981, PNAS). These experiments
allowed them to conclude that an endogenous metabolic process was responsible for
forming nitrogen oxides. Over the following decade, an elegant series of experiments
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across different research groups biochemically characterized this mechanism and its
necessary components (Stuehr & Marletta 1985; Hibbs et al. 1987; Iyengar et al. 1987;
Marletta et al. 1988). It was discovered that the radical nitric oxide is an endogenously
synthesized intermediate generated during the process of nitrite and nitrate formation
(Ignarro et al. 1987a; Ignarro et al. 1987b; Palmer et al. 1987; Palmer et al. 1988).
•

NO is synthesized from L-arginine and oxygen by the enzyme nitric oxide

synthase (NOS) (Moncada & Higgs, 1993). Nitric oxide synthases are 150 kiloDaltons
and composed of a homodimer containing an oxygenase domain and a reductase domain
that are linked by a calmodulin recognition site. The oxygenase domain contains binding
sites for the cofactors tetrahydrobiopterin (BH4), protoporphyrin IX haem, and L-arginine
while the reductase domain contains binding sites for the electron carriers FAD & FMN,
and the reductant NADPH (Ghosh & Stuehr 1995). In summary, electrons supplied by
NADPH are shuttled across the reductase domain by FAD and FMN to the heme iron of
the oxygenase domain where they can oxidize L-arginine. A guanidino nitrogen of Larginine undergoes a 5-electron oxidation via two mono-oxygenation steps to form •NO
and L-citrulline (Marletta et al. 1993; White & Marletta et al. 1992; Mayer et al. 1991;
Bredt & Snyder 1990; Bredt et al. 1991). Binding of calmodulin is required for the flow
of electrons from the reductase domain to the oxygenase domain.
Three nitric oxide synthase isoforms exist: neuronal nitric oxide synthase (nNOS;
NOS1), inducible nitric oxide synthase (iNOS; NOS2), and endothelial nitric oxide
synthase (eNOS; NOS3). They differ in their regulation, quantity, and location of •NO
production. Neuronal NOS was the first isoform to be purified and cloned (Bredt &
Snyder 1990) using extracts from rat cerebellum (Bredt et al. 1991). It is expressed in the
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brain and skeletal muscle (Salter et al. 1991; Nakane et al. 1993). Endothelial NOS is
found in endothelial cells, cardiac myocytes, neurons, and epithelial cells. Typical output
from eNOS and nNOS is in the nM range. iNOS produces a large burst of •NO in
response to cytokines and endotoxins across a variety of cell types including neutrophils,
epithelial cells, vascular smooth muscle, hepatocytes and chondrocytes (Xie et al. 1992;
Lincoln et al. 1997). nNOS and eNOS differ from iNOS in their dependency upon
calcium (Ca2+) to produce synthesize •NO (Cho et al. 1992;Garcin et al. 2004; Dudzinski
et al. 2007; Venema et al. 1996). The efficiency of calmodulin binding for nNOS and
eNOS is mediated by intracellular calcium levels whereas calmodulin is already tightly
bound to iNOS.
The presence of so many cofactors suggests that nitric oxide synthases are very
highly regulated. Lack of the cofactor BH4 can cause the uncoupling of the eNOS dimer
leading to production of superoxide (Chen et al. 2011). NOSs have also been shown to be
regulated by posttranslational modifications. S-Glutathionylation can also uncouple the
eNOS dimer serving as an autoregulatory mechanism for •NO production (Chen et al.
2010). S-nitrosylation of iNOS has also been shown to destabilize the dimer (Rosenfeld
et al. 2010).

1.2.3 Nitric oxide in health and disease

Nitric oxide has long played an important role in human health and disease, even
when it had not yet been identified as the culprit (Butler et al. 2006). As with most great
scientific discoveries, it all began with an observation. An English surgeon noticed that
when he had a patient suffering from severe chest pain, he could alleviate the symptoms
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by removing blood (Butler et al. 2006). This suggested to him that the remedy for angina
pectoris was somehow related to lowering blood pressure. The surgeon’s friend told him
of how inhaling amyl nitrite helped to lower the blood pressure of his animals and so the
surgeon commenced in using this therapeutic remedy for those suffering from chest pain
(Gamgee et al. 1868; Brunton et al. 1867). Nitroglycerin which contained a nitro group (NO2) was also used as a vasodilator over the next century. It would be many years later
before a series of experiments conducted by Moncada, Furchgott, Ignarro & Murad
revealed the identity of nitric oxide as the true vasodilator. This Nobel Prize winning
discovery will be discussed in the following section.
Nitric oxide has been classically identified as having a role in the body’s innate
immune response and neurotransmission. As was previously described, macrophages
were instrumental in revealing the endogenous production of nitric oxide (Hibbs et al.
1987; Stuehr et al. 1989; Marletta et al. 1988; Hibbs, et al. 1989). In response to certain
stimuli, iNOS can produce a burst of the •NO which targets invading pathogens and
participates in anti-tumor activities through a variety of mechanisms. Mice lacking the
gene for iNOS are much more susceptible to parasitic infection and replication of bacteria
(Wei et al. 1991; MacMicking et al. 1995). •NO has been shown to impair mitochondrial
function by disrupting iron-sulfur centers within oxidoreductases as well as altering
mitochondrial membrane potential (Kroncke et al. 1995; Hibbs et al. 1987; Stuehr et al.
1989). •NO can also react with non-heme iron, resulting in Fe release which might also
promote lipid peroxidation and serve as an additional mechanism of cellular damage
(Reif et al. 1990).
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While all three isoforms of NOS are found throughout the brain, nitric oxide
produced from neuronal NOS has been the best characterized within the central nervous
system. A few of its important roles involve neuroprotection, neurotoxicity, and synaptic
plasticity. Glutamate binds to the NMDA-receptor which allows calcium (Ca2+) entry into
the neurons thereby activating NOS. Once it is produced, •NO acts as a retrograde
messenger to strengthen synaptic activity. It has been postulated that this function of
nitric oxide is important during long term potentiation (LTP), an important process
underlying learning and memory in the brain.
Nitric oxide can also serve a neuroprotective function by regulating its own
production. Disulfide bridge formation in the NMDA-receptor channel has been
previously shown to decrease the influx of Ca2+ through the channel (Lei et al. 1992).
Nitric oxide can modify these same two cysteines and help promote the formation of this
disulfide bridge (Lipton, Singel, & Stamler, 1994; Lipton & Stamler, 1994). In addition,
•

NO can also inhibit the binding of glutamate to the NMDA receptor, preventing the flow

of Ca2+ through the channel and regulate NO synthesis.
When observing the presence of •NO throughout the central nervous system,
peripheral nervous system, and immune system, it is easy to imagine how its dysfunction
might lead to disease. Dysregulation of nitric oxide has been implicated in ischemia
(Mugge et al. 1991; Harrison et al. 1992; Maseri et al. 1991), atherosclerosis (Rubanyi et
al. 1993), septic shock (Thiemermann et al. 1993; Petros et al. 1991), pre-eclampsia
(Buhimschi et al. 1998) and many others disorders.
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Nitric oxide has also been used as a therapeutic agent as it has been found to play
an important role in wound healing (Frank et al. 2002; Shi et al. 2000) and protection
after ischemic injury (Lima et al. 2009). In fact, researchers Jonathan Stamler and Joseph
Bonaventura hold a United States patent for “Red blood cells loaded with S-nitrosothiol
and its uses”. As the patent abstract states, “loaded red blood cells can be used in methods
of therapy for conditions which are characterized by abnormal O2 metabolism of tissues,
oxygen-related toxicity, abnormal vascular tone, abnormal red blood cell adhesion, or
abnormal O2 delivery by red blood cells.” United States Patent #6153186
(http://www.wikipatents.com/US-Patent-6153186/red-blood-cells-loaded-with-snitrosothiol-and-uses-therefor). Direct inhalation of nitric oxide has been used to treat
preterm infants with bronchopulmonary dysplasia (Kinsella, et al. 2007). As researchers
continue to identify the role of nitric oxide in human physiology, it is even more pressing
to identify the mechanisms by which nitric oxide may exert its function and how these
functions are regulated.

1.2.4 Nitric oxide as a signaling molecule
Although nitrovasodilators such as nitroglycerin were known to alleviate the
symptoms of pectoris angina since 1867, their mechanism of action was not fully
elucidated until over 120 years later. The discovery of nitric oxide as an endogenous
vasodilator came from a series of elegantly designed experiments across multiple
laboratories. In 1977 & 1978, the Murad laboratory demonstrated that both gaseous •NO
and •NO released from different nitrovasodilators could activate guanylate cyclase,
converting GTP to cyclic GMP (Katsuki et al. 1977; Arnold et al. 1977; Schultz &
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Schultz, 1977). It was also noted that this effect was inhibited by hemoglobin and
myoglobin (Murad, et al. 1978). Shortly thereafter, the Ignarro laboratory reported that
activation of guanylate cyclase by •NO resulted in smooth muscle relaxation (Gruetter, et
al. 1979); however, it was still unknown that •NO existed endogenously.
The Furchgott Laboratory monitored the response of the aorta to the cholinergic
agonist carbachol using a protocol which required the isolation of aortic rings; however,
when a new technician prepared helical strips of the aorta instead of rings, he found that
he could no longer induce smooth muscle relaxation. This finding highlighted two
important discoveries: 1) an intact endothelium was necessary for smooth muscle
relaxation and 2) acetylcholine must bind to receptors on the surface of the endothelium
to produce the molecule responsible for smooth muscle relaxation (Furchgott et al. 1980).
This yet identified molecule was later termed “endothelium-derived relaxation factor”
(EDRF).
While both Furchgott and Ignarro independently speculated that EDRF was in
fact •NO, it still remained inconclusive (Moncada et al. 1988). Once concurrent research
identified the endogenous synthesis of nitrites and nitrates (Ignarro, et al. 1981; Iyengar,
et al. 1987), this speculation immediately became more concrete. A series of experiments
by Moncada and Ignarro finally revealed that EDRF was nitric oxide (Ignarro, et al.
1987; Ignarro, et al. 1987; Palmer et al. 1987) and it was synthesized from terminal
guanidine nitrogen of L-arginine in vascular endothelial cells (Palmer et al. 1988).
In 1998, Furchgott, Ignarro, and Murad were awarded the Nobel Prize in
Medicine and Physiology for their combined contributions in elucidating the role of nitric
oxide in vasodilation. The press release accompanying the award made mention of nitric
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oxide as a “signaling molecule”. This newly identified role for nitric oxide was clinched
with the key discovery that eNOS produced •NO within endothelial cells. Previous work
had shown that nitric oxide was produced in response to a stimulus, specifically targeted
to the heme of soluble guanylate cyclase, and necessary for a specific physiological
response, i.e. dephosphorylation of myosin light chain resulting in vasodilation. This new
discovery added that nitric oxide was spatially restricted after its production by eNOS.
This series of events became the canonically described cGMP-dependent pathway
whereby which nitric oxide can act as a second messenger and induce a physiological
response.

1.3

S-nitrosylation
modification

as

an

emerging

posttranslational

Once it was determined that nitric oxide bound to the heme of soluble guanylate
cyclase, it still remained unclear how •NO stably diffused from nitric oxide synthase to its
target sGC. As was previously described, •NO can react with a variety of intracellular
targets. Nitric oxide derived species are known to react with sulfhydryls and form more
stable adducts of S-nitrosothiols (Oae, et al. 1983). Stamler et al. hypothesized that •NO
could prolong its half-life and deliver •NO to targets such as sGC by reacting with
reduced thiols on protein cysteine residues (Stamler, et al. 1992). By using both
endogenous and exogenous sources of •NO, they found that several proteins could form
S-nitroso adducts, including serum albumin. A series of later experiments by this same
group detected S-nitrosylated serum album circulating in human plasma, suggesting that
S-nitrosylated proteins could serve as endogenous intermediates for •NO delivery
(Stamler et al. 1992).
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In 1996, the Stamler group identified an S-nitrosylated cysteine residue on the
Beta chain of hemoglobin (Cysβ93) (Jia, et al. 1996). Upon oxygenation of hemoglobin,
Cysβ93 was S-nitrosylated (SNO-Hb) in the lung resulting in release of nitric oxide and
delivery of O2 to peripheral tissues through circulation. This suggested that SNO-Hb may
be involved in the normal regulation of blood flow and maintenance of blood pressure.
The role of •NO in vasodilation was thought to be a very well characterized mechanism.
Therefore, the identification of a new role for nitric oxide in vasodilation was a bit
shocking, especially since it involved a new role for an enzyme which had also been
heavily scrutinized for decades previously.
Even with the discovery of functional consequences of S-nitrosylation, there are
still large deficits in our understanding and validation that it is a newly identified means
of nitric oxide signaling within the body. The mechanism by which S-nitrosylation occurs
has not conclusively been identified. Additionally, how specificity is derived still remains
unclear. The following sections discuss how recent advances in the identification of Snitrosylated proteins have increased our knowledge of this emerging posttranslational
modification.

1.3.1 Methods for identification of S-nitrosylated cysteines

The crux to categorizing any emerging posttranslational modification is to
identify its targets. With recent advances in technology, the development of techniques
for detecting S-nitrosylated proteins has exponentially enhanced our understanding of Snitrosylation and helped to elucidate its ubiquitous role in nitric oxide signaling. Proof of
an S-nitrosylation event initially began using spectroscopic techniques to identify S-
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Nitroso bovine serum albumin (Stamler et al. 1992). Stamler et al. utilized UV-Visible
spectroscopy and NMR spectroscopy to show that •NO was bound to the protein. To
quantify the amount of SNO present, they developed an assay which lysed the S–NO
bond resulting in liberated •NO which could be detected via chemiluminescence after its
reaction with ozone (Stamler et al. 1992; Stamler & Feelisch, 1996). Utilizing Saville
chemistry, mercury (II) chloride (HgCl2) was also used to remove nitric oxide for the
purposes of quantification (Saville et al. 1958; Xu et al. 1998; Mannick et al. 1999). In
the case of hemoglobin, a very well characterized protein, UV-Vis spectroscopy proved
extremely informative in proving that nitric oxide was bound to a thiol and not the heme
(Jia et al. 1996). However, it required its isolation, thereby mandating previous
knowledge of its identity. Therefore, initial identifications of S-nitrosylated proteins did
not allow for a priori hypotheses regarding their existence or identification.
In 2001, Jaffrey et al. published the first method which globally identified Snitrosylated proteins contained within complex mixtures such as tissues (Jaffrey et al.
2001). The biotin switch technique (BST) consisted of three main steps: 1) the blocking
of reduced thiols with methyl methanethiosulfonate (MMTS), 2) reduction of Snitrosylated cysteine residues using ascorbate, and 3) biotinylation of previously Snitrosylated

cysteine

residues

with

N-[6-(biotinamido)hexyl]-3’-(2’-

pyridyldithio)propionamide (biotin–HPDP). Because MMTS is a thiol-specific agent,
ascorbate selectively decomposes nitrosothiols, and biotin-HPDP is a sulfhydryl-specific
agent, the method allows for the specific labeling of S-nitrosylated cysteine residues.
Biotinylated proteins were purified using avidin, then separated and resolved using SDSPAGE. Known proteins can be probed with the corresponding antibody or individual
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bands can be excised and identified by mass spectrometric analysis. While the BST was
the first tool of its kind, concerns still exist regarding its efficiency to identify Snitrosylated proteins. The reduction of S-nitrosothiols by ascorbate has been called into
question due to its poor sensitivity and its ability to reduce disulfide bonds (Zhang, et al.
2005; Giustarini et al. 2008). Moreover, a key objective for identifying scores of Snitrosylated proteins is to reveal the specificity of cysteines endogenously targeted for
this modification. However, this is impossible to do when identifying the protein without
the specific site of modification. Two papers were published in 2006 which offered
proteomic techniques for identifying sites of S-nitrosylation in complex mixtures (Hao et
al. 2006; Greco et al. 2006). Briefly, the two comparable methods introduced a
trypsinization step before biotinylation which allowed for enrichment of peptides
containing modified cysteines.
Since the development of the BST in 2001, there have been many derivatives
aimed at improving its deficiencies (Sun et al. 2007; Kettenhofen et al. 2008,; Sinha et al.
2010) and development of other promising techniques which directly label and detect Snitrosocysteine (Torta et al. 2010; Wang et al. 2008; Faccenda et al. 2010; Zhang et al.
2010). More recently, Benhar et al. developed a quantitative BST method using stable
isotope labeling by amino acids in cell culture (SILAC) (Benhar et al. 2010). The authors
employed their technique to characterize the denitrosylation of SNO-cysteines by
thioredoxin in Jurkat cells. While the above described methods point toward significant
advances in the field of S-nitrosylation, detection of S-nitrosylated proteins is often still
dependent upon supplementation by exogenous sources of nitric oxide. An optimal
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method would be sensitive enough to detect and accurately quantify endogenous Snitrosylation events.

1.3.2 Alteration of protein activity as a function of Snitrosylation
With the advent of the Biotin Switch Technique and its derivatives, many more
proteins have been identified as S-nitrosylated. For many researchers, S-nitrosylation has
provided the missing link between observing a role of nitric oxide in human physiology
and pinpointing its specific mechanism of action. A comprehensive discussion of all such
proteins would prove to be impossible within the limits of this dissertation; therefore,
several key studies are highlighted which demonstrate how S-nitrosylation can alter a
wide range of protein functions and further extend the role of nitric oxide in human
health and disease.
Nitric oxide has long been known to play an important role in neurophysiology. In
2004, the Lipton group identified a role for S-nitrosylation in sporadic Parkinson’s
disease (Yao et al. 2004). S-nitrosylation of the E3 ubiquitin ligase parkin in SH-SY5Y
cells led to an increase in its activity and ultimately resulted in its own ubiquitination.
Inhibition of parkin can result in a decreased clearance of its substrates and ultimately
lead to cell death. This fact is made even more apparent by the detection of S-nitrosylated
parkin in human brains of those with sporadic Parkinson’s disease. Later studies
involving the S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
led to an additional role of nitric oxide in regulating E3 ubiquitin ligase activity. It has
been well established that GAPDH translocates to the nucleus during apoptosis (Sawa, et
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al. 1997; Ishitani, et al. 1998; Dastoor, et al. 2001). Because GAPDH lacks a nuclear
localization signal, how GAPDH is able to enter the nucleus has remained a mystery. In
2005, Hara et al. showed that nitric oxide S-nitrosylates GAPDH thereby increasing its
ability to bind to the E3 ubiquitin ligase Siah1, and induces translocation of the complex
into the nucleus (Hara et al. 2005). Once inside, GAPDH promotes the stabilization of
Siah1, allowing for it to carry out its role in apoptosis. This discovery propelled a myriad
of studies which continue to identify how this mechanism is regulated (Sen, et al. 2008;
Sen, et al. 2009; Kornberg, et al. 2010).
In addition to regulating the activity of ubiquitin ligases, S-nitrosylation has also
been shown to modulate other posttranslational modifications such as phosphorylation.
Previous reports have shown that nitric oxide can negatively regulate the signaling
cascade of c-Jun N-terminal kinases also known as JNKs (Park et al. 1996; Lo, et al.
1996; Kim et al. 1997; Wang et al. 1998; Lander et al. 1996; Jun et al. 1999). As a
member of the mitogen activated protein (MAP) kinase family, JNKs are important in the
cellular response to different stresses. They are activated through phosphorylation by
MAP kinases MKK4 and MMK7 and typically inactivated by phosphatases (Ip, et al.
1998). Park et al. demonstrated that endogenous production of •NO by activation of iNOS
resulted in suppression of JNK activity in microglia and macrophages (Park et al. 2000).
Using a series of experiments, the authors showed that JNK activity was attenuated by
nitric oxide, more specifically, by a cGMP-independent chemical modification of Cys116
which they identified as S-nitrosylation. Conversely, S-nitrosylation has also been shown
to enhance the activity of other kinases. Rahman et al. presented an investigation into
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tyrosine kinase c-Src and found that S-nitrosylation of Cys498 resulted in its activation
and ultimately its invasion into cancer cells (Rahman, et al. 2010).
S-nitrosylation has also been shown to play a role in the regulation of DNA
transcription. NF-κB is a transcription factor thought to regulate over 200 genes which
are involved in the inflammatory response (Marshall, et al. 2000; Shishodia, et al. 2004;
Xie, et al. 1994). It is activated by its release from inhibitory proteins within the
cytoplasm and translocation to the nucleus. IκB kinase (IKK) is one of the proteins
responsible for inducing the degradation of these inhibitory proteins thereby activating
NF-κB. Reynaert et al. demonstrated that S-nitrosylation of Cys179 in IKK inhibited its
activity resulting in prolonged inactivation of NF-κB (Reynaert et al. 2004). By inhibiting
endogenous production of •NO in Jurkat cells, the authors were able to again activate
IKK. Interestingly, additional evidence has also shown that NF-κB itself is S-nitrosylated,
offering an additional mechanism for by which •NO can regulate its transcriptional
activity (Matthews, et al. 1996; delaTorre, et al. 1997).
Major classes of proteins have been found to be S-nitrosylated. Coupled with the
discovery of S-nitrosylation across different types of cells and tissues (Gow et al., 2002),
this underscores the widespread effects that nitric oxide can have across different
biological processes. Nevertheless, it is important to acknowledge that identifying a
protein as being susceptible to S-nitrosylation does not prove that it is endogenously Snitrosylated. Lack of sensitive detection technologies often mandate that proteins are
frequently supplemented with exogenous sources of nitric oxide to aid in their
identification. Exogenous donors can vary greatly in the nitric oxide moiety that is
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produced. And as is described in the following sections, the chemistry of a nitric oxide
moiety may influence which cysteines are actually targeted.

1.3.3 Proposed mechanisms of S-nitrosylation formation
Perusing the literature on S-nitrosylation may leave the reader slightly confused
due to the assorted terminology. Several key terms are used to describe this newly
emerging protein modification by nitric oxide. The difference in their definitions stems
from the proposed mechanism by which •NO modifies cysteine residues to form Snitrosocysteine (Protein-Cys-NO). The most commonly used term is “S-nitrosylation”.
This historically describes the reaction of a nitric oxide radical with a transition metal
(“nitrosylation”) to form a product which then reacts with a protein cysteine thiol (“Snitrosylation”) (Stamler, et al. 1992). Another term very commonly used is “nitrosation”
or “transnitrosation”. This term traditionally refers to the addition or transfer of a
nitrosonium ion (NO+) to a thiolate anion (SH-) whereas “trans-S-nitrosation” specifies
the transfer to a protein cysteine residue. “S-nitrosylation” is now more routinely used to
encompass any reaction resulting in the addition of a nitric oxide moiety to a protein
cysteine thiol.
There are several proposed mechanisms which can result in the formation of
protein S-nitrosocysteine. The first mechanism describes the direct reaction of an NO
radical with a transition metal. •NO can react with a metal at a heme center such as Fe3+
to form Fe2+ and NO+ (Pacher et al. 2007). The nitrosonium ion is then capable of
reacting with the reduced thiol of nearby cysteine residues (Wade & Castro 1990). An
additional metal-catalyzed mechanism hypothesizes that proteins can react with free
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pools of iron in the cell to form dinitrosyliron complexes which can S-nitrosylate cysteine
residues (Bosworth et al. 2009; Boese et al. 1995).
Additional mechanisms for forming S-nitrosocysteine involve the transfer of a
nitrosonium ion to a reduced thiol of a cysteine residue. It has been proposed that Snitrosoglutathione (GSNO), a major endogenous S-nitrosothiol, is involved in the
transnitrosation of protein cysteine. Although it can be synthesized within the laboratory
using sodium nitrite and GSH in an acidic environment, the mechanism by which GSNO
forms endogenously still remains unclear (Zhang et al. 2004; Keszler et al. 2009; Gow et
al. 1997; Tullett et al. 2001). It is also possible for S-nitrocysteine residues within
proteins to then react with the reduced thiols of GSH or other protein cysteine residues
and transfer a nitrosonium ion. This is what is referred to as a “protein-assisted”
transnitrosation. This mechanism was observed with the protein thioredoxin (Mitchell et
al. 2005). After its own reaction with GSNO, SNO-thioredoxin (SNO-Trx) can
transnitrosate a select cysteine residue in the enzyme caspase-3. Experiments conducted
by the Marletta group illustrate that SNO-Trx and not GSNO is the favored mechanism
by which this specific cysteine forms S-nitrosocysteine (Mitchell et al. 2007).
The last proposed mechanism of S-nitrosation involves the autoxidation of •NO to
form higher oxides that serve as transnitrosating agents. Due to its lipophilic character,
•

NO is known to favor hydrophobic environments (Moller et al. 2007). Therefore, •NO

can congregate in hydrophobic regions of the protein where it can also react with O2 and
nitrogen dioxide to form the transnitrosating agent dinitrogen trioxide N2O3 (Nedospasov
et al. 2000; Gow et al. 1997; Liu et al. 1998; Moller, et al. 2007).
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There is a diversity of mechanisms which ultimately result in the formation of
protein-SNO, each of which is dependent upon the chemical structure of nitric oxide.
Therefore, being able to identify the chemical species of nitric oxide may help to pinpoint
which mechanism is occurring and may contribute to our understanding of the specificity
of this posttranslational modification.

1.3.4 Denitrosylation: Reversing the signal
To convincingly describe S-nitrosylation as a signaling mechanism of nitric
oxide, it is essential to show the reversibility of the modification. There are two major
endogenous systems which have been identified to influence the stability of Snitrosocysteine: the GSH/S-nitosoglutathione/S-nitrosoglutathione reductase system and
the thioredoxin/thioredoxin reductase system. Thioredoxin (Trx) is directly involved in
an enzyme-mediated mechanism of denitrosylation whereas the glutathione system
indirectly mediates S-nitrosylation through metabolism of GSNO by the enzyme Snitrosoglutathione reductase (GSNOR).
In addition to its roles as both a reductant and transnitrosating agent (Mitchell et
al. 2005; Mitchell et al. 2007), thioredoxin has also been shown to serve as a
denitrosylating enzyme. Nikitovic and Holmgren first demonstrated an indirect role for
the thioredoxin system through its metabolism of the low molecular weight thiol GSNO
(Nikitovic et al. 1996). Stoyanovsky and colleagues further demonstrated that the Trx
system was also capable of denitrosating protein-SNO (Sengupta, et al. 2007). The
proposed mechanism involves active site cysteines 32 and 35 (Sengupta, et al. 2007).
Because of its increased nucleophilicity, Cys32 is thought to be the target of NO. Cys32
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and Cys35 then form a disulfide bond allowing NO to then be transferred
intramolecularly to the other cysteine residues (Cys62, Cys69, & Cys72) which have
previously been shown to be S-nitrosylated. For protein denitrosation, the work of
Mitchell & Marletta with caspase-3 may provide insight as to how thioredoxin might
interact with target proteins (Mitchell et al. 2007). E70A/K72A mutations in hTrx
resulted in some loss of contact, suggesting that these charged residues may help
facilitate protein-protein interactions between the denitrosating agent and its targets.
Proteomic studies have also been used to identify proteins which might be potential
denitrosylation targets of thioredoxin (Benhar et al. 2010). Using a model which
overexpressed Trx, recent work done by Fu et al. identified 55 putative protein targets of
thioredoxin in the mouse heart (Fu et al. 2009). Interestingly, previous reports have
identified several of these proteins as being targets of S-nitrosylation.
The thioredoxin system can be regulated through a variety of mechanisms.
Stamler and colleagues first demonstrated that caspase-3 activation was tightly tethered
to its denitrosylation upon induction of the Fas apoptotic pathway (Mannick et al. 1999).
Nearly 10 years later, they were able to show that denitrosylation of caspase-3 was
carried out by mitochondrial thioredoxins (Benhar et al. 2008), suggesting a stimuluscoupled regulatory mechanism. Recently, Forrester and colleagues have identified
Thioredoxin-interacting protein (Txnip), a protein which can also regulate the
denitrosation activities of thioredoxin (Forrester et al. 2009). And most obviously,
thioredoxin requires the presence of NADPH and thioredoxin reductase to control the
redox state of its catalytic cysteines.
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Glutathione has long been known for its essential antioxidant properties in the
cell. Although the specific in vivo mechanism remains elusive, GSH can react with a
nitric oxide moiety to form the transnitrosating agent GSNO (Zhang et al. 2005; Gow et
al. 1997). Once it was determined that GSNO readily forms S-nitrosocysteine
endogenously, understanding how this process was regulated became of great
importance. In 2001, Liu et al. identified GSNO reductase (GSNOR), an endogenous
enzyme which could regulate the intracellular levels of GSNO (Liu et al. 2001). GSNOR
is an endogenous alcohol dehydrogenase (Class III) which can oxidize an alcohol to a
ketone or aldehyde. Previous investigations showed that it was highly specific for GSNO
(Jensen et al. 1998). GSNOR regulates the availability of GSNO by converting it to
oxidized glutathione (GSSG) in the presence of NADPH. The Stamler group generated
knockouts of this enzyme showing increased levels of SNO-hemoglobin as compared to
wildtype (Liu et al. 2004). This suggests that the equilibrium that exists between GSNO
and protein-SNO is disrupted upon removal of GSNOR.
Glutathione itself is also capable of denitrosating protein-cysteine residues
(Romero et al. 2009; Paige et al. 2008). Denitrosation of proteins by GSH was
investigated using a quantitative proteomic method which monitored the stability of Snitrosylated cysteine residues (Paige et al. 2008). The authors revealed a subset of
proteins that were insensitive to denitrosation via GSH and even remained modified after
synthesis of •NO was inhibited. Additional experiments with the reductant DTT also
revealed no decrease in S-nitrosylation. Only after the proteins were denatured were they
able to remove SNO. This suggested that conformational changes within the protein may
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take place to prevent denitrosation from occurring, thereby increasing the longevity of Snitrosocysteine.
Investigations continue into identifying additional proteins which might serve as
denitrosating agents or aid in the process of regulating denitrosylation events. To date
studies have shown that other enzymes including protein disulfide isomerase (Sliskovic et
al. 2005), xanthine oxidase (Trujillo et al. 1998), superoxide dismutase (Jourd’heuil et al.
1999; Johnson et al. 2001), and glutathione peroxidase (Hou et al. 1996) may play a role
in the metabolism of S-nitrosothiols.

1.4 Specificity of cysteines targeted for S-nitrosylation
A large gap in knowledge exists regarding the specificity of endogenous Snitrosylation. While it has been well documented that not all proteins are S-nitrosylated
and more specifically, not all cysteine residues within an S-nitrosylated protein are
modified, it is very important to determine how this specificity is derived. The best
example for illustrating this phenomenon is the skeletal muscle Ca2+ release
channel/ryanodine receptor 1 (RYR1) protein (Sun et al. 2001). With a total of 50
cysteines per subunit, only a single cysteine, Cys3635, has been identified as being Snitrosylated (Sun et al. 2003).

1.4.1 Cysteine reactivity

Although cysteine residues are not the most frequently occurring amino acids,
they are among one of the most conserved (Fomenko et al. 2008). Cysteine residues are
most notably known for their role in maintaining protein structure by forming disulfide
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bonds. However, with a nucleophilic sulfhydryl side chain and a pKa of 8.3, cysteines are
highly reactive under physiological conditions. Not only are they susceptible to
oxidation, but they can be coordinated to metals, serve as catalytic sites, or sites of
posttranslational modification. Many investigations have been aimed at predicting the
propensity of cysteines to undergo different chemical modifications (Fomenko et al.
2007). Marino et al. utilized the structures of oxidoreductases and the biophysical
properties of their catalytic cysteines to predict similarly reactive cysteine residues
(Marino et al. 2009). They developed an algorithm which took into account the primary
and secondary structures, cysteine accessibility, and reactivity. This algorithm was then
applied to a test set of proteins as well as the entire Saccharomyces cerevisiae proteome.
Their results correctly identified all thiol oxidoreductases in the test set and identified 42
proteins in the S. cerevisiae proteome, 33 of which were known oxidoreductases. This
suggests that the reactivity of cysteines to undergo a specific chemical modification can
be deciphered from its surrounding environment. This was also seen in global
investigations into disulfide bridge formation (Petersen et al. 1999). In addition,
identifying the specificity of cysteines which undergo S-glutathionylation has long been a
subject of interest (Thomas et al. 1995; Giustarini et al. 2005; Tao et al. 2004).

1.4.2 S-nitrosylation and the cysteine microenvironment
A study conducted by Marino and Gladyshev was the first comprehensive
interrogation into the specificity of S-nitrosylation (Marino & Gladyshev 2010). Using a
dataset of S-nitrosylated cysteines (and a randomly chosen set of Cys residues) curated
from the literature, the authors investigated their structural and biophysical properties in
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an attempt to uncover any attributes specific to S-nitrosylation. As was described
previously, a potential mechanism of S-nitrosylation is the autoxidation of •NO which is
favored in hydrophobic environments (Liu et al. 1998; Nedaspov et al. 2000; Moller et al.
2007); therefore, cysteines targeted for S-nitrosylation via this mechanism would likely
be present in hydrophobic regions of a protein. Hydrophobic SNO-cysteines were
observed in several proteins including the ryanodine receptor and argininosuccinate
synthetase (Hao et al. 2004; Sun et al. 2001). Using both the flanking amino acid
sequence and an 8 Angstrom radius, Kyte-Doolittle hydropathy indices were calculated
for each SNO-Cys and random Cys. Both approaches revealed no significant difference
between modified and random cysteines, suggesting that hydropathy was not a major
determinant.
Based upon an observation of SNO-Cys93β in hemoglobin, Stamler et al.
hypothesized that the presence of charged residues flanking a cysteine residue may
regulate its nucleophilicity and ultimately target it for S-nitrosylation (Stamler et al.
1997). Using these data, the authors derived a linear consensus motif of
(H,K,R)(C)(hydrophobic)X(D, E) where X can be any amino acid (Stamler et al. 1997).
Perez-Mato et al. later proposed that pairs of charged residues could also play a role in
navigating GSNO-mediated mechanisms of transnitrosation (Perez-Mato et al. 1999).
Many individual S-nitrosylated proteins have since been identified as containing either a
linear or structural acid/base motif within a 6 Å radius (Choi et al 2000; Kim et al. 2002).
Several studies have attempted proteomic investigations into the occurrence of this
acid/base motif, but were limited in their findings due to low numbers (Greco et al. 2006;
Hao et al. 2006). Marino et al. found that a more distant motif existed with surface
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exposed charged residues which were thought to help stabilize GSNO and/or facilitate
protein-protein interactions necessary for transnitrosation.
Surface exposure has also been used to evaluate the ability of cysteines to be Snitrosylated. With several proposed S-nitrosylation mechanisms, the size of the Snitrosylating or transnitrosating agent would undoubtedly influence its accessibility to
different cysteines within the protein. A high-resolution structure of tubulin illustrated
this fact when only one of the four cysteines modified endogenously was found to be
surface exposed; however, upon supplementation with GSNO, four additional cysteine
residues were modified (Nogales et al. 1999; Roychowdhury et al. 2000; Kim et al.
2004). Knipp et al. demonstrated that Cys221 of Zn(II)-free dimethylarginase-1 (DDAH1) was S-nitrosylated via gaseous •NO yet supplementation by S-nitrosohomocysteine
only modified solvent-accessible cysteine residues (Knipp et al. 2003). Marino et al.
found used a 1.2 Å probe to calculate that 35% of SNO-cysteines were buried and not
accessible to a •NO molecule.
The investigation by Marino et al. represents a great effort into the global
investigation of the specificity of S-nitrosylation. While the diversity of data initially
appears to be inconclusive for a specific mechanism, the authors themselves suggest that
this may represent that different cysteines are modified by different mechanisms. The
better experiment would be to isolate a specific population or subpopulation of Snitrosylated cysteine and characterize its attributes specific to its precise mechanism. An
additional limitation of the Marino et al. study is the use of proteins that are modified ex
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vivo and therefore represent putative targets but not necessarily the in vivo sites of Snitrosylation.

1.5 Structural implications of S-nitrosylation
1.5.1 Insights from the structures of S-nitrosylated proteins
While a host of proteins have been identified as being S-nitrosylated, a current
search of the Protein Data Bank yields only 9 structures of S-nitrosylated proteins, four of
which are related structures of similar proteins. It has been suggested that this obvious
deficit of structures is due not only to the lability of the modification (Derakshan et al.
2008) but also to the sensitivity of the S-NO bond to radiation (Scheiter et al. 2007;
Weischel et al. 2007; Rosenfeld et al. 2010). Therefore, our present understanding of the
structural consequences of S-nitrosylation is limited to these six unique/individual (nonredundant) proteins.
Not surprisingly, the first published structure of an S-nitrosylated protein was that
of human hemoglobin (SNO-HbA: PDBid 1BUW) (Chan et al. 1998). The Arnone Group
at the University of Iowa determined the X-ray crystal structure at a resolution of 1.8 Å.
Crystals of SNO-HbA were prepared by repeatedly exposing the carbonmonoxy form of
the protein to gaseous NO under anaerobic conditions over a time-course of 10 days. This
resulted in residue Cysteine-93 of both β chains being converted from cysteine to Snitrosocysteine (with nitric oxide additionally replacing the four CO ligands bound to the
heme of each tetramer). Of the 6 total cysteines contained within hemoglobin, Cys-93
was the single residue modified (Chan et al. 1998; Jia et al. 1996).
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Previous studies have shown that Cysteine-93 is more reactive than its
unmodified counterparts (Chiancone et al. 1989). Additionally, it has been well
characterized that Cys93 is more susceptible to modification (S-nitrosylation) while
hemoglobin is in its relaxed state rather than tense state. Therefore, it was originally
thought that Cys93 became more surface accessible due to conformational changes
resulting from oxygen binding. Surface accessible calculations proved, however, that the
residue remained buried and only partially exposed when comparing the oxyHbA R
structure, the carbonmonoxyHbA R2 structure, and the deoxyHbA structure (Fermi et al.
1984; Kavanaugh et al. 1992). Hydrogen exchange experiments in conjunction with a
comparison of the B-factors of high resolution hemoglobin structures revealed an
increase in mobility and local unfolding near of COOH-termini of β-subunits (Englander
et al. 1992). Because cysteine-93 is in such close proximity to the COOH-terminus, it
was deduced that this increased mobility upon ligand binding allows for transient
exposure of the residue, thereby making it susceptible/accessible to S-nitrosylation.
Comparison of the carbonmonoxyHbA and SNO-nitrosylHbA structures revealed
an obvious absence of electron density at the COOH-termini of SNO-nitrosylHbA.
Residues Tyr145β and His146β (which are present in the carbonmonoxy form of the
protein) are highly disordered and no longer visible after S-nitrosylation of Cysteine-93.
Examination of carbonmonoxyHbA reveals that Cys93β lies near the end of an α-helix
and is adjacent to Tyr145β. Upon S-nitrosylation, Cys93β clashes with the side chain of
Tyr145β, disrupting the binding pocket that it also shares with Val98β and Pro100β and
causing residues 145-146 to become disordered. While S-nitrosylation of hemoglobin
induced no obvious conformational changes in the quaternary structure of the protein,
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this study offered the first crystallographic evidence of any structural changes which may
occur as a structural consequence of S-nitrosylation.
The second structure of a S-nitrosylated protein is an isoform of Nω,Nω-dimethylL-arginine dimethylaminohydrolase (DDAH-1) which was published nearly 8 years later
(PDBid: 2CI1) (Frey, et al. 2008) [clean up]. A cysteine hydrolase, DDAH is responsible
for the in vivo metabolism of L-Nω-methylarginine (MMA) and L-Nω, Nωdimethylarginine (ADMA), two well characterized inhibitors of NOS (Ogawa et al.
1989). There are two isoforms of DDAH in mammals, DDAH-1 and DDAH-2 (Leiper et
al. 1999) which share less than 50% sequence homology. DDAH-2 is found primarily in
the heart, placenta, lung, liver, skeletal muscle, kidney, and pancreas (Leiper et al. 1999).
In addition to the liver, kidney, pancreas, and skeletal muscle at very low levels, DDAH1 is also detected in the brain (Leiper et al. 1999). Increases in DDAH-1 and neuronal
NOS expressions were found in injured neurons, underscoring the important role of
DDAH-1 in regulation of neuronal nitric oxide generation (Nakagomi et al. 1999).
It was originally discovered that DDAH-1 is inhibited when Zn(II) is coordinated
to the enzyme via two sulfur atoms belonging to cysteine residues (Fundel et al. 1996;
Bogumil et al. 1998; Knipp, et al. 2001). More recently, it has been shown that DDAH-1
is susceptible to S-nitrosylation when Zn(II) is not bound resulting in abatement of its
activity (Knipp et al. 2003). Therefore, S-nitrosylation serves as an additional regulatory
mechanism for inhibiting DDAH-1 activity. Upon incubation with the NO donor DEA
NONOate (2-N,N-diethylamino)-diazenolate-2-oxide)), Knipp et al. identified Cys221
and Cys273 (the active site cysteine) as being S-nitrosylated in bovine DDAH-1 (Knipp
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et al. 2003). At the time this study was conducted, there were no available crystal
structures of a mammalian DDAH. Therefore, a crystal structure of DDAH from the
bacterium Pseudomonas aeruginosa (PDBid: 1H70) was used to build a homology model
of DDAH-1 (Murray-Rust et al. 2001).
The homology model suggests a conservation of five (5) ββαβ-modules from
bacterial DDAH to bovine DDAH-1. However, the two structures diverge significantly
when observing the secondary structure near the opening of the active site. An N-terminal
loop closes the active site in the bacterial protein whereas a helix-turn-helix motif exists
in the homology model. The S-nitrosylated form of bovine DDAH-1 was obtained by
incubating the protein with S-nitroso-L-homocysteine before crystallization (Frey et al.
2008). Upon binding of S-nitroso-L-homocysteine, the lid of the protein which opens the
active site adopts a closed conformation. Instead of Cys221 and Cys273 which were
previously identified as being S-nitrosylated, Cysteine-83 is the only residue found to be
modified. This was thought to be an off target effect since cysteine 83 is solvent-exposed
and on the opposite end of the pore, away from the active site. Modification of cysteine83 does not appear to alter the overall structure of the protein. It is thought that the major
structural changes observed in the structure are due to substrate binding (SNO-cys) rather
than the posttranslational modification.
Human SNO-thioredoxin was first crystallized by Weischel et al. in 2007 and
then by Hashemy & Holmgren in 2008 (Weischel et al. 2007; Hashemy & Holmgren
2008). Because a comparison of the two resolved structures shows conflicting results,
SNO-thioredoxin is one of the most well-studied S-nitrosylated proteins. At a resolution
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of 1.65 Å, the structure by Weischel et al. revealed the formation of S-nitrosocysteine at
residues Cys62 and Cys69 after exogenous treatment of S-nitrosoglutathione.
Comparison of the wildtype and SNO-form revealed a 0.5 Angstrom rotation of a helix
after S-nitrosocysteine formation which is hypothesized to move out even farther to
accommodate GSNO. This same helix was found to be disordered in the S-nitrosylated
form, showing that large [dynamic] motions were taking place as was previously
hypothesized (Watson et al. 2003). An additional structure of thioredoxin was determined
in 2008 by Hashemy & Holmgren. When thioredoxin was fully reduced, Snitrosocysteine formed on Cys69 and Cys73 after treatment with S-nitrosoglutathione.
When two-disulfide bonds were formed in thioredoxin, only Cys73 was S-nitrosylated.
This showed that the redox state of the protein was important in which cysteine residues
were susceptible to S-nitrosylation.
The fourth structure of an S-nitrosylated protein was that of blackfin tuna
myoglobin (PDBid: 2NRM), (Schreiter et al. 2007). Tuna myoglobins contain a single
cysteine within an N-terminal helix. Based upon the reactivity of the single cysteine
residue in human myoglobin, it was hypothesized that tuna myoglobins might also be
susceptible to S-nitrosylation in vivo (Rayner et al 2005; Witting et al. 2001). Crystals of
SNO-Mb were obtained by reacting purified blackfin tuna myoglobin with a 10-fold
excess of S-nitrosocysteine. This led to a structure of S-nitrosomyoglobin at 1.09 Å
resolution using a rotating copper anode x-ray generator [rotating anode source]. The
authors attempted to collect structures of SNO-Mb at an even higher resolution using a
synchrotron source but found that this resulted in loss of the NO moiety. The presence of
a NO moiety near cysteine-10 was confirmed with electron density maps. Two unique
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conformations were observed which displayed different rotations around the Cα-Cβ bond
(χ1 rotamer). When compared to the reduced cysteine in the unmodified structure of
myoglobin, the first conformation (conformer A) was rotated 25° whereas the second
conformation (conformer B) displayed a χ1 rotamer of 115°. The χ3 values of both
conformers however remained near 0°.
S-nitrosylation of blackfin tuna myoglobin induced significant changes/alterations
in the positions of secondary structural elements near the site of modification.
Superimposing the unmodified (PDBid: 2NRL) and S-nitrosylated structures resulted in a
RMSD value of 1.2 Å for this particular region of the protein. To prevent steric clashes
between residues, Leucine-117 (in Loop GH) and Alanine-6 (in Helix A) were wedged
apart moved to accommodate the NO moiety. As a result, Helix H and Loop EF (which
lie next to Helix A) were also displaced. The authors demonstrated that these structural
changes were a direct consequence of S-nitrosylation. With sodium dithionite, they were
able to reduce the S-nitrosylated cysteine and observed that the structure of the protein
was identical to the unmodified form of myoglobin (“reverts to the same conformation it
had prior to S-nitrosylation”). Upon reduction of SNO-cysteine, the authors demonstrate
that the NO moiety is removed from cysteine-10 and binds to the heme of myoglobin
converting it to its ferrous nitrosyl (FE II-NO) form. When Cys10 is S-nitrosylated, a
water molecule is bound to the iron at the heme. After removal of the NO moiety, NO is
then free to react with the iron at the heme converting the protein to its ferrous nitrosyl
form (FeII – NO).
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The S-nitrosylated structure of protein-tyrosine phosphatase 1B (PTP1B) was
resolved in 2008 by Chen et al. (Chen et al. 2008). In the presence of the NO-donor
SNAP, PTP1B was crystallized and resolved at a 2.6 Angstrom resolution. Snitrosocysteine formed at Cys215 which is located in the active site of the protein.
Examination of the structure revealed a subtle conformational change in the positions of
side chains near Cys215. By comparing the reduced and S-nitrosylated forms of PTP1B,
the authors show the emergence of a hydrogen bond network which they hypothesize
might play a role in the stabilization of the structure.
The most recently resolved structure of an S-nitrosylated protein is that of
hypoxia inducible factor prolyl hydroxylase domain 2 (EGLN). After treatment with NO
donors, the structure of EGLN exhibited a positive difference density consistent with Snitrocysteine formation at Cys302; however, attempts to further refine the structure using
stereochemical restraints for an S-nitrosocysteine residue failed since the SNO group
could not be fitted within the experimental electron density. The authors concluded that
what they were not observing S-nitrosocysteine but instead a reaction intermediate of
•

NO with the thiol.
A comprehensive study conducted by Marino et al. superimposed the structures of

these same S-nitrosylated proteins with their corresponding non-nitrosylated structures
(Marino et al. 2010). Most strikingly, the authors found that charged residues within the
proteins were the most responsive to S-nitrosocysteine formation as they were the major
residues which were rearranged. Collectively, these data suggest that the protein does
make an attempt to accommodate the presence of S-nitrosocysteine in place of a reduced
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thiol. However, the ultimate assessment would be to examine only those structures which
are endogenously modified.

1.5.2 Computational tools for extracting structural information
from S-nitrosylated proteins
While the aforementioned studies may provide novel insight into the structural
consequences of S-nitrosylation, it is presumptive to draw conclusions about hundreds of
proteins based upon six different structures. Therefore, it is important to extract as much
information as possible from the wildtype structures of proteins found to be Snitrosylated.
Three-dimensional structures of proteins which have been resolved by NMR or
X-ray crystallography are made available in the RCSB Protein Data Bank (www.pdb.org)
which presently contains 76,288 structures (as of 10/04/11). In identifying S-nitrosylation
as a far-reaching posttranslational modification, SNO-proteins encompass those which
have been very well characterized as well as those which are not as well known.
Therefore, homology models are often generated for S-nitrosylated proteins without
corresponding structures.
Several interesting cases exist where additional information was gleaned by
generating homology models of S-nitrosylated proteins. In their investigations into the
role of S-nitrosylation in Alzheimer’s disease, Cho et al. generated a homology model of
dyanamin-related protein 1 (DRP-1) using the structure of bacterial dynamin-like protein
(Cho et al. 2009). The three dimensional structure of the protein revealed a spatial
consensus motif flanking S-nitrosocysteine and that the modified cysteine was highly
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surface accessible. S-nitrosylation results in the dimer formation of DRP-1, contributing
to neuronal synaptic damage or cell death. The authors hypothesize that due to the
increased presence of copper found in human AD brains, DRP-1 may be S-nitrosylated
via a metal-catalyzed mechanism. Therefore, understanding how the protein environment
plays a role in such mechanism may assist in developing DRP-1 as a potential drug
target.
Molecular dynamics (MD) simulations are another useful tool for understanding
the influence of S-nitrosocysteine formation on the remaining structure of the protein.
The motions of a protein can be monitored over time to see if there is a global or local
response to different stimuli. Han et al. conducted a molecular dynamics simulation of Snitrosylated thioredoxin in its oxidized and reduced states (Han et al. 2008). Because Snitrosocysteine is not a commonly occurring amino acid, the author had to first develop
force field parameters which could characterize the movements and constraints of SNOproteins. Comparison of thioredoxin with and without SNO-Cys-69 across MD
trajectories showed no large global motions. The RMSD of oxidized thioredoxin was
rigid when compared to the RMSD of reduced thioredoxin; however, this difference was
also observed independent of S-nitrosocysteine. This suggests that differences in
structural constraints are due instead to the redox state of the protein. While MD
simulations may not have been fruitful in the case of thioredoxin, when combined with
homology modeling, it can serve as a powerful tool for structurally interrogating the
influence of S-nitrosocysteine on any protein.
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1.6 Rationale and Objectives
S-nitrosylation proves to be an exhaustive body of work which only seems to
increase as time goes on. With the advances in technology over the past 10 years, Snitrosylated proteins modified in vivo are being identified on a much more consistent
basis. They have been found to play a role in biological and cellular processes already
thought to be very well characterized, sometimes involving proteins which are much less
characterized.
However, as more information emerges regarding S-nitrosylation, there are still
several large gaps in our knowledge which prevent us from better understanding Snitrosylation. Firstly, we want to understand why certain cysteines are targeted for Snitrosylation and not others. Identifying the specificity of S-nitrosylation will help us to
better regulate the activity of S-nitrosylation. This mandates that we need to identify Snitrosylated cysteines and their unmodified counterparts in vivo. Chapter 2 describes a
novel method which allows for the global identification of S-nitrosylated cysteines within
the mouse liver. This large dataset also provides a control comparison of SNO-cysteines
to their unmodified counterparts allowing for a side-by-side comparison of reactive vs.
non-reactive cysteines.
Once •NO is produced, it is important to understand the mechanism by which Snitrosylated proteins are formed. As was previously described, several hypotheses exist
regarding how SNO-proteins are formed. Therefore, being able to identify which
mechanism is responsible for modifying which cysteines will provide us with a greater
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understanding of how to regulate this process. To this end, Chapter 3 describes a novel
proposed mechanism of GSNO-mediated transnitrosation.
Lastly, I explored the proposition that S-nitrosocysteine formation alters the
structure of a protein. While hundreds of proteins have been identified as being modified,
very few structures of S-nitrosylated proteins exist which offer a structural explanation of
the observed alteration in protein functionality. Chapter 4 describes a comprehensive
study beginning with the identification of an S-nitrosylated protein directly involved in
the beta oxidation of fatty acids and attempts to unravel the structural consequences of Snitrosylation in relation to its observed alterations in protein activity.
This body of work illustrates how the development of a global technique has
allowed for the generation of several testable hypotheses. Chapter 5 concludes with a
discussion regarding the implications of the results described in the preceding chapters as
well as a comprehensive analysis of future works in the field of S-nitrosylation.
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2.1

Abstract
S-nitrosylation, the selective posttranslational modification of protein cysteine

residues to form S-nitrosocysteine, is one of the molecular mechanisms by which nitric
oxide influences diverse biological functions. In this study, unique MS-based proteomic
approaches precisely pinpointed the site of S-nitrosylation in 328 peptides in 192 proteins
endogenously modified in WT mouse liver. Structural analyses revealed that Snitrosylated cysteine residues were equally distributed in hydrophobic and hydrophilic
areas of proteins with an average predicted pKa of 10.01±2.1. S-nitrosylation sites were
over-represented in α-helices and under-represented in coils as compared with
unmodified cysteine residues in the same proteins (χ2 test, P < 0.02). A quantile–quantile
probability plot indicated that the distribution of S-nitrosocysteine residues was skewed
toward larger surface accessible areas compared with the unmodified cysteine residues in
the same proteins. Seventy percent of the S-nitrosylated cysteine residues were
surrounded by negatively or positively charged amino acids within a 6-Å distance. The
location of cysteine residues in α-helices and coils in highly accessible surfaces bordered
by charged amino acids implies site directed S-nitrosylation mediated by protein–protein
or small molecule interactions. Moreover, 13 modified cysteine residues were
coordinated with metals and 15 metalloproteins were endogenously modified supporting
metal-catalyzed

S-nitrosylation

mechanisms.

Collectively,

the

endogenous

S-

nitrosoproteome in the liver has structural features that accommodate multiple
mechanisms for selective site-directed S-nitrosylation.
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2.2

Introduction
Cysteine S-nitrosylation is a post-translational modification that results from the

formal transfer of nitrosonium from a nitrosating agent to a reduced cysteine (Snitrosation) and is a mechanism by which nitric oxide can regulate important biological
processes within a variety of organs and cellular systems (Hess et al. 2005; Whalen et al.
2007; Hara et al. 2005; Cho et al. 2009; Rizzo et al. 2003; Guo et al. 2008). Data
gathered from individual proteins have collectively indicated that this reversible and
apparently

selective

post-translational

modification

regulates

protein

activity,

localization, and stability (Hara et al. 2005; Cho et al. 2009; Rizzo et al. 2003). Despite
the considerable biological importance of this post-translational modification significant
gaps exist regarding its in vivo specificity and origin. The identification of in vivo Snitrosylated proteins has indicated that not all reduced cysteine residues, and not all
proteins with reduced cysteine residues, are modified implying a biased selection.
Several biological chemistries have been proposed to account for the S-nitrosylation of
proteins in vivo (Hess et al. 2005; Bosworth et al. 2009; Zhang et al. 2005). Broadly these
include: i) oxidative nitrosation by higher oxides of nitric oxide, ii) trans-nitrosation by
either small molecular weight nitric oxide carriers such as S-nitrosoglutathione or
dinitrosyliron complexes, iii) catalysis by metalloproteins and iv) protein-assisted
transnitrosation as elegantly documented for the S-nitrosylation of caspase-3 by Snitrosothioredoxin (Mitchell et al. 2005; Benhar et al. 2008). With the exception of the
protein-assisted trans-nitrosylation and metalloprotein catalyzed S-nitrosylation, which
we presume necessitates protein-protein interaction, the other proposed mechanisms are
rather non-discriminatory unless the microenvironment of selective cysteine residues in
proteins can specifically accommodate these chemical modifications.

Therefore

structural interrogation of endogenous S-nitrosylated proteins with site specific
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identification of the modified cysteine residues could provide valuable insights to
appreciate the biological selectivity of this post-translational modification. Attempts to
investigate this very important biological question have not been possible largely because
of the deficit of datasets of in vivo modified proteins (Marino et al. 2010). Previous
structural analyses have been attempted using limited data sets or by including all sites of
modification identified after exposing tissues or cells to S-nitrosylating agents (Marino et
al. 2010).

However, as the authors of these articles have indicated these sites of

modification represent putative sites but not necessarily those modified in vivo (Marino et
al. 2010). We employed organomercury reagents that react directly, efficiently and
specifically with S-nitrosocysteine and thus enable the precise identification of Snitrosocysteine containing peptides and independently S-nitrosylated proteins to assemble
the in vivo S-nitrosocysteine proteome of the mouse liver. Using bioinformatic tools we
then interrogated this enriched endogenous S-nitrosocysteine proteome to define the
biochemical, biophysical and structural environment of the cysteine residues modified by
S-nitrosylation, elements that might inform on how specificity of S-nitrosylation is
achieved.
2.3

Materials and Methods

Chemicals and Reagents. All HPLC solvents were purchased from Burdick and Jackson,
and unless stated all other reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Mercury/PEG/biotin compound was designed by us and synthesized by SoluLink (San
Diego, CA). Mercury resin was synthesized as described in Supplementary Methods.
Mouse monoclonal antibodies against Hsp70 and GAPDH were purchased from
Stressgen (Ann Arbor, MI) and Abcam (Cambridge, MA) respectively. Rabbit polyclonal
antibody against very long chain specific acyl-CoA dehydrogenase (VLCADH) was
obtained from Santa Cruz (Santa Cruz, CA).
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Isolation and preparation of mouse liver protein homogenates for capture of Snitrosylated proteins. All mouse studies were reviewed and approved by the Institutional
Animal Care and Use Committee of the Children’s Hospital of Philadelphia Research
Institute. Wild type or Nos3tm1Unc (eNOS-/-) C57BL/6J adult mice were obtained from
Jackson Laboratories (Bar Harbor, ME). Mice were anesthetized by CO2 and perfused
through the left ventricle. Intact livers were collected, immediately frozen in liquid
nitrogen and stored at -80 °C until use. Liver tissues were homogenized in preparation for
proteomic analysis as described in Supplementary Methods online.
Capture of S-nitrosylated proteins using organomercury resin (MRC). MRC solid-phase
capture columns were prepared and activated as described in Supplementary Methods.
Protein homogenates were loaded onto activated MRC columns, and incubated under
stationary conditions for 1h at RT. Next, the columns were extensively washed followed
by elution of the bound proteins under reducing conditions. Samples were concentrated
500-fold and analyzed by GeLC-MS/MS analysis as described below and in the
Supplementary Methods.
Labeling and affinity capture of S-nitrosylated proteins using organomercurypolyethyleneglycol-biotin (mPEGb). Livers lysates were prepared and then captured by
mPEGb compound as described in the Supplementary Methods. After capture,
biotinylated proteins were precipitated with 3 volumes of acetone and protein
concentration was determined by the BCA assay. Equal protein amounts were incubated
with washed neutravidin-agarose beads for 2h at RT with gentle rocking. The supernatant
was discarded and the beads were extensively washed. Bound proteins were then eluted
under reducing conditions for 20 min at RT under gentle rocking. Samples were
concentrated 25-fold and analyzed by gel electrophoresis liquid chromatography-mass
spectrometry analysis as described below and in the Supplementary Methods.
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Protein digestion and neutravidin affinity peptide capture. For neutravidin affinity
capture of biotinylated peptides, S-nitrosylated proteins were labeled with mPEGb,
precipitated and resuspended into ammonium bicarbonate containing 0.1 % SDS. Equal
amounts of proteins were transferred to Ultra-free MC 10kDa cut-off filters (rinsed with
methanol and washed with water) and incubated with trypsin (1:100 enzyme:protein
ratio) in the dark for 16h at 37 oC.

Biotinylated peptides were recovered by

centrifugation of the filters and incubated with neutravidin beads for 2 hours at RT with
gentle rocking. Beads were then extensively washed and peptides were released by
reduction of the mercury-thiol bond with 3 % performic acid. Eluted peptides were
reduced in volume by Speedvac to < 5 ul and resuspended in 10 ul of 0.1% formic acid.
A volume of 5 ul was analyzed by LC-MS/MS. A detailed protocol is available in the
Supplementary Methods.
GeLC-MS/MS analysis. The protein fractions obtained from MRC and mPEGb protein
capture methods were analyzed by GeLC-MS/MS as described in the Supplementary
Methods online. Peptides obtained from mPEGb peptide capture method were analyzed
by LC-MS/MS directly as described in the Supplementary Methods.
Generation and evaluation of SEQUEST peptide assignments. A detailed protocol for the
generation and evaluation of SEQUEST peptide assignments is available in
Supplementary Methods. See Supplementary Figure 2.2 for an overview of the criteria
for SEQUEST peptide assignment evaluation.
Denitrosylation assays. Denitrosylation assay was performed by exposing liver lysates to
150 nM Trx, 150 nM Trx reductase and 100 mM NADPH for 30 min at 37 oC. Proteins
were processed by both MRC and mPEGb protein capture methods, followed by GeLCMS/MS analysis.
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Gene ontology and functional protein analysis. Subcellular localization was determined
by either existing UniProt (www.uniprot.org) annotation, while gene ontology
classification and analysis was performed by UniProt and FatiGO (www.fatigo.org).
Protein sequence and structural analysis. The unprocessed protein precursors obtained
from UniProt (www.uniprot.org) were used for all sequence analyses (see accession
numbers in Supplementary Table 2.1). Prediction of consensus S-nitrosylation sequence
motifs was examined by motif-x, a linear sequence prediction algorithm). Kyte-Doolittle
hydropathy plots were generated for each protein using a window of 13 with hydropathy
values greater than zero considered hydrophobic. Three-dimensional protein structures
were obtained from the Protein Data Bank (PDB, requiring greater than 50 % homology
and conservation of the modified cysteine residue. The predicted pKa’s for ionizable
cysteine residues were calculated using PROPKA 2.0, while relative residue surface
accessibility

was

calculated

by

Naccess

2.1.1

(http://www.bioinf.manchester.ac.uk/naccess/).
Statistical analyses. Graphs were constructed and statistical analyses were performed
using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA).

Statistical

significance was determined by either paired or unpaired non-parametric two-tailed ttests using either the Mann-Whitney (unpaired) or Wilcoxon matched pairs test.

2.4

Results and Discussion

Complementary MS-Based Proteomics Identify the Endogenous Liver SNitrosocysteine Proteome
The reaction of phenylmercury compounds with S-nitrosocysteine results in the
formation of a relatively stable thiol–mercury bond (Saville et al. 1958). Therefore, we
used an organomercury resin (MRC) synthesized by conjugation of ρ-amino-
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phenylmercuric acetate to N-hydroxysuccinimide–activated Affi-Gel 10 agarose beads
and a phenylmercury-polyethyleneglycol-biotin (mPEGb) compound to capture Snitrosylated proteins and peptides (Fig.S2.1). The method consists of three steps: (i)
blocking of reduced cysteine residues with methyl methanethiosulfonate (MMTS), (ii)
capture and release of S-nitrosylated proteins or peptides, and (iii) liquid
chromatography/tandem MS analysis. β-Mercaptoethanol or performic acid was used to
release captured proteins or peptides, respectively. Mild performic acid was used to
selectively and quantitatively release the bound peptides and more importantly oxidize
cysteine thiols to sulfonic acid, thereby creating a unique MS signature that permits sitespecific identification of the modified cysteine residues (Pesavento et al. 2007). Under
the workflow used (Fig. S2.1), 100% of cysteine-containing peptides were detected with
the sulfonic acid modification.
To further explore this possibility we used the Trx ex vivo denitrosylation assay
(Paige et al. 2008) to identify sites of S-nitrosylation that can interact with Trx. Freshly
isolated liver homogenates were treated with a Trx system (Trx/Trx-reductase/NADPH).
This treatment resulted in a 72% reduction in protein S-nitrosocysteine levels as
quantified by chemiluminescence. In comparison with the untreated liver Snitrosoproteome (Table S2.1), 72 proteins were no longer identified after Trx treatment
(Table S2.4). Linear motif analysis revealed two motifs in this subset of S-nitrosylated
proteins. The highest-scoring motif had exclusively aspartic acid at position −1, whereas
the second motif had exclusively threonine at position +5 (Fig. 2.3E). Notably, both
motifs contained charged amino acids at positions before and after the cysteine residue,
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consistent with the idea that charged amino acids in S-nitrosocysteine–containing motifs
may facilitate interaction with Trx.
To control for the inclusion of false-positive protein S-nitrosocysteine that may
result from incomplete blocking of reduced cysteine residues or nonspecific interactions
with the resins
during enrichment, pretreatment with UV, DTT, and copper ascorbate (Cu-Asc)
reduction or reaction with mercury chloride were used to displace NO before the reaction
with the phenylmercury compounds (Fig. 2.1A and Fig. S2.2A). For these experiments,
we used mouse liver homogenates with 50 ± 10 pmol protein S-nitrosocysteine per
milligram of protein as quantified by reductive chemistries coupled to ozone-based
chemiluminescence. Displacement of NO from S-nitrosocysteine residues by
pretreatment with UV, DTT, Cu-Asc, or mercury chloride decreased protein Snitrosocysteine levels by greater than 99% as quantified by chemiluminescence (n = 3)
and also eliminated reaction with the phenylmercury compounds (Fig. 2.1A and Fig.
S2.2A). On average, only 3% of peptides (Fig. 2.1B) and 5% of proteins (Fig. S2.2B)
were identified as false positives (present in untreated and UV-pretreated samples),
demonstrating that the method maintains high specificity at each step. This false positive
rate compares favorably with the greater than 90% specificity reported for immobilized
metal affinity
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Figure 2.1: Site-specific identification and UV photolysis confirmation of Snitrosocysteine. (A) Representative short (approximately 2 cm) colloidal blue-stained
protein gel of mPEGb protein capture from WT mouse liver that was processed by
GeLC-MS/MS analysis. Colloidal blue protein staining of bound fractions from mPEGb
protein capture of untreated liver homogenates showed protein enrichment. Pretreatment
with UV (for 30 min), DTT (10 mM), Cu-Asc (5 mM Asc/copper 0.1 mM), or HgCl2 (20
mM) prevented this capture, demonstrating specificity for protein S-nitrosocysteine. (B)
Representative base peak chromatograms from mPEGb peptide capture demonstrates
reduction in ion intensity after UV treatment (red) compared with the untreated sample
(black). For clarity, the chromatogram corresponding to UV treatment was plotted with a
y-axis offset of 1E4. Inset: Average false-positive identification rate (FIR ± SD) from
mPEGb and MRC represented the percentage of peptides that were identified in both the
UV-treated and untreated samples across three independent biological replicates. Also
reported is the percent of noncysteinyl peptides identified (Supplemental Materials and
Methods). (C) Representative MS spectra of doubly charged sulfonic acid-containing
tryptic peptides, YLLGTSLARPC97IAR (monoisotopic m/z, 791.4256; Top, Left) and
FELTC132YSLAPQIK (monoisotopic m/z, 780.8851; Bottom, Left), from
argininosuccinate synthase. MS/MS spectra confirmed the sequence and site of sulfonic
acid-containing peptides (C+48) from argininosuccinate synthase identified in mouse
liver (Supplemental Materials and Methods). MS/MS spectra passed automatic and
manual filter criteria (Fig. S2), and were identified with high SEQUEST cross correlation
(Xc) scores at ppm mass error. Cys132 has been previously reported as a target of Snitrosylation in human argininosuccinate synthase (20), whereas the identification of
Cys97 corresponded to a previously unidentified site of S-nitrosocysteine formation. (D)
Colloidal blue protein staining of bound fractions from MRC and mPEGb enrichment of
S-nitrosylated proteins from WT and eNOS−/− mouse livers. UV photolysis
demonstrated specificity of the enrichment. The levels of protein S-nitrosocysteine were
quantified by reductive chemistries coupled to chemiluminescent based detection (41).
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The amount of S-nitrosylated protein captured by mPEGb from eNOS−/− livers (lane 8)
was below the limit of detection by colloidal blue staining. (E) Western blot analysis of
bound and unbound fractions from WT mouse liver that were processed by MRC protein
capture.

chromatography used for the enrichment of phosphopeptides from mouse liver (Villén et
al. 2008). Therefore, pretreatment with UV served as negative control throughout based
on previous studies that documented the elimination of S-nitrosocysteine without
affecting other cysteine modifications (Forrester et al. 2007; Derakhshan et al. 2007).
Collectively, these experiments showed that the reaction of protein S-nitrosocysteine with
the phenylmercury compounds is specific and efficient and achieved selective
identification of the modified residue, the ultimate qualifier for the unambiguous
assignment of S-nitrosylated proteins through the inclusion of negative controls.
The ability of the method to reveal endogenous S-nitrosoproteomes was assessed
in WT mouse liver homogenates. Initially, three different mouse livers were analyzed
independently for protein and peptide capture by using both the MRC and mPEGb
approach with 3 mg of starting material. From the three biological replicates, sulfonic
acid-containing peptides identified by SEQUEST database searches were pooled and
those also present in the UV-pretreated samples were removed. Similarly, all proteins
identified by protein capture were pooled (those also identified in the UV-pretreated
samples were removed). The use of solid-phase and in-solution–based enrichment
approaches was largely complementary, as the number of shared protein identifications
between protein capture methods was approximately 50%, whereas each method
individually contributed about the same number of unique protein identifications (Table
S2.1). As the MRC capture method allows for higher input, site-specific peptide capture
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by this method was also performed with the use of 30 mg of liver extract originating from
three different mice. The inclusion of these additional biological replicates reduced
biological variance and improved the depth of the analysis while maintaining less than
3% false identification rate. Overall by matching sulfonic acid containing peptides with
corresponding protein identifications, we precisely pinpointed 328 S-nitrosocysteine–
containing peptides in 192 proteins in untreated livers with a high level of confidence
(complete list is provided in Table S2.1 and all of the MS/MS spectra from peptide
capture can be viewed at http://www.research.chop.edu/tools/msms/spectra.pdf). The
depth of this analysis represents a significant advancement versus present methodologies
(Paige et al. 2008). The majority of the proteins identified in the current study, 186,
corresponded to previously unidentified endogenous targets of S-nitrosylation in the
mouse liver, whereas six proteins (GAPDH, hemoglobin, β-tubulin, argininosuccinate
synthase, alcohol dehydrogenase, and catalase) have been previously identified as
endogenously S-nitrosylated in hepatocytes and other organ systems (Jaffrey et al. 2001;
Hao et al. 2006; Hao et al. 2004; López-Sánchez et al. 2008). Proteins were also
distributed across a wide range of molecular weights (13–272 kDa) and cellular
localization including membrane-associated proteins, demonstrating the efficacy of the
method to identify S-nitrosocysteine independent of protein size and location. We
selected very long chain specific acyl-CoA dehydrogenase, heat shock cognate 71
protein, for which endogenous S-nitrosylation was not previously described, and
GAPDH, which has been known to be S-nitrosylated and independently confirmed their
selective enrichment by Western blot analysis after protein capture (Fig. 2.1E).
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To further probe the biological specificity of our method while demonstrating its
utility for comparison of endogenous S-nitrosoproteomes, we analyzed livers from mice
lacking

endothelial

NO

synthase

(eNOS−/−).

Using

chemiluminescence-based

quantification, a 10-fold decrease in protein S-nitrosocysteine levels of eNOS−/− livers
was measured as compared with WT livers. Concomitantly, a reduced reactivity with
phenylmercury compounds was observed (Fig. 2.1D). From the eNOS−/− livers, 36
sulfonic acid-containing peptides in 26 proteins were identified (Supplemental Table 2.2),
of which 24 were also identified in the WT liver. The data indicate that the majority of
the endogenous liver S-nitrosoproteome is dependent on eNOS-generated NO.
S-Nitrosylation Is Implicated in Multiple Metabolic Pathways
Proteomic experiments generate rich, diverse datasets that benefit from
computational analysis to extract biologically relevant and potentially novel information.
Consequently, functional and ontological analyses were conducted to assist in identifying
cellular, molecular, and biological functions in which S-nitrosylation may play a role in
the liver. Sixty-five percent of S-nitrosylated proteins were localized to the cytoplasm
and mitochondrion, representing a significant enrichment compared with the mouse
genome (P=4.9e−34 and P=7.2e−22, respectively; Figure S2.3A). A subset of Snitrosylated proteins were found to be present in cell membranes, whereas the remaining
proteins were distributed across nearly all cellular compartments (Figure S2.3A). Gene
ontology analysis revealed that 99 S-nitrosylated proteins had catalytic activity largely
composed of oxidoreductases (39%) and transferases (17%; Fig. S2.3B). These functions
were also found to be significantly overrepresented (P=1.28e−20 and 3.2e−3,
respectively) in the liver S-nitrosoproteome compared with the mouse genome (Al-
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Shahrour et al. 2004). This is not surprising, as the molecular functions of S-nitrosylated
proteins were assigned to diverse metabolic processes (i.e., amino acid synthesis, energy
synthesis, lipid metabolism) that take place within the liver. Analysis of the data has also
confirmed the presence of multiple S-nitrosylated cysteine residues in nearly 45% (86 of
192) of the liver S-nitrosoproteome. Poly-S-nitrosylation is present in all top-ranking
molecular functions, suggesting that multiple sites of S-nitrosylation in vivo may regulate
protein activity. This is in accordance with other known posttranslational modifications
such as phosphorylation and lysine acetylation in which poly-phosphorylation and polyacetylation are considered regulators of protein function and signaling (Olsen et al. 2006;
Choudhary et al. 2009). To place these functional assignments into the context of
biochemical and molecular signaling pathways, S-nitrosylated proteins were assembled
into biological protein interaction and signaling networks (Ingenuity Systems). The
analysis was restricted to investigate liver-related pathways. Sixteen S-nitrosylated
proteins were significantly clustered in a network that encompassed liver responses to the
hormone leptin (Fig. S2.3C). Leptin is an adipocyte-secreted hormone that primarily acts
on the central nervous system to regulate energy homeostasis. Leptin also regulates liver
metabolism, evident by the significant accumulation of lipids (fatty liver) in mice
deficient in leptin (ob/ob) (Halaas et al. 2005; Pelleymounter et al. 1995) or leptin longform receptor (db/db) (Mohan et al. 2008). The regulation of liver metabolism is
attributed to the leptin-dependent repression of liver stearoyl-CoA desaturase-1, the rate
limiting step in monosaturated fat biosynthesis (Cohen et al. 2004). In addition, recent
data indicate that leptin also regulates liver mitochondrial respiratory chain protein
expression, mitochondrial function and structure (Singh et al. 2009), remarkably similar
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to the previously recognized regulation of mitochondrial function by NO (Brown et al.
1994; Nisoli et al. 2004). Interestingly, delivery of S-nitroso-N-acetylcysteine by gavage
to ob/ob mice prevented the development of fatty liver (de Oliveira et al. 2008). Mice
deficient in eNOS also experience abnormal fat deposition in the liver (Schild et al.
2008), which was attributed in part to regulation of mitochondrial fatty acid synthesis and
activation of AMP-activated protein kinase (Schild et al. 2008). Moreover, 14 of the 16
proteins in the leptin network (Fig. S2.3C) were absent in eNOS−/− liver Snitrosocysteine proteome analysis, suggesting a potential relationship between eNOSderived S-nitrosylation and leptin regulation of fatty acid metabolism. Although it
requires further experimentation, the data indicate that S-nitrosylation may be a
molecular link between the actions of leptin and NO in liver fatty acid biosynthesis and
mitochondrial metabolism. Overall, cellular localization and functional analyses revealed
that the S-nitrosylated proteins identified in the liver were largely cytosolic and
mitochondrial enzymes that function as oxidoreductases and transferases, which are
critical for regulating amino acid, energy, and lipid biosynthesis, and may coordinate the
regulation of metabolic pathways by leptin and NO.

Biochemical, Biophysical, and Structural Properties of the Modified Cysteine
Residues
This enriched S-nitrosoproteome was interrogated for the structural properties of
the modified cysteine residues by using various bioinformatic tools and available crystal
structures of proteins. Table 2.1 provides the basic biochemical and biophysical
properties of the modified cysteine residues using reduced unmodified cysteine residues
in the same proteins as a comparison group. Kyte-Doolittle hydropathy indices in 13-
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residue windows were calculated to determine the influence of primary structure of the
protein on modified cysteine residues (Figure 2.2A).The average hydropathy index value
was calculated to be −0.03 ± 0.69 (n=309) which did not differ significantly when
compared with the mean value of the unmodified cysteines within the same proteins (0.10
± 0.77, n = 1,382). Using crystal structures (Protein Data Bank) and the Propka 2.0
algorithm (Li et al. 2005), the average predicted pKa of 142 cysteine residues Snitrosylated in vivo was 10.0, which was not significantly different from the average pKa
of reduced unmodified cysteine residues in the same proteins (pKa of 9.88). Only 15
modified cysteine residues had predicted pKa values lower than 7.4 (5.66 ± 1.24),
indicating that these particular residues may be deprotonated at physiological pH (Figure
2.2B). Secondary structure analysis revealed that S-nitrosocysteine residues were present
in β-sheets (28%), helices (40%), and coils (32%). Unmodified cysteine residues within
the same proteins were localized primarily

Table 2.1: Biochemical and biophysical properties of S-nitrosylated and unmodified
cysteine residues within the same proteins
Variable

S-nitrosocysteine
residues

Hydropathy Index

0.03 ± 0.69 (n=309)

Unmodified cysteine
residues
0.1 ± 0.77 (n=382)

Predicted pKa

10.0 ± 2.10 (n=142)

Helices, %

40*

29

β-sheets, %

28

32

Coils, %

32#

39

RSA^

71% buried (n=99)

9.88 ± 2.20 (n=559)

77% buried (n=561)
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29% exposed (n=40)

23% exposed (n=171)

*P < 0.02, #P < 0.01 using unmodified residues as control group.
^Residue surface accessibility (RSA) for cysteine residues was calculated by the accessible surface area
normalized
by the accessible surface area of cysteine in the extended tripeptide Ala-Cys-Ala. A value of ≤10% was
used as
cutoff to denote a buried cysteine.

in coils (39%) and equally distributed across helices and β-sheets (Table 2.1). Statistical
analysis revealed an overrepresentation and underrepresentation of modified cysteines in
helices and coils, respectively (P < 0.02). None of the cysteine residues found to be Snitrosylated participate in disulfide bonding in their known structures and none has been
reported

to

date

to

be

modified

by glutathiolation

and

alkylating

agents

(www.uniprot.org). Furthermore, by using predictive algorithms and literature searches, it
was found that less than 20% of the cysteine residues were predicted to be sites of
oxidation (Sanchez et al. 2008). These data and analysis indicate that the majority of the
in vivo sites of S-nitrosylation represent a unique population of cysteine residues not
chemically modified through other biological processes.

S-Nitrosocysteine Residues Are Equally Distributed in Hydrophobic and
Hydrophilic Areas of the Proteins
The overall slightly negative hydropathy index (Table 2.1) is not indicative of a
trend for S-nitrosylated cysteine residues to localize in hydrophilic regions of the protein.
Further inspection of the hydropathy indices of modified cysteine residues revealed that
139 of the 309 cysteine residues reside nearly in hydrophobic regions, whereas 170 of the
309 are located in hydrophilic regions. This observation led us to further examine
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whether S-nitrosylated cysteines belong to two distinct populations regarding their
hydrophobicity/hydrophilicity. Kernel density estimation revealed that hydropathy
indices exhibited a roughly normal distribution (Figure 2.2A, Left), indicating that they
corresponded to a single population of cysteine residues. Unmodified cysteine residues
within the same proteins also showed a roughly normal distribution as well (Figure 2.2A,
Right), indicating that there is no distinction between S-nitrosylated and unmodified
cysteine residues within the same proteins to localize in hydrophobic or hydrophilic areas
of proteins. Previous studies have indicated that S-nitrosylation is favored in hydrophobic
regions of the proteins (Nedospasov et al. 2000), presumably because of the increased
localized concentration of NO-derived oxides, which may provide a suitable
microenvironment for the S-nitrosylation of these cysteine residues. The present data
imply that, for a subset of proteins, hydrophobicity may serve as a determinant for
selective targeting of cysteine residues for S-nitrosylation.
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Figure 2.2: Hydropathy index and pKa values of S-nitrosylated residues. (A) Kernel
density plot of hydropathy indices for S-nitrosocysteine (Left) and unmodified cysteine
residues (Right). Hydropathy index was calculated for all S-nitrosylated (n = 170
hydrophilic, n = 139 hydrophobic) and unmodified (n = 635 hydrophilic, n = 747
hydrophobic) cysteine residues within a 13 amino acid window, with a negative value
indicating hydrophilicity. (B) Predicted pKa value for each S-nitrosylated cysteine was
calculated from the experimental structures and the distribution was represented as a
histogram.

S-Nitrosylation Occurs on Cysteine Residues Adjacent to Flexible Regions Within
the Protein
To further explore the location of S-nitrosylated cysteine residues in protein
secondary structure, the frequency of secondary structures for flanking residues
(positions −10 to +10) was calculated and compared with the respective frequencies of
the unmodified cysteine residues using the χ2 test. A shift in secondary structure mainly
from coils to helices was observed over the range of positions from −6 to 0 (P < 0.05),
consistent with the presence of the majority of S-nitrosocysteine residues in α-helices
(Figure 2.3A). Moreover, a 10% increase in the frequency of coils from positions 0 to +3
(P < 0.001) concomitant with a reduction in β-sheet frequency (P < 0.001) indicative of a
change in secondary structure was observed C-terminal from the modified cysteine
residues. Unmodified cysteine residues within the same proteins were localized primarily
in coils and with lower frequency in β-sheets and helices (Fig. S2.4A). Moreover, the
frequency of coils did not change significantly across all flanking residues (−10 to +10),
indicating that shifts in secondary structure were only between helices and β-sheets.
Collectively, these data demonstrate that modified cysteine residues are predominantly
present in secondary structures of proteins which may facilitate site-directed Snitrosylation by protein-protein interactions.
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Surface Accessibility of S-Nitrosocysteine Residues
The relative residue surface accessibility (RSA) for all cysteines (modified and
unmodified) within the S-nitrosoproteome was calculated with Naccess 2.1.1 using the
radius of a water molecule (1.4 Å2) as a probe (Lee et al. 1971). Ninety-nine Snitrosylated residues (71%) were calculated with an RSA of 10% or lower, indicating that
those residues were not accessible to the solvent, whereas the remaining 40 modified
cysteines (29%) had a relative RSA greater than 10%, meaning they were solventaccessible. Unmodified cysteines within the same proteins exhibited similar distribution
between buried (77%) and solvent-accessible residues (23%). A quantile–quantile
probability plot was used to determine if there was enrichment for exposed or buried
cysteines within the modified versus the un-modified group of cysteine residues (Figure
2.3C). To produce this plot, the RSA values of modified and unmodified cysteine
residues were sorted and values of RSA for each percentile were plotted against each
other (i.e., RSA of smallest 1% of modified cysteine residues vs. RSA of smallest 1% of
unmodified cysteine residues, smallest 2% vs. smallest 2%). The plot demonstrates that
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Figure 2.3: Analysis of primary sequence, distribution in secondary structures, and
surface accessibility of S-nitrosylated cysteine residues. (A) The frequency of Snitrosocysteine (n = 142; black bars) and unmodified cysteine residues (n = 473; white
bars) within the same proteins in different secondary structures was calculated using the
available crystal structures. (B) Distribution of residues flanking S-nitrosylated cysteines
in secondary structures. SNO-cysteines are located at position 0 and the frequency for 10
residues upstream (−10) and 10 residues downstream (+10) was calculated as described
earlier. (C) Quantile–quantile plot of relative RSA for S-nitrosylated (x axis) versus
unmodified (y axis) cysteine residues. RSA values were calculated from the biological
assemblies defined by PISA (42) for available crystal structures. (D) Top three scoring
sequence motifs for residues flanking S-nitrosylated cysteine residue. Note the presence
of charged as well as aliphatic amino acids able to “accommodate” protein and smallmolecule binding. (E) Top two sequence motifs assigned to the residues sensitive to Trx
system.

S-nitrosocysteine residues have a distribution skewed toward larger surface-accessible
areas than unmodified cysteine residues within the same proteins. In addition, 70% of Snitrosylated cysteine residues within 6 Å were surrounded by negatively or positively
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charged amino acids that had their side chains pointed away from cysteine thiol groups.
Although the presence of charged residues in the vicinity of the modified residues did not
impact their predicted pKa, it may facilitate site specific modification by accommodating
protein or S-nitrosoglutathione association. This is in agreement with findings of Mitchell
et al., who demonstrated that charged residues near cysteine 73 were required for
interaction and transnitrosylation of procaspase-3 (Mitchell et al. 2007). Accordingly, the
presence of cysteine residues in highly exposed areas of proteins and in proximity to
charged amino acids suggests a protein or small molecule transnitrosation assisted
mechanism of S-nitrosylation.

Metal Catalyzed S-Nitrosylation
Studies exploring the S-nitrosylation of proteins in cells indicated that more than
50% of the cellular formation of protein S-nitrosocysteine is derived by dinitrosyliron
complexes (Bosworth et al. 2009). Within the liver S-nitrosoproteome, 13 S-nitrosylated
cysteine residues, which are directly involved in the chelation of metal ions, were
identified (Table S2.3). Metal ligation may provide site-directed modification of these
residues. Alternatively, dinitrosyliron complexes could be stabilized near cysteine
residues by interactions with neighboring acidic residues. As stated, more than 70% of
the modified cysteine residues are in close proximity (<6 Å) to acidic residues, which
could serve as interacting sites for dinitrosyliron complexes. Moreover, 15
metalloproteins were identified as endogenously S-nitrosylated, suggesting a selfcatalyzed mechanism of S-nitrosylation similar to the proposed mechanism for the
selective S-nitrosylation of hemoglobin (Weichsel et al. 2005). The possibility also exists
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that these metalloproteins can catalyze S-nitrosylation of interacting proteins, as has been
indicated previously (Weichsel et al. 2005). This will require protein–protein association
and, as discussed later, the majority of the S-nitrosylated proteins, either in primary
sequence or within the tertiary structure, contain charged amino acids that can provide
interactive interfaces for specific transfer of a NO equivalent from a metalloprotein to
cysteine residues.

Linear Motifs
To further interrogate structural elements that may distinguish modified cysteines
from unmodified within the same proteins, flanking amino acids were examined for the
presence of linear motifs using the program Motif-X (Schwartz et al. 2005). The top
scoring motif for modified cysteines (n = 37, 12%) had glycine exclusively at position −1
(P ≤ 0.001) and consisted mostly of hydrophobic residues (Figure 2.3D). Remarkably, the
second (n = 31, 10%) and third (n=25, 8%) top scoring motifs had negatively charged
amino acids exclusively at positions +3 and −1, respectively (P ≤ 0.001; Figure 2.3D).
The same analysis for unmodified cysteines within the same proteins revealed top
sequence motifs lacking negatively charged amino acids flanking cysteine residues (Fig.
S2.4B), indicating that specific elements of the primary structure are required for a
cysteine to be S-nitrosylated in vivo. These motifs could serve as scaffolds for protein
and small molecule binding such as thioredoxin (Trx) or S-nitrosoglutathione. To further
explore this possibility we used the Trx ex vivo denitrosylation assay (Paige et al. 2008)
to identify sites of S-nitrosylation that can interact with Trx. Freshly isolated liver
homogenates were treated with a Trx system (Trx/Trx-reductase/NADPH). This
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treatment resulted in a 72% reduction in protein S-nitrosocysteine levels as quantified by
chemiluminescence. In comparison with the untreated liver S-nitrosoproteome (Table
S2.1), 72 proteins were no longer identified after Trx treatment (Table S2.4). Linear
motif analysis revealed two motifs in this subset of S-nitrosylated proteins. The highestscoring motif had exclusively aspartic acid at position −1, whereas the second motif had
exclusively threonine at position +5 (Figure 2.3E). Notably, both motifs contained
charged amino acids at positions before and after the cysteine residue, consistent with the
idea that charged amino acids in S-nitrosocysteine–containing motifs may facilitate
interaction with Trx.
In conclusion, by using unique, highly specific MS-based proteomic methods, we
identified an expanded endogenous S-nitrosoproteome from WT mouse liver. Despite
that S-nitrosylated cysteine residues had, in general, similar hydropathy distribution and
predicted pKa values as nonmodified cysteine residues in the same proteins, closer
interrogation of the surrounding primary and secondary structures revealed distinctions
that direct site-specific S-nitrosylation of certain cysteine residues. The structural analysis
of these proteins also uncovered structural features that can accommodate multiple
mechanisms for S-nitrosylation in vivo. In addition, the data also revealed a putative link
among leptin, eNOS, and protein S-nitrosylation in the regulation of liver fatty acid
metabolism. Overall, the use of global proteomic methods enabled structural and
functional characterization of the in vivo S-nitrosocysteine proteome and the formulation
of testable new hypotheses that can be explored in the future using targeted approaches.
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2.5

Supplementary Methods

Affi-Gel-10 mercury resin (MRC). An organomercurial derivative of Affi-Gel-10 Nhydroxysuccinimide-activated agarose gel was synthesized according to the protocol on
the Biorad web site (Hercules, CA).

One hundred ml of settled Affi-Gel 10 was

transferred into a Buchner funnel and washed with 300 ml of anhydrous isopropyl
alcohol. Two grams of para-amino-mercuric acetate, dissolved in 30 ml of
dimethylformamide, was added to 100 ml of washed Affi-Gel 10 and incubated for 4h at
RT with gentle rocking. Unreacted succinimide groups are then blocked with 130 mM
ethanolamine for 1h at RT with gentle rocking. Next, the gel slurry is transferred into a
Buchner funnel and washed sequentially with 250 ml dimethylformamide and 700 ml of
anhydrous isopropyl alcohol. Resin was stored as a 1:1 slurry in anhydrous isopropyl
alcohol at 4 oC and was used within 3 months (Mcdonagh et al. 1976).
Synthesis

of

mPEG-biotin.

Biotinyl

(3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-

propyl)-amide (Scheme 2.1) 4: To a solution of 4,7,10-trioxododecane1,13-diamine (3;
30 g; 145 mmol; 9 equiv; Fluka, Scheme 2.1) in anhydrous DMF (40 ml) was added drop
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Scheme 2.1: Chemical synthesis of mPEG-biotin compound.

wise a solution of biotin succinimidyl ester (2; 5.44 g 16.0 mmol; SigmaAldrich, Scheme
2.1) in 120 ml dry DMF over 30 minutes under argon.

The resulting thick white

suspension is stirred a further 30 min and the solid that formed was removed by filtration
and washed with DMF. The clear filtrate was concentrated and the crude product was
precipitated by the addition of diethyl ether. The solids were isolated by filtration and a
slurry solution was made and filtered repeatedly with ether (3 times) and ethyl acetate (3
times). The solids were dried under high vacuum overnight to afford the crude 4 (6.05g,
85% yield) as a white sticky solid (Scheme 2.1). The product was purified by flash
chromatography using dichloromethane/methanol/ triethylamine (95/5/1).
Biotin/Peg3/(4-chloromercuriobenzamide) (Scheme 2.1, 1):

To a mixture of 4-

chloromercuriobenzoic acid (1.0 g: 2.8 mmol; Spectrum Chemical) in anhydrous DMF (5
ml) was added a solution of pentafluorophenol (0.515 g; 2.8 mmol; SigmaAldrich) and
EDC (0.537 g; 2.8 mmol; SigmaAldrich, Scheme 2.1). The reaction mixture was stirred
at room temperature for 5 hours until complete as determined by TLC (hexanes/ethyl
acetate (1/2)). Triethylamine (0.73 ml ml; 3 equivalents) and a solution of 4 (1.175 g; 1.0
equivalents) in DMF (3 ml) were then added (Scheme 2.1). The reaction was completed
after stirring for 1 h as determined by TLC (DCM/MeOH/TEA (90/10/1; UV and
dimethylaminocinnaldehyde spray detections). The solvent was removed on the rotavap
and the crude product was precipitated by the addition of diethyl ether. The solids were
washed repeatedly with ether (3X), ethyl acetate (3X). The desired product 1 (0.57 g:
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27.5% yield) was purified by flash chromatography using DCM/MeOH/TEA (90/10/1).
Mass spectral analysis revealed a mass of 809 (785.6 + Na); expected mass =785.6.
Quantification of Protein-SNO using reductive chemistries coupled to ozone-based
chemiluminescence. Liver lysates were exposed to GSNO for 30 min or left untreated
(endogenous levels of protein-SNO), followed by acetone precipitation to remove low
molecular weight nitrosothiols. An aliquot of each sample was illuminated under a
conventional UV-transilluminator for 7 or 30 min to serve as a negative control. The UVilluminated, untreated, and GSNO-exposed samples were blocked with MMTS. The
reaction efficiency of the phenylmercury reagents was assessed by splitting the GSNOexposed sample into 3 aliquots. One aliquot was mixed for 1 hr at RT with 2 ml activated
mercury resin (MRC), the second was mixed for 1h at RT with 3.5mM mPEG-biotin, and
the third was left untreated (GSNO-treated control). The MRC-treated sample was
centrifuged at 1000 x g for 5 min and the supernatant was collected. Protein from the
mPEG-biotin-treated sample was precipitated with acetone to remove excess mPEGbiotin and resuspended in MES/DTPA/SDS buffer. Total protein was normalized
between all samples, and protein S-nitrosocysteine content was quantified by reductive
chemistries coupled to ozone-based chemiluminescence as previously described (Fang et
al. 1998; Greco et al. 2006).
Isolation and preparation of mouse liver protein homogenates for capture of Snitrosylated proteins. Isolated livers were homogenized into 3 ml of lysis buffer (250 mM
Hepes-NaOH, pH 7.7, containing 1 mM DTPA, 0.1 mM neocuproine, 1 % Triton X-100,
and protease inhibitors) on ice using a Teflon pestle and a Jumbo Stirrer (Fisher
Scientific). The homogenates were then centrifuged at 13, 000xg for 30 min at 4 oC. The
soluble protein fraction was collected and the protein concentration was determined by
the Bradford assay. Each sample consisted of 24 mg of protein in 48 ml of lysis buffer
(0.5 mg/ml). Liver protein lysates were supplemented with 100 mM mannitol, 5 mM
MMTS and split into equal aliquots (24 ml). One aliquot was illuminated under a
conventional UV-transilluminator for 7 min on ice and the other left untreated on ice. As
an alternative to UV photolysis, negative controls were generated by treatment with 10

64

mM DTT for 30 min at 37 oC unless otherwise mentioned. Next, samples were
precipitated by the addition of 3 volumes of acetone for 20 min at -20 oC followed by
centrifugation at 3,000xg for 10min at 4 oC. Pellets were then washed twice with 1ml of
cold acetone, solubilized in 24 ml blocking buffer (250 mM HEPES-NaOH, pH 7.7,
containing 1 mM DTPA, 0.1 mM neocuproine, 2.5% SDS, and 20 mM MMTS), and
incubated for 30 min at 50 oC with frequent vortexing. Following blocking, excess
MMTS was removed by protein precipitation with 3 volumes of acetone for 20 min at -20
o

C followed by centrifugation at 3000xg for 10min at 4 oC. Protein pellets were

resuspended into 5 ml of blocking buffer (without MMTS) per sample and precipitated as
described above. Protein pellets were then resuspended in 1.6 ml of loading buffer (250
mM MES, 1 mM DTPA, pH 6.0, 1% SDS) and aliquoted into 0.8 ml for analysis by
organomercury resin and 0.8 ml for analysis by organomercury-polyethyleneglycolbiotin-based enrichment, as described below. Both protein capture methods were
performed in parallel and uninterrupted up to the point of Colloidal blue gel staining (see
GeLC-MS/MS analysis below).
Capture of nitrosylated proteins using organomercury resin (MRC). MRC solid-phase
capture columns were prepared as follows: 4 ml of gel slurry was added to disposable
polypropylene columns and washed with 3 bed volumes of isopropanol. Next the resin
was washed with 6 bed volumes of H2O. Then, the resin was activated by washing with
40 ml of 0.1 M NaHCO3, pH 8.8, and then equilibrated by washing with 40 ml of 50 mM
MES, pH 6.0, containing 50 mM NaCl, and 1 mM DTPA. Blocked protein lysates (0.4
ml), prepared as described above, were diluted to 1.5 ml with loading buffer, applied to
activated MRC columns and incubated under stationary conditions for 1h at RT. Next,
the columns were washed with 10 bed volumes of 50 mM Tris-HCl, pH 7.4, containing
300 mM NaCl, 1 % SDS, followed by 10 bed volumes of the same buffer except
containing 1 % Triton X-100 instead of SDS. Columns were washed with 5 bed volumes
of 50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl, followed by elution of the bound
proteins with 10 ml of the same buffer containing 50 mM β-mercaptoethanol. Samples
were concentrated 500-fold and analyzed by GeLC-MS/MS analysis.
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On-column protein digestion (MRC peptide capture). Blocked protein lysates (0.8 ml)
were adjusted to the volume of the resin bed using loading buffer and applied to activated
MRC columns (as described above) and incubated under stationary conditions for 1h at
RT. Next, the columns were washed with 20 bed volumes of 50 mM Tris-HCl, pH 7.4,
containing 300 mM NaCl, 0.5 % SDS, followed by 20 bed volumes of the same buffer,
except containing 1 % Triton X-100 instead of SDS and with 1M urea. Columns were
then washed with 20 bed volumes of deionized water, followed by 2 bed volumes of
0.1M ammonium bicarbonate. Lysates were incubated with 1 bed volume of 0.1M
ammonium bicarbonate containing trypsin (5 g) in the dark for 16h at RT. The resin was
washed with 20 volumes of 1 M ammonium bicarbonate, pH 7.4, containing 300 mM
NaCl, followed by 20 volumes of the same buffer without NaCl. Columns were then
washed with 20 volumes of 0.1 M ammonium bicarbonate followed by 50 volumes of
deionized water. To elute bound peptides, the resin was incubated with 1 bed volume of
performic acid in water (produced by reacting 1.0 M formic acid with 0.8 M H2O2 for 30
min in the dark) for 30 min at RT. Eluted peptides were recovered by washing the resin
with 1 bed volume of deionized water. The volume is then reduced by Speedvac to < 5 l
and adjusted to 10 L with 0.1% formic acid. Eluted peptides (5 l) were analyzed by
LC-MS/MS as described below.
Labeling and affinity capture of S-nitrosylated proteins using organomercurypolyethyleneglycol-biotin (mPEG-biotin). Blocked protein lysates (0.8 ml) were adjusted
to 3.5 mM mPEG-biotin (50 mM mPEG-biotin stock in DMSO) and incubated at RT for
1h with gentle rocking. Biotinylated proteins were split into 2 equal aliquots (one for
protein capture, one for peptide capture) and precipitated with 3 volumes of acetone.
Protein pellets for mPEG-biotin protein capture were resuspended in 0.2 ml of 25 mM
HEPES-NaOH, pH 7.7, containing 0.1 mM DTPA, 0.01 mM neocuproine, and 0.1 %
SDS. Protein pellets for mPEG-biotin peptide capture were resuspended in 0.5 ml of
0.1M ammonium bicarbonate containing 0.1 % SDS and immediately processed as
described below. Protein concentration of mPEG-biotin protein capture samples were
determined by the BCA protein assay and then adjusted to 0.8 ml with 25 mM HEPESNaOH, pH 7.7, containing 0.1 mM DTPA, 0.01 mM neocuproine. Equal protein amounts
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were incubated with washed neutravidin beads (200 L of slurry per mg of protein
washed with 25 mM HEPES-NaOH, pH 7.7, containing 0.1 mM DTPA and 0.01 mM
neocuproine) for 2h at RT under gentle rocking. Samples were centrifuged at 800xg for 4
min and then the unbound fraction was removed. Beads were washed with 10 volumes of
50 mM Tris-HCl, pH 7.4, containing 300 mM NaCl and 1 % Triton X-100 followed 10
volumes of 50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl. Bound proteins were
eluted with 0.5 ml of 50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl and 100 mM βmercaptoethanol for 20 min at RT under gentle rocking. Samples were centrifuged at
1000xg for 4 min and the supernatant (eluted peptides) were recovered. This step was
repeated to ensure removal of neutravidin-agarose beads. Samples were concentrated 25fold and analyzed by GeLC-MS/MS analysis.
Protein digestion and mPEG-biotin-neutravidin affinity peptide capture. The protein
concentration of mPEG-biotin-labeled proteins (0.5 ml) (prepared above) was determined
by the BCA assay and equal amounts of proteins were transferred to Ultra-free MC
10kDa cut-off filters (previously rinsed with methanol and washed with water) and
incubated with trypsin (1:100 enzyme:protein ratio) in the dark for 16h at 37 oC. The
following day if densitometric analysis of Colloidal blue-stained gel was satisfactory (see
GeLC-MS/MS analysis below), samples were then passed through the filters and the
filtrate containing the biotinylated peptides was recovered and incubated with neutravidin
beads (200 L slurry per mg of initial protein; washed with 10 volumes of 0.1 M
ammonium bicarbonate) for 2 hours at RT under gentle rocking. Samples were
centrifuged at 1000xg for 4 min and the unbound fraction was removed. The beads were
washed 4 x 2.5 volumes of 1 M ammonium bicarbonate containing 50 mM NaCl, 4 x 2.5
volumes of 1 M ammonium bicarbonate, 2 x 2.5 volumes of 0.1 M ammonium
bicarbonate, and finally 2 x 5 volumes of deionized water. Between each wash beads
were rocked for 2 min and centrifuged at 1000xg for 1 min. Bound peptides were eluted
with 0.5 ml of performic acid in water (produced by reacting 1.0 M formic acid with 0.8
M H2O2 for 30 min in the dark) for 30 min at RT with gentle rocking. Samples were
centrifuged at 1000xg for 5 min and supernatant (eluted peptides) were recovered. This
step was repeated to ensure removal of neutravidin-agarose beads. Samples were reduced
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in volume by Speedvac to < 5 l and adjusted to 10 l with Millipore water. Eluted
peptides (5 l) were analyzed by LC-MS/MS as described below.
GeLC-MS/MS analysis. The protein fractions obtained from MRC and mPEG-biotin
protein capture methods were analyzed by GeLC-MS/MS. For each treatment condition
described above, the proteins were mixed with 6X Laemmli sample buffer and equal
volumes (20 l) were loaded on NuPAGE 10% Bis-Tris gels (Invitrogen, Carlsbad, CA).
Proteins were electrophoresed in MOPS running buffer for approximately 1 cm and
visualized by Colloidal blue (Invitrogen, Carlsbad, CA). Visual inspection and
densitometric analysis was performed to verify that the intensity of UV-treated samples
were less than 90% of the untreated samples, otherwise samples were not processed.
Stained gels can be immediately processed by in-gel trypsin digestion or stored in 2 %
acetic acid for up to 1 month. In-gel digestion with trypsin was performed as previously
described except each lane was cut into 3 slices and individually digested with trypsin.
Tryptic peptide digests were analyzed by either an LTQ linear ion trap (IT) or hybrid
LTQ-Orbitrap mass spectrometer (Thermo Electron, San Jose, CA) coupled to an
Eksigent 2D LC system (Eksigent Technologies, Livermore, CA) and autosampler.
Buffers A and B were 0.1 % formic acid/1 % methanol and 80% acetonitrile/0.1 %
formic acid/1 % methanol, respectively. Peptides were loaded isocratically onto a C18 trap
column (75 um i.d. x 25 mm; New Objective Proteopep 2) at a flow rate of 1 μl per
minute in 2% B. Peptides were then eluted onto a C18 analytical column (75 um i.d. x 150
mm; New Objective Proteopep 2). A linear gradient was then initiated at a flow rate of
300 nL per minute for 90 min from 3 - 40% B. The mass spectrometer was set to
repetitively scan from 375 to 1600 m/z followed by data-dependent MS/MS scans on the
five most abundant ions with dynamic exclusion enabled.
Generation and evaluation of SEQUEST peptide assignments. DTA files were generated
from MS/MS spectra extracted from the RAW data file (intensity threshold of 2500 for
protein capture and 1000 for peptide capture approaches; minimum ion count of 50) and
processed by the ZSA and Correction algorithms of the SEQUEST Browser program.
DTA files were submitted to Sorcerer-SEQUEST (ver. 4.0.3, rev 11; Sagen Research,
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San Jose, CA) using the following parameters: Database searching was performed against
a Uniprot database (Release 12.7; 1/2008) containing Mus musculus sequences from
Swiss-Prot plus common contaminants, which were then reversed and appended to the
forward sequences (29, 294 sequences). The database was indexed with the following
parameters: mass range of 600 – 3500, tryptic cleavages with a maximum of 1 missed
cleavage and static modifications of cysteine by carboxyamidomethylation (+57 amu) for
in-gel digestion or by sulfonic acid (+48 amu) and methionine sulfone (+32 amu) for
peptide affinity capture. The DTA files were searched with a 2.0 amu or 50 ppm peptide
mass tolerance for LTQ or LTQ-Orbitrap, respectively, 1.0 amu fragment ion mass
tolerance, and variable modification of methionine (+16 amu) for in-gel digestion, and
maximum number of variable modifications of 3.
Potential sequence-to-spectrum peptide assignments generated by Sorcerer-SEQUEST
were loaded into Scaffold (version 2.2; Proteome Software, Portland, OR) to validate
protein identifications and perform manual inspection of MS/MS spectra as well as to
compare protein identifications across experimental conditions.

For in-gel digestion

experiments, protein identifications were accepted at a threshold of ≥ 99 % protein
confidence with ≥ 2 unique peptides at ≥ 90 % confidence. These criteria resulted in an
estimated protein false discovery rate (FDR) of ≤ 5 %, as calculated by the number of hits
to the reverse protein sequences. For in-solution digestion/peptide affinity capture,
empirically defined SEQUEST Xcorr thresholds were applied to filter peptides IDs with at
least one peptide per protein. Xcorr thresholds were applied to sulfonic acid-containing
and non-modified peptides independently so peptide FDR was ≤ 5%. Since one unique
peptide per protein was permitted, manual inspection of all MS/MS spectra was
performed. The criteria for manual inspection were the following: (i) assignment of the
majority of fragment ion abundance, (ii) sulfonic acid (+48 amu) modification supported
by either y- or b- ions series (≥ 4 consecutive fragments), and (iii) assigned charge state
and diagnostic markers, such as N-terminal proline, C-terminal aliphatic amino acids, and
loss of H2O/ammonia consistent with amino acid sequence (Tabb et al. 2006). Cysteine
residues that participated in redox cycling and reflect catalytically active residues, e.g.
thioredoxins, peroxiredoxins, and glutaredoxins were included, while eight cysteinyl
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peptides that were predicted or experimentally determined to form disulfide bonds were
excluded. Although these cysteine residues may represent true S-nitrosylation sites as
evidenced by previous studies that have documented endogenous S-nitrosocysteine
residues that also participate in disulfide bond formation (Guo et al. 2008; Takahashi et
al. 2007), a conservative approach was taken.
Denitrosylation assays. Liver homogenates (6mg of protein per condition) were (1)
remained untreated (2) exposed to 150nM Trx, 150nM TrxReductase and 100μmM
NADPH for 30 min at 37⁰C (3) exposed to 1mM GSH for 30min at 37 oC. Unreacted
reagents was removed by acetone precipitation (20 min at -20 oC) followed by
centrifugation at 3000 x g for 10 min at 4 oC. Then, proteins were processed by MRC and
mPEG-biotin protein capture approaches and GeLC/MS/MS analysis.
Gene ontology and functional protein analysis. Subcellular localization was determined
by either existing UniProt (www.uniprot.org) annotation, while gene ontology
classification was provided by UniProt. Functional Analysis identified the biological
functions that were most significant was performed using Uniprot and Fatigo
(www.fatigo.org).
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2.6

Supplemental Figures

Figure S2.1: Characterization of protein S-nitrosocysteine. (A) The chemical
structure of MRC, containing a phenylmercuric acetate functional group tethered to
agarose solid-phase resin. (B) The chemical structure of mPEGb, containing a
phenylmercury functional group conjugated to biotin by a polyethyleneglycol spacer. (C)
The identification and validation of protein S-nitrosocysteine (SNO) was performed by
phenylmercury-based capture (PMC). As outlined, SNO-PMC used a complementary
solid-phase mercury resin capture (i.e., MRC) and mPEGb. The method is divided into
three main steps: (i) homogenization of mouse liver and blocking of reduced protein
cysteine, (ii) displacement of cysteine-bound NO by organomercury and/or Neutravidinbased affinity enrichment, and (iii) liquid chromatography-MS/MS analysis. Step I was
performed for all analyses. In step II, MMTS-blocked proteins were loaded onto activated
solid-phase MRC columns or incubated in-solution with mPEGb. For protein
identification, bound proteins from MRC were eluted with b-mercaptoethanol (b-ME),
whereas mPEGb-labeled proteins were captured by Neutravidin agarose beads and eluted
with b-ME (i). Captured proteins were separated by one-dimensional SDS/PAGE and ingel trypsin digested. Site-specific identification of S-nitrosocysteine residues was
performed by on-column (MRC) and in-solution (mPEGb) peptide capture. From a
parallel MRC sample, captured proteins were digested on-column with trypsin, and
cysteinyl peptides were eluted by mild performic acid (3%), which cleaved the
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phenylmercury mercaptide bond and oxidized the cysteine thiol to sulfonic acid. Also, a
parallel mPEGb-labeled protein sample was digested in-solution with trypsin. Then,
mPEGb-labeled peptides were enriched by Neutravidin-based capture (ii) and eluted by
mild performic acid. Step III (LC-MS/MS peptide analysis) was performed for all
approaches, with differences in post-acquisition data analysis between protein and
peptide capture approaches (Greco et al. 2006). RAW files generated by LC-MS/MS
analysis from protein and peptide capture experiments were processed ExtractMSN to
obtain MS2 spectra, searched by Sorcerer-SEQUEST against a concatenated forwardreverse database , and then analyzed by Scaffold (Greco et al. 2006).

Figure S2.2: GeLC-MS/MS analysis of protein S-nitrosocysteine. (A) Representative
short (approximately 2 cm) colloidal blue-stained protein gels of MRC protein capture
from WT mouse liver that were processed by GeLC-MS/MS analysis. (B) Representative
base peak chromatograms from mPEGb protein capture demonstrate reduction in ion
intensity after UV photolysis (red) compared with untreated sample (blue).
Chromatograms represent analysis of tryptic peptides derived from a single gel slice. The
equivalent gel slice was analyzed from the UV-treated sample. The base peak intensity in
the UV-exposed trace (red) corresponded to trypsin autolysis peptides (asterisk). Inset:
Average false-positive identification rate (FIR ± SD) represents the percentage of
proteins that were identified in both the UV-treated and untreated samples across three
independent biological replicates.
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Figure S2.3: Ontological analysis of liver S-nitrosoproteome. (A) Histogram of
subcellular localization represented by number of proteins (black bars) and total Snitrosocysteine (SNO) sites (open bars). The primary cellular localization reported by
UniProt was used for proteins with multiple subcellular compartments. (B) Histogram of
molecular function gene ontology analysis as a function of number of proteins (black
bars) and total S-nitrosocysteine (SNO) sites (open bars). The top four catalytic activities
are shown, with oxidoreductase and transferase activities significantly overrepresented in
the liver S-nitrosoproteome compared with the entire mouse genome (P = 1.28e−20 and
3.2e−3, respectively). (C) Sixteen S-nitrosylated proteins from WT liver as determined by
Ingenuity Knowledge Base comprised the most significant protein interaction network
and clustered around the hormone leptin.
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Figure S2.4: Distribution of residues flanking unmodified cysteine residues in
secondary structures. (A) Cysteine residues are denoted by Cys (position 0) and the
frequency for 10 residues upstream (−10) and 10 residues downstream (+10) was
calculated using the available crystal structures. Beta sheets (black bars), helices (white
bars), coils (gray bars). (B) Primary sequence motifs for unmodified cysteine residues
within S-nitrosylated proteins.

2.7

Supplemental Tables

Supplementary Table 2.1: Endogenously S-nitrososylated proteins in wild type mice liver
Protein name

Peptide sequence2

Uniprot
Accession

MW,
kDa

Unique
Peptides
(MRC)1

Unique
Peptides
(mPEGb)1

Q9D6Y9

80

3

3

2-hydroxyacyl-CoA lyase 1

Q9QXE0

64

7

3

3-hydroxyanthranilate 3,4-dioxygenase

Q78JT3

33

-

5

3-ketoacyl-CoA thiolase A, peroxisomal

Q921H8

44

-

5

3-ketoacyl-CoA thiolase B, peroxisomal
precursor

Q8VCH0

44

5

-

10-formyltetrahydrofolate dehydrogenase

Q8R0Y6

99

33

29

3-ketoacyl-CoA thiolase, mitochondrial

Q8BWT1

42

17

-

40S ribosomal protein S2

P25444

31

-

3

40S ribosomal protein S3

P62908

27

3

5

40S ribosomal protein S3a

P97351

30

-

3

40S ribosomal protein S4, X isoform

P62702

30

-

3

40S ribosomal protein S6

P62754

29

-

3

DC177LTPMGMTSENVAER
DC177LIPMGITSENVAER
GC218FHAEIVPVTTTVLNDK
VNPLGGAIALGHPLGC381TGAR
QC123SSGLQAVANAIAGGIR
MKAVGQSLFGQEVYC17QLRK
LRGEDGESEC404VINYVEK
SC662ALSNVK
TAAC587LAAGNTVVIKPAQVTPLTALK
EDC179DRYALQSQQR
VVGYFVSGC287DPTIMGIGVPAINGA
GC229TATLGNFAK
GLC97AIAQAESLR
RAC119YGVLR
NC96LTNFHGMDLTR
AC201QSIYPLHDVFVR
TTDGYLLRLFC139VGFTK
FDTGNLC181MVTGGANLGR
LREC41LPLIIFLR
MKLNISFPATGC12QK

40S ribosomal protein S14

P62264

16

-

2

C85KELGITALHIK

11,4-alpha-glucan-branching enzyme

Q9D6Y
C473VAYAESHDQALVGDK
9
80,349
GVVPDNNHPNC264VGAAR
KLVEQC243SLPFLPTPMGK
TMLQNC415LPR
ASFQPPVC23NKLMHQEQLK

74

24

-

3

LLAC174IASRPGQC182GR

4-hydroxyphenylpyruvate dioxygenase

P62242
P49429

45

-

9

HGDGVKDIAFEVEDC103DHIVQK

5-oxoprolinase

Q8K010

138

2

-

GHDPSAHVLACFGGAGGQHAC497AIAR

60kDa heat shock protein, mitochondrial
precursor

P63038

61

11

10

60S ribosomal protein L3

P27659

46

-

4

60S ribosomal protein L12

P35979

18

-

2

60S ribosomal protein L17

Q9CPR4

21

-

2

60S ribosomal protein L27a

P14115

17

2

-

C17TGGEVGATSALAPK
INPYMSSPC144HIEMILTEK
YSLDPENPTKSC15K
QC57VPFR
GVGAC144VLVA

60S ribosomal protein L30

P62889

13

2

-

TGVHHYSGNNIELGTAC85GK

60S ribosomal protein L7a

P12970

30

-

3

Acetyl-CoA acetyltransferase, cytosolic

Q8CAY6

41

3

2

Acetyl-CoA carboxylase 1

Q5SWU9

265

3

-

Acetyl-CoA acetyltransferase,
mitochondrial precursor

Q8QZT1

45

6

5

TC199TTVAFTQVNSEDKGALAK
VNIDGGAIALGHPLGASGC360R
VAPEEVSEVIFGHVLTAGC65GQNPTR
RPGALDPGC812VAK
IHMGNC193AENTAK
AIMMASQSLMC138GHQDVMVAGGMESMSNVPYVMS
R

Acyl-CoA dehydrogenase family member
11

Q80XL6

87

-

2

C546KIAIVLGR

Acyl-CoA dehydrogenase family member
9, mitochondrial

Q8JZN5

69

-

3

AYIC617AHPLDR

Aconitate hydratase, mitochondrial

Q99KI0

85

11

9

Actin, cytoplasmic 1
Acyl-coenzyme A synthetase ACSM5,
mitochondrial precursor

P60710

42

11

-

FSMGSAVAGMLKKLIELTAEYAC331TR
VAVPSTIHC126DHLIEAQVGGEK
C410KSQFTITPGSEQIR
VGLIGSC385TNSSYEDMGR
C257PEALFQPSFLGMESC272GLHETTFNSMK

Q8BGA8

64

2

-

HC342LTGGEALNPDVR

P55264

40

3

4

AATFFGC105IGIDK
TGC352TFPEKPDFH

40S ribosomal protein S8

75

Adenosine kinase

C237EFQDAYVLLSEK
AAVEEGIVLGGGC442ALLR
C447IPALDSLKPANEDQK
TVFAEHISDEC114K

SKFDNLYGC195R
VAVVAGYGDVGKGC228AQALR
GLGDC160LVK
TEVNQIHEDC463K
GAYHGC199SPYTLGLTNVGIYK

Adenosylhomocysteinase

P50247

48

-

13

ADP/ATP translocase 2
Alanine--glyoxylate aminotransferase 2,
mitochondrial precursor

P51881

33

-

3

Q3UEG6

57

6

-

Alcohol dehydrogenase [NADP+]

Q9JII6

36

4

3

Alcohol dehydrogenase 1

P00329

40

7

8

Q8BH00

54

5

4

Q9CZS1

58

5

-

TIPMDGEHFC171FTR

O35945

55

-

2

KFPVLNPATEEVIC50HVEEGDKADVDK

P47738

56

14

14

LLC388GGGAAADR

Q9DBF1

56

3

3

Amine oxidase [flavin-containing] B
Apoptosis-inducing factor 1,
mitochondrial precursor

Q8BW75

58

3

2

C633GGLPAPEHSDNPLR
SSVVPVEGC342PELPHK
GSDC450GIVNVNIPTSGAEIGGAFGGEKHTGGGR
LLHDC26GLSVVVLEAR

Q9Z0X1

67

-

5

C255LIATGGTPR

Argininosuccinate lyase

Q91YI0

52

7

-

Argininosuccinate synthase

P16460

46

-

19

Arginyl-tRNA synthetase, cytoplasmic

Q9D0I9

76

4

3

Aspartate aminotransferase,
mitochondrial precursor

P05202

47

12

9

ATP synthase subunit alpha,

Q03265

60

16

18

Aldehyde dehydrogenase family 8
member A1
Aldehyde dehydrogenase X,
mitochondrial
Aldehyde dehydrogenase, cytosolic 1
Aldehyde dehydrogenase, mitochondrial
precursor
Alpha-aminoadipic semialdehyde
dehydrogenase

HIDC46ASVYGNETEIGEALKESVGSGK
KVIC260IPK
VIPLFSPQC98GEC101R
IC104KHPESNFC112SR
VTPGSTC196AFGLGGVGLSVILGC212K
IDGASPLDKVC171LIGC175GFSTGYGSAVK
ILC354GEGVDQLSLPLR
ITQLSAPHC347K

76

VFGRC307AGLLMTLK
QTC129SKLSALLRVLIGTMVDR
FELTC132YSLAPQIK
YLLGTSLARPC97IAR
MLLC638EAVAAVMAKGFDILGIKPVQR
TC187GFDFSGALEDISK
VGAFTVVC295K
NLDKEYLPIGGLAEFC106K
LYC244IYVAIGQKR

mitochondrial
ATP synthase subunit gamma,
mitochondrial precursor
ATP-binding cassette sub-family D
member 3

Q91VR2

33

3

2

GLC103GAIHSSVAK

P55096

75

5

3

NTSLAGAAFLLLC24LLHKR

Q91V92

120

5

5

KPASFMTSIC835DER

GVTIIGPATVGGIKPGC623FK
ATP-citrate synthase

Betaine--homocysteine Smethyltransferase 1
Bifunctional aminoacyl-tRNA synthetase
Calcium-binding mitochondrial carrier
protein Aralar 2

O35490

45

14

-

Q8CGC7

170

-

3

YIC20TTSAIQNR
QVADEGDALVAGGVSQTPSYLSC131K
AGASIVGVNC267HFDPSVSLQTVK
YIGGC299C300GFEPYHIR
AYLMSQPLAYHTPDC256GK
VTEAVEC856LLSLK

Q9QXX4

101

14

14

AGQTTYNGVTDC566FRK

Carbamoyl-phosphate synthase
[ammonia],
mitochondrial precursor

Q8C196

165

-

64

Carbonic anhydrase 3

P16015

29

-

8

Calreticulin

P14211

48

7

6

Catalase

P24270

60

-

17

Catechol O-methyltransferase

O88587

29

2

2

VVAVDC225GIK
C920LGLTEAQTR
TSAC761FEPSLDYMVTK
SAYALGGLGSGIC600PNKETLIDLGTKA
EAPFTHFDPSC182LFPAC187R
TC68RVVFDDTYDRSMLR
C163KDDEFTHLY
SALEHSVQC425AVDVKR
LC460ENIAGHLK
GSSSFEC234THYSSYLEYMK

Cathepsin B

P10605

37

2

3

GENHC319GIESEIVAGIPR

Complement C3

P01027

186

6

3

VELLHNPAFC873SMATAK

Corticosteroid 11-beta-dehydrogenase
isozyme 1

P50172

32

4

2

C78LELGAASAHY

Cystathionine gamma-lyase

EEC241ALEIIK
Q8VCN5

44

2

-

ISFVDC136SK
LADIGAC171AQIVHK

77

Cytochrome b-c1 complex subunit 1

Q9CZ13

53

4

-

Cytochrome c, somatic

P62897

12

3

-

NALVSHLDGTTPVC410EDIGR
LC380TSATESEVTR
IFVQKC15AQC18HTVEK

Q9DBG1

61

-

3

IGC230LKPSIPEDTAAFIR

Cytochrome P450 3A11

Q64459

58

5

4

FALMNMKLALTKIMQNFSFQPC469K

Cytochrome P450 3A41

Q9JMA7

56

2

-

Cytochrome P450 2C50

Q91X77

56

3

4

Cytochrome P450 2C54

Q6XVG2

56

9

-

VMQNFSFQPC469QETQPLK
FIDLVPNSLPHEVTC372DIK
RIC435AGEGLAR
DIC51QSFTNLSK
VQEEARC151LVEELRK
FIDLVPNNLPHEVTC372DIK

Cytochrome P450 2D10

P24456

57

5

4

Cytochrome P450 2E1

Q05421

57

3

-

Cytochrome P450 2F2

P33267

56

7

4

Cytosol aminopeptidase

Q9CPY7

56

8

3

D-beta-hydroxybutyrate dehydrogenase,
mitochondrial

Q80XN0

38

-

5

D-dopachrome decarboxylase

O35215

13

-

6

Delta-1-pyrroline-5-carboxylate
dehydrogenase, mitochondrial

Q8CHT0

62

8

4

Cytochrome P450 27, mitochondrial

Dimethylaniline monooxygenase [Noxide-forming] 3
Dihydrolipoyl dehydrogenase,
mitochondrial precursor
Dihydropteridine reductase

RSC446LGEPLAR
DVTDC268LLIEMEKEK
SLDINC261PR
RVC437VGEGLAR
EFKLC488VIPR
DFIDC267FLTK
PFQLC487MHIR
RLC436LGEPLAR
QVIDC445QLADVNNLGK
AILITGC63DSGFGFSLAK
GFLVFAGC86LMK
TIQLNVC115NSEEVEK
LC24AATATILDKPEDR
STEPC57AHLLVSSIGVVGTAEQNR
FC94YADKALLNR
LAGEC314GGKNFHFVHSSADVDSVVSGTLR
GTC397TLPSVMDMMDDIDEK
VLVGLGNSGC197DIAAELSHVAQK

P97501

61

5

-

O08749

54

3

2

VC484HAHPTLSEAFR

Q8BVI4

26

2

4

GAVHQLC158QSLAGK

78

KMLALGITGPEGHELC220RPEAVEAEATLR
AITIASAVNC242PLYVVHVMSK
DQTC484TPVPVKR
IC382TTLIGLEEHLNALDR
LKTEGSDLC546DR
VAC478ITEQVLTLVNKR

Dihydropyrimidinase

Q9EQF5

57

7

-

Dihydroxyacetone kinase
Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1
Electron transfer flavoprotein subunit
alpha, mitochondrial
Electron transfer flavoprotein subunit
beta
Electron transfer flavoproteinubiquinone oxidoreductase,
mitochondrial

Q8VC30

60

7

7

Q91YQ5

68

6

4

Q99LC5

35

4

6

QFSYTHIC109AGASAFGK

Q9DCW4

28

5

5

HSMNPFC42EIAVEEAVR

Q921G7

68

7

7

Elongation factor 2

P58252

95

5

9

Enoyl-CoA hydratase, mitochondrial

Q8BH95

31

6

5

Epoxide hydrolase 2

P34914

63

13

11

Ester hydrolase C11orf54 homolog

Q91V76

35

2

-

Estradiol 17 beta-dehydrogenase 5

P70694

37

-

14

Fatty acid synthase

P19096

272

-

12

Fatty acid-binding protein, liver

P12710

14

-

9

Formimidoyltransferase-cyclodeaminase

Q91XD4

60

4

2

Fructose-1,6-bisphosphatase 1

Q9QXD6

37

13

10

Fructose-bisphosphate aldolase B

Q91Y97

39

14

-

AAQIGAHTLSGAC118LDPAAFK
VTVFAEGC248HGHLAK
LQINAQNC585VHC588K
STLTDSLVC41K
DLEEDHAC567IPIKK
TFC290QLILDPIFK
C369ELLYEGPPDDEAAMGIK
LVEEAIQC225AEK

79

VTGTQFPEAPLPVPC230NPNDVSHGYVTVKPGIR
AHIMPAEFSSC226PLNSDEAVNK
RTGELNFVSC187MR
VC98LEQSLK
YKPVC188NQVEC193HPYLNQGK
LLDFC206R
FVFTPHMEAEC1128LSESTALQK
DC1590MLGMEFSGR
C1464ILLSNLSNTSHAPK
NEFTLGEEC69ELETMTGEK
TVYTFVGQPEC60VVEGALHAAR
AC438ALQEGLR
AQGTGELTQLLNSLC39TAIKAISSAVR
C135AQYKKDGVDFGK
IADQC158PSSLAIQENANALAR
RAMANC336QAAQGQYVHTGSSGAAATQSLFTASYTY

Glutamate dehydrogenase 1,
mitochondrial

P26443

61

-

20

Glutathione peroxidase 1

P11352

22

-

8

IIKPC112NHVLSLSFPIR
C172AVVDVPFGGAKAGVK
AC254VTGKPISQGGIHGR
GLVVLGFPC76NQFGHQENGK

Glutathione S-transferase A3

P30115

25

-

3

KPFDDAKC212VESAK

Glutathione S-transferase Mu 1

P10649

26

8

7

Fumarylacetoacetase

P35505

40

7

-

Glutamine synthetase

P15105

42

4

3

P16858

36

7

-

C174LDAFPN
VGFGQC408AGK
GEGMSQAATIC315R
TFLLDGDEVIITGHC396QGDGYR
RPSANC346DPYAVTEAIVR
C269IEEAIDK
LVLC99EVFK
AC183LYAGVK
VPTPNVSVVDLTC245R
IVSNASC150TTNC154LAPLAK

Q64521

81

3

2

C270KDVLTGQEFDVR

P13707

38

4

5

C341LQNHPEHM

Q64516

61

2

-

Q91W43

113

3

-

Glycine N-methyltransferase

Q9QXF8

33

-

5

Glycogen phosphorylase, liver form

Q9ET01

97

10

14

C299VFSEHGLLTTVAYK
C230HPQTIAVVQTR
TFC763IPHGGGGPGMGPIGVK
SFAHLPDC147K
LSYYPHC247LASFTELVR
NYDYILSTGC186APPGK
INMAHLC446IVGC450HAVNGVAK

Heat shock cognate 71 kDa protein
Heat shock protein 75 kDa,
mitochondrial

P63017

71

18

15

GPAVGIDLGTTYSC17VGVFQHGK

Q9CQN1

80

Hemoglobin subunit beta

P02088/
P02089

16

2

4

GTFASLSELHC94DK

Homogentisate 1,2-dioxygenase

O09173

50

3

-

YISGFGNEC14ASEDPRC21PGSLPK
SNNGLAVHIFLC138NSSMENR
QGGFLPGGSLHSAMTPHGPDADC377FEK

Glyceraldehyde-3-phosphate
dehydrogenase
Glycerol-3-phosphate dehydrogenase,
mitochondrial
Glycerol-3-phosphate dehydrogenase
[NAD+], cytoplasmic
Glycerol kinase
Glycine dehydrogenase
[decarboxylating], mitochondrial

IIIHLKSDC263KDFASESR

80

Hydroxymethylglutaryl-CoA lyase,
mitochondrial

P38060

34

2

2

Hydroxymethylglutaryl-CoA synthase,
mitochondrial

P54869

57

-

15

Isocitrate dehydrogenase [NADP],
mitochondrial

P54071

51

3

3

Kynurenine 3-monooxygenase
L-gulonolactone oxidase

Q91WN4

54

2

2

P58710

50

5

3

KNANC141SIEESFQR
LLEAGDFIC307QALNR
MGFC96SVQEDINSLC106LTVVQR
ALDRC269YAAYR
MIFHTPFC305K
C113ATITPDEARVEEFKLK
DLAGC418 IHGLSNVK
SHC299VLMGDAAHAIVPF
C139IPEEGVLTVLGPDKVPR
TYGC19SPEMYYQPTSVGEVR
DSC360YMNIIMYRPYGK
DYC84VTANSK
ITVVGVGAVGMAC35AISILMK
VIGSGC163NLDSAR
DASINPPMC100LQDVER

L-lactate dehydrogenase A chain

P06151

36

2

8

Liver carboxylesterase 31

Q63880

63

14

10

Q8VCU1

63

3

-

P51174

48

2

3

Long-chain-fatty-acid--CoA ligase 1

P41216

78

20

18

Long-chain-fatty-acid--CoA ligase 5

Q8JZR0

76

6

3

P08249

36

6

6

GYLGPEQLPDC89LK

O55022

22

4

3

GLATFC129LDK

Q3ULD5

61

3

3

AATGEEVSAEDLGGADLHC267R

Q68FL6

101

-

2

ILATSFIC789TLPAGHR

Q91VS7

18

4

3

VFANPEDC50AGFGKGENAK

Liver carboxylesterase 31-like precursor
Long-chain specific acyl-CoA
dehydrogenase, mitochondrial

Malate dehydrogenase, mitochondrial
precursor
Membrane-associated progesterone
receptor component 1
Methylcrotonoyl-CoA carboxylase beta
chain, mitochondrial
Methionyl-tRNA synthatase, cytoplasmic

81

Microsomal glutathione S-transferase 1

DASINPPMC97LQDVEK
C166IGAIAMTEPGAGADLQGVR
LAELKTHIC342VTR
ALKPPC55DLSMQSVEIAGTTDGIRR
GIQVSNNGPC109LGSR
C242GVEIISLK
GAMITHQNIINDC298SGFIK
C226GVEMLSLHDAENIGK
KPVPPKPEDLSVIC259FTSGTTGDPK
TAGHVGTPVAC471NFVK

EQGKEVGETLLYYGC566R
NADPH--cytochrome P450 reductase
Nicotinate-nucleotide pyrophosphorylase
[carboxylating]
Non-specific lipid-transfer protein
Ornithine aminotransferase,
mitochondrial
Peptidyl-prolyl cis-trans isomerase A

P37040

77

5

3

LIHEGGAHIYVC630GDAR
VHPNSVHIC472AVAVEYEAK
C111SGIASAAATAVEVAR
YGLQVGGAAC159HR
ADC495TITMADSDLLALMTGK

Q91X91

32

2

3

P32020

59

12

12

P29758

48

-

3

VLPMNTGVEAGETAC150K

P17742

18

7

3

IIPGFMC62QGGDFTR

Q9DBM2

78

10

13

LC17NPPVNAISPTVITEVR

Peroxiredoxin-4

O08807

31

-

4

TRENEC54HFYAGGQVYPGEASR

Peroxiredoxin-6
Peroxisomal carnitine Ooctanoyltransferase
Peroxisomal coenzyme A diphosphatase
NUDT7

O08709

25

3

4

DFTPVC47TTELGR

Q9DC50

70

3

-

AFVFDVLHEGC210LITPPELLR

Q99P30

27

-

5

IDFDLHDLIPSC223ER

79

7

12

Peroxisomal bifunctional enzyme

NNIHC189NTIAPNAGSR

P51660

Peroxisomal sarcosine oxidase

Q9D826

44

2

-

Peroxisomal trans-2-enoyl-CoA reductase

Q99MZ7

32

2

-

P16331

52

5

4

Q8VEM8

40

4

-

Phosphoglycerate kinase 1

P09411

44

5

3

IC277DFSNASKPQTIQESTGGIVEVLHK
TFSDIQDVQILC299HFVR
C319MYTNTPDEHFILDC333HPK
ELLHLGC43NVVIASR
VFHC265TQYIR
NLADSINSEVGILC445HALQK
AVEEYSC52EFGSMK
C272AIVSHPADSVVSVLNK
AAVPSIKFC50LDNGAK

Phosphoglucomutase-1

Q9D0F9

62

5

11

LSLC374GEESFGTGSDHIR

Plastin-3
Probable D-lactate dehydrogenase,
mitochondrial precursor
Probable 2-oxoglutarate dehydrogenase

Q99K51

70

8

3

VDLNSNGFIC34DYELHELFK

Q7TNG8

52

5

-

ALALGGTC439TGEHGIGLGK

A2ATU0

103

-

2

LVGC393AIIHVNGDSPEEVVR

Phenylalanine-4-hydroxylase
Phosphate carrier protein, mitochondrial

82

Peroxisomal multifunctional enzyme type
2

E1 component DHKTD1, mitochondrial
Probable imidazolonepropionase

Q9DBA8

46

2

-

ELHLSLSATYC189GAHSVPK

Probable urocanate hydratase

Q8VC12

74

10

9

AAAIVGC265IGVIAEVDKAALVK

Profilin-1
Propionyl-CoA carboxylase beta chain,
mitochondrial
Protein disulfide-isomerase A3

P62962

15

-

4

C128YEMASHLR

Q8VC12

58

2

-

C92ADFGMAADKNKFPGDSVVTGR

P27773

57

-

16

FIQDSIFGLC244PHMTEDNKDLIQGK

Q01405

86

P61620

52

3

-

Pyruvate carboxylase, mitochondrial
precursor

Q05920

130

24

14

Regucalcin

Q64374

33

10

10

Retinal dehydrogenase 1

P24549

54

17

18

Retinol dehydrogenase 7

O88451

36

2

-

Ribosome-binding protein 1

Q99PL5

173

10

22

S-adenosylmethionine synthetase isoform
type-1

Q91X83

43

-

4

Sarcoplasmic/endoplasmic reticulum
calcium ATPase 2

O55143

115

6

6

Sarcosine dehydrogenase mitochondrial
precursor

Q99LB7

102

-

13

SEC14-like protein 4

Q8R0F9

46

-

2

Selenium-binding protein 1

P17563

52

-

10

Selenium-binding protein 2

Q63836

52

-

15

Protein transport protein Sec23A
Protein transport protein Sec61 subunit
alpha isoform 1

MVQVHELGC180EGISK
FLEVIKPFC13VILPEIQKPER
ADFAQAC131QDAGVR
FC663EVAKENGMDVFR
DMAGLLKPAAC752TMLVSSLR
MEKDEQIPDGMC207IDAEGK
DYSEMYVTC262AR
IGPALSC186GNTVVVKPAEQTPLTALHLASLIK

83

VLAAC60LTEK
LKELESQVSC1198LEK
C1136EELSSLHGQLK
IC35DQISDAVLDAHLK
VALEQQSPDIAQC121VHLDR
TAC377YGHFGR
C560LALATHDNPLK
NYLEQPGKEC998VQPATK
STVC382GPESFTPDHKPLMGEAPELR
DPLHEELLGQGC498VFQER
C672QLMDSSEDLGMLSIQGPASR
VC128EMLLHEC135ELQSQK
YNAHMVPEDGSLNC355LK
GPREEIVYLPC31IYR
C8GPGYSTPLEAMK
GGSVQVLEDQELTC371QPEPLVVK
C8GPGYPTPLEAMK

Sodium/potassium-transporting ATPase
subunit alpha-1

Q8VDN2

113

6

7

Sorbitol dehydrogenase

Q64442

38

6

-

Src substrate cortactin

Q60598

61

2

-

Staphylococcal nuclease domaincontaining protein 1

Q78PY7

102

Succinate dehydrogenase [ubiquinone]
flavoprotein subunit, mitochondrial

Q8K2B3

72

10

6

Sulfite oxidase, mitochondrial

Q8R086

61

6

-

C131NVSNTHTSHC141LASGEVMVNTLGDLQGNGK
FLHDPSATQGFVGC268ALSSNIQR
GGSVQVLEDQELTC371QPEPLVVK
AC663VVHGSDLK
LIIVEGC705QR
VMIKC350DPNDQNP
VLVC179GAGPVGMVTLLVAK
HC112SQVDSVR
EVC96FTIENKTPQGR
GIVKMVLSGC31AIIVRGQPR
GVIALC238IEDGSIHR
TYFSC266TSAHTSTGDGTAMVTR
HEVTVTLQC265AGNR

Sulfotransferase 1A1

P52840

34

2

-

Synaptic glycoprotein SC2
Thioredoxin domain- containing protein4
Thiosulfate sulfurtransferase

Q9CY27

36

2

-

LC300DVLAQAGHR
LMTGC283DFTFR
IPFLEFSC82PGVPPGLETLK
LC18FLDKVEPQATISEIK

Q9D1Q6

47

3

-

VDC92DQHSDIAQR

P52196

33

7

-

KVDLSQPLIATC248R

Threonyl-tRNA synthetase, cytoplasmic

Q9D0R2

83

5

-

FMADTDLDPGC655TLNKK

Triosephosphate isomerase

P17751

27

-

3

IIYGGSVTGATC218K

Tryptophan 2,3-dioxygenase
Tubulin beta chain

P48776
P68372
(+5)

48

9

-

VSHALAEGLGVIAC127IGEK
EVLLC266LFDEK

50

9

2

EIVHIQAGQC12GNQIGAK

Q02053

118

7

-

YSRPAQLHIGFQALHQFC340ALHNQPPRPR

Q8C5H8

51

3

-

UDP-glucuronosyltransferase 1-1

Q63886

60

-

7

SEGHLC181LPVR
VKNVLLAVSENFMC225R
MVFIGGINC282LQK

84

Ubiquitin-like modifier-activating
enzyme 1
UPF0465 protein C5orf33 homolog

UDP-glucuronosyltransferase 2B5

P17717

61

-

8

FLSLC128KDVVSNK

Uricase

P25688

35

3

6

NGIKHVHAFIHTPTGTHFC141EVEQMR

Valyl-tRNA synthetase

Q9Z1Q9

140

8

3

NIETFAMNIC95EHFLSSFNHVTR
C681GEMAQAASAAVTR

Very long-chain acyl-CoA synthetase
Very long-chain specific acyl-CoA
dehydrogenase, mitochondrial precursor
Vigilin

O35488

70

11

9

GEVGLLVC427KITQLTPFIGYAGGK

P50544

71

11

9

SSAIPSPC238GK

Q8VDJ3

142

7

4

RC948DIIIISGR

Xanthine dehydrogenase/oxidase

Q00519

146

4

-

C828MLDRDEDMLITGGR

Sequence-to-spectrum assignments from three biological replicates were combined in Scaffold. The proteins listed above satisfied three criteria: (1)
identified by at least one protein capture method (≥2 unique peptides), (2) confirmed by a sulfonic acid-containing peptide sequence and (3) not
identified in the respective UV-exposed samples. Uniprot accession numbers correspond to the full-length unprocessed precursor when available
(www.uniprot.org). Additional accessions were listed if the observed peptides could not distinguish between protein isoforms. All the MS/MS
spectra from peptide capture can be viewed at http://www.research.chop.edu/tools/msms/spectra.pdf;.
1
Number of unique peptides identified in protein capture experiment from 3 biological replicates (does not include sulfonic acid-containing
peptides). A null value indicates the protein did not meet the threshold criteria and was considered not identified.
2
Cysteinyl-containing tryptic peptide sequences identified by peptide capture. The indicated cysteine residue(s) was identified as sulfonic acid
and corresponds to the unprocessed mouse precursor protein.
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Supplementary Table 2.2. Endogenously S-nitrosylated proteins in eNOS-/- mouse liver
MW,
kDa

Unique
Peptides
(MRC)1

Unique
Peptides
(mPEGb)1

Peptide sequence2

40S ribosomal protein S3

P62908

27

4

-

GLC97AIAQAESLR3

60S ribosomal protein L12

P35979

18

2

4

60S ribosomal protein L17

Q9CPR4

21

2

6

60S ribosomal protein L24

Q8BP67

18

4

-

C17TGGEVGATSALAPK3
QC57VPFR3
INPYMSSPC144HIEMILTEK3
C36ESAFLSK

Alcohol dehydrogenase 1

P00329

40

4

3

Argininosuccinate synthase

P16460

46

2

2

ATP synthase subunit gamma, mitochondrial precursor

Q91VR2

33

2

2

Betaine--homocysteine S-methyltransferase 1

O35490

45

4

-

Carbamoyl-phosphate synthase [ammonia],
mitochondrial precursor

Q8C196

165

9

7

Catalase

P24270

60

3

4

Cytochrome P450 2C29

Q64458

56

5

3

Cytochrome P450 2E1

Q05421

57

3

-

VIPLFSPQC98GEC101R3
YLLGTSLARPC97IAR3
FELTC132YSLAPQIK3
GLC103GAIHSSVAK3
AYLMSQPLAYHTPDC256GK3
AGASIVGVNC267HFDPSVSLQTVK3
YIGGC299C300GFEPYHIR3
VVAVDC225GIK3
TSAC761FEPSLDYMVTK3
C920LGLTEAQTR3
GNDVLVIEC1256NLR
SALEHSVQC425AVDVKR3
LC460ENIAGHLK3
VQEEAQC151LVEELR
FIDLLPTSLPHAVTC372DIK
IC435AGEGLAR
SLDINC261PR3

Dehydrogenase/reductase SDR family member 1

Q99L04

34

2

-

LAADC177AHELR

Dihydroxyacetone kinase
Electron transfer flavoprotein-ubiquinone oxidoreductase,
mitochondrial precursor
Elongation factor 2

Q8VC30

60

3

-

GLC155GTVLIHK

Q921G7

68

4

-

LQINAQNC585VHC588K3

P58252

95

3

3

C728LYASVLTAQPR

Formimidoyltransferase-cyclodeaminase

Q91XD4

60

2

-

AC438ALQEGLR3
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Uniprot
Accession

Protein name

Glyceraldehyde-3-phosphate dehydrogenase
Iron-sulfur cluster assembly enzyme ISCU,
mitochondrial precursor
Isocitrate dehydrogenase [NADP] cytoplasmic

P16858

36

2

-

VPTPNVSVVDLTC245R3

Q9D7P6

18

3

-

LHC139SMLAEDAIK

O88844

47

-

2

DLAAC379IK

L-lactate dehydrogenase C chain

P00342

36

3

-

VIGSGC163NLDSAR

Long-chain-fatty-acid--CoA ligase 1

P41216

78

3

2

C242GVEIISLK3

Nicotinate-nucleotide pyrophosphorylase [carboxylating]

Q91X91

32

4

3

C111SGIASAAATAVEVAR3

Peptidyl-prolyl cis-trans isomerase A

P17742

18

-

3

IIPGFMC62QGGDFTR3

Selenium-binding protein 1

P17563

52

2

4

C8GPGYSTPLEAMK3

S-formylglutathione hydrolase

Q9R0P3

31

-

3

C11FGGLQK

-/-

Three eNOS mouse livers were analyzed by MRC and mPEG-biotin protein capture methods and the mPEG-biotin
peptide capture method (see Fig. 1C). Sequence-to-spectrum assignments from three biological replicates were
combined in Scaffold. The proteins listed above satisfied three criteria: (1) identified by at least one protein capture
method (≥2 unique peptides), (2) confirmed by a sulfonic acid-containing peptide sequence, and (3) not identified in
the respective UV-exposed samples. Uniprot accession numbers correspond to the full-length unprocessed precursor
when available (www.uniprot.org). Additional accessions were listed if the observed peptides could not distinguish
between protein isoforms.
1
Number of unique peptides identified in protein capture experiment from 3 biological replicates (does not include
sulfonic acid-containing peptides). A null value indicates the protein did not meet the threshold criteria and was
considered not identified.
2
Cysteinyl-containing tryptic peptide sequences identified by peptide capture. The indicated cysteine residue(s) was
identified as sulfonic acid and corresponds to the unprocessed mouse precursor protein.
3
Cysteinyl-containing peptide sequences that were also identified in the wild type mouse liver (Supplementary Table
1).
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Protein name
Alcohol dehydrogenase 1
Betaine--homocysteine Smethyltransferase 1
Cytochrome c,
Cytochrome P450 2D10
Cytochrome P450 2E1
Cytochrome P450 2F2
Sulfite oxidase, mitochondrial

Accession
number
P00329
O35490
P62897
P24456
Q05421
P33267
Q8R086

PDB file

Coordinated cysteines

1u3w

98, 101, 104, 112, 175

1umy

299, 300

2b4z

15, 18

2f9q

443

3e6i

437

2nnj

436

2a9d

265

Supplementary Table 2.3: Cysteine residues coordinated with metals
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Supplementary Table 2.4: Endogenously S-nitrosylated proteins sensitive to Trx/TrxR-mediated denitrosylation.
Trx-sensitive proteins

Accession
number

Molecular
weight
(kDa)

1,4-alpha-glucan-branching enzyme

Q9D6Y9

80

10-formyltetrahydrofolate dehydrogenase

Q8R0Y6

99

2-hydroxyacyl-CoA lyase

Q9QXE0

64

40S ribosomal protein S3

P62908

27

40S ribosomal protein S4, X isoform

P62702

30

4-hydroxyphenylpyruvate dioxygenase

P49429

45

5-oxoprolinase

Q8K010

138

60S ribosomal protein L17

Q9CPR4

21

Q8CAY6

41

Acetyl-CoA acetyltransferase, mitochondrial precursor

Q8QZT1

45

Aconitate hydratase, mitochondrial

Q99KI0

85

Adenosine kinase
Alanine--glyoxylate aminotransferase 2, mitochondrial
precursor
Aldehyde dehydrogenase family 8 member A1

P55264

40

Q3UEG6

57

Q8BH00

54

Aldehyde dehydrogenase X, mitochondrial precursor

Q9CZS1

58

Aldehyde dehydrogenase, mitochondrial precursor

P47738

57

Alpha-aminoadipic semialdehyde dehydrogenase

Q9DBF1

56

Argininosuccinate lyase

Q91YI0

52

Aspartate aminotransferase, mitochondrial precursor

P05202

47

Acetyl-CoA acetyltransferase, cytosolic

89

ATP-citrate synthase

Q91V92

120

Betaine--homocysteine S-methyltransferase 1

O35490

45

Bifunctional aminoacyl-tRNA synthetase

Q8CGC7

170

Catalase

P24270

60

Cystathionine gamma-lyase

Q8VCN5

44

Cytochrome b-c1 complex subunit 1

Q9CZ13

53

Cytochrome c, somatic

P62897

12

Cytochrome P450 27, mitochondrial

Q9DBG1

61

Cytochrome P450 2C54

Q6XVG2

56

Cytochrome P450 2E1

Q05421

57

Cytochrome P450 2F2

P33267

56

Cytosol aminopeptidase

Q9CPY7

56

Dihydrolipoyl dehydrogenase, mitochondrial precursor

O08749

54

Dihydroxyacetone kinase

Q8VC30

60

Dimethylaniline monooxygenase [N-oxide-forming] 3

P97501

61

Elongation factor 2

P58252

95

Enoyl-CoA hydratase, mitochondrial precursor

Q8BH95

31

Epoxide hydrolase 2

P34914

63

Ester hydrolase C11orf54 homolog

Q91V76

35

Fatty acid synthase

P19096

272

Q9QXD6

37

P13707

38

Fructose-1,6-bisphosphatase 1
Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic

90

Q91W43

113

Glycogen phosphorylase, liver form

Q9ET01

97

Heat shock cognate 71 kDa protein

P63017

71

Hemoglobin subunit beta-1

P02088

16

Hydroxymethylglutaryl-CoA lyase, mitochondrial
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial
precursor
Liver carboxylesterase 31 precursor

P38060

34

Q9D6R2

40

Q63880

63

Q8VCU1

63

L-lactate dehydrogenase A chain

P06151

36

Long-chain specific acyl-CoA dehydrogenase, mitochondrial

P51174

48

Long-chain-fatty-acid--CoA ligase 1

P41216

78

Long-chain-fatty-acid--CoA ligase 5

Q8JZR0

76

Malate dehydrogenase, mitochondrial precursor

P08249

36

Membrane-associated progesterone receptor component 1

O55022

22

Microsomal glutathione S-transferase 1

Q91VS7

18

Non-specific lipid-transfer protein

P41216

78

Peroxisomal carnitine O-octanoyltransferase

Q9DC50

70

Peroxisomal sarcosine oxidase

Q9D826

44

Phenylalanine-4-hydroxylase

P16331

52

Phosphoglucomutase-1

Q9D0F9

62

Probable urocanate hydratase

Q8VC12

75

Profilin-1

P62962

15

Liver carboxylesterase 31-like precursor

91

Glycine dehydrogenase [decarboxylating], mitochondrial

Pyruvate carboxylase, mitochondrial precursor

Q05920

130

Regucalcin

Q64374

33

Sarcoplasmic/endoplasmic reticulum calcium ATPase 2

O55143

115

Sodium/potassium-transporting ATPase subunit alpha-1

Q8VDN2

113

Sorbitol dehydrogenase

Q64442

38

Staphylococcal nuclease domain-containing protein 1
Succinate dehydrogenase [ubiquinone] flavoprotein subunit,
mitochondrial
Sulfotransferase 1A1

Q78PY7

102

P32020

59

P52840

34

Thiosulfate sulfurtransferase

P52196

33

Ubiquitin-like modifier-activating enzyme 1 X

Q02053

118

UDP-glucuronosyltransferase 2B5

P17717

61

Uricase

P25688

35

Very long-chain acyl-CoA synthetase
Very long-chain specific acyl-CoA dehydrogenase,
mitochondrial precursor

O35488

70

P50544

71

Liver lysates remained untreated or exposed to 150nM Trx, 150nM TrxR, 100uM NADPH, for 30 min at 37 oC. Following this, protein lysates
were processed by the MCR and mPEGb protein capture approaches. Comparisons were made between the protein identifications from Trx
sample and the untreated sample. Proteins confirmed as endogenously S-nitrosylated by complementary proteomic approaches (see Supplementary
Table 1, main text), which were subsequently identified in the untreated sample but not in the Trx-treated sample were considered as sensitive to
reduction and are putative targets for denitrosylation by these species.
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3.1

Abstract
S-nitrosylation is defined as the covalent addition of nitric oxide to selective

protein cysteine residues that can regulate protein activity across a variety of organs and
cellular systems. Nevertheless, fundamental questions regarding S-nitrosylation still
remain unanswered, including the mechanism by which •NO selectively modifies protein
cysteine residues to form S-nitrosocysteine. One proposed mechanism mandates the
transfer of a nitrosonium ion to a reduced thiol of a cysteine residue. S-nitrosoglutathione
(GSNO), a major endogenous S-nitrosothiol, has been proposed as a mediator of these in
vivo trans-S-nitrosation reactions. Herein, we precisely mapped the site of modification in
a population of cysteine residues targeted for transnitrosation by GSNO and reveal
specific electrostatic properties within the protein environment for S-nitrosocysteine
formation. Using a transnitrosation intermediate, we describe a mechanism for GSNO
catalysis that requires a single basic residue rather than the acid-base pair which has
previously been described (Perez-Mato et al. 1999). Using this novel mechanism for
transnitrosation via GSNO, our GSNOR-/- dataset was then revisited to identify cysteines
which may also be targeted via this mechanism. By extracting the structural elements that
mediate GSNO transnitrosation, we explore the influence of protein structure on cysteine
selectivity.

3.2

Introduction
S-nitrosothiols (RSNOs) are thioesters of nitrite thought to be a major store of

nitric oxide (•NO) within the body. RSNOs have been identified across a variety of cell
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types and found in many different tissues signifying their role in transport of nitric oxide
throughout the body. They have also been shown to play an important role in health and
disease (Butler et al. 2006) and have been used in many studies as exogenous sources of
nitric oxide. While it is possible to synthesize and utilize these compounds for in vitro
studies, the in vivo mechanisms of S-nitrosothiol formation and stability are not very well
understood.
Because of the proposed role of S-nitrosothiols in nitric oxide signaling, many in
vitro studies have been aimed at investigating those factors that can influence the stability
of S-nitrosothiols in vivo (Al-Sa’doni et al. 2000). S-nitrosothiols can modify thiols by
transfer of a nitrosonium equivalent through a process known as transnitrosation. When
this process occurs on reduced cysteine residues within proteins, it can result in alteration
of protein function. These S-nitrosylated proteins have been implicated in a variety of
cellular processes including apoptosis (Hara et al. 2001), chromatin remodeling (Nott et
al. 2008), and cell permeability (Thibeault et al. 2010). Data have shown that it is a
discriminating modification that only targets select cysteine residues on specific proteins.
However, what remains unclear is how the selectivity of this modification is derived. It
has been proposed that multiple chemistries occur in vivo resulting in different sites of Snitrosylation. While it is known that S-nitrosothiols can transnitrosate protein cysteine
residues, the mechanism of this exact process (or processes) is unknown.
It has been proposed that S-nitrosoglutathione is a major endogenous trans-Snitrosating agent. As a tripeptide, GSNO is a much larger molecule than the diatomic
species nitric oxide. While its size may appear to be an impediment when compared to
•

NO, the presence of its two additional residues (glutamic acid and glycine) may allow
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for more controlled delivery of nitrosonium ion to the targeted cysteine. The literature
provides several examples of GSNO-binding proteins that may offer insight into this
mechanism during transnitrosation. Crystal structures of human glutathione transferase
P1-1 (hGSTP1-1) show that GSNO binds to the enzyme in a manner similar to its
substrate GSH by forming hydrogen bonding interactions with glutamic acid and glycine
(Oakley et al., Tellez-Sanz et al.). Molecular modeling studies of the transcription factor
OxyR also showed that GSNO docks to the protein via hydrogen bonding interactions
between the γ-glutamyl amine of GSNO and the γ-carboxylate of Asp202 (Kim et al.
2002). Docking simulations by Staab et al. similarly showed that residues in alcohol
dehydrogenase 3 (most recently also identified as GSNO reductase) are capable of
forming hydrogen bonds with the tripeptide (Staab et al. 2009).
In addition to hydrogen bonding, electrostatic interactions have also been
proposed to influence transnitrosation reactions involving GSNO. Stamler et al. posited
that charged residues within hemoglobin were capable of influencing the S-nitrosylation
of Cys93β (Stamler et al. 1997). Depending on the conformational state of the protein,
the proximity of basic or acidic residues to Cys93β would either promote the Snitrosylation or denitrosylation of the cysteine, respectively. The role of flanking
acidic/basic residues in S-nitrosylation has since been extended to incorporate the
reactivity of GSNO within the three dimensional microenvironment of the targeted
cysteine. Perez-Mato et al. proposed that γ-COOH of Asp355 in methionine
adenosyltransferase (MAT) protonated GSNO resulting in the donation of a nitrosonium
ion from GSNO to form SNO-Cys121 (Perez-Mato et al. 1999). Mutation of this Asp355
to serine significantly reduced the ability of GSNO to transnitrosate Cys121 thereby
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inactivating MAT. Acidic residues were now thought to play a more direct role in
catalysis of GSNO.
Several studies have been aimed at understanding the chemical reactivity of Snitrosothiols such as GSNO (Aruslamy et al 1999; Wang et al. 2002, Baciu et al. 2003).
More recently, work within our own group utilized theoretical studies to better explain
which resonance forms of RSNOs were favored under varying conditions (Timerghazin
et al. 2007). Density-functional theory coupled with natural resonance theory analysis
showed that S-coordination of the SNO group with various Lewis acids can promote the
formation of an ionic species, i.e. a nitrosonium ion. While Lewis acids were used as
models of basic protein residues, the best assessment of RSNO reactivity would be to
investigate its stability within its endogenous protein environment.
To further explore mechanisms necessary for GSNO-mediated transnitrosation to
occur in vivo, the S-nitrosoproteomes of mouse S-nitrosoglutathione reductase null
(GSNOR-/-) liver and thymus were resolved. GSNOR is an enzyme previously shown to
endogenously metabolize S-nitrosoglutathione (Liu et al. 2004). By comparing these
data to their wildtype SNO-proteomes, a GSNOR-/- unique population was derived and
further analyzed structurally for insight regarding the underlying molecular mechanism of
GSNO-mediated transnitrosation.
Herein, we present a novel approach for investigating the reactivity of GSNO as a
function of its protein environment. Using a transnitrosation intermediate, we show that
coordination of atoms in the surrounding cysteine environment controls the formation of
specific reaction products. Surprisingly, our model suggests that a lone basic residue
rather than an acid-base pair is sufficient for GSNO catalysis in vivo. Using this novel
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mechanism for transnitrosation via GSNO, our GSNOR-/- dataset was then revisited to
identify cysteines which may also be targeted via this mechanism.

3.3

Materials and Methods

Chemicals and Reagents. Unless otherwise stated, all chemicals and reagents were
purchased from Sigma-Aldrich.
Generation of GSNOR null mice. All mouse studies were reviewed and approved by the
Institutional Animal Care and Use Committee of the Children’s Hospital of Philadelphia
Research Institute. Generation of GSNOR-/- mice has been previously described and
characterized (Liu et al. 2004). WT C57BL/6 mice were obtained from Jackson
Laboratories and intact organs were recovered as previously described (Doulias et al.
2010). Intact livers and thymus were then immediately frozen in liquid nitrogen and
stored at -80 °C until needed.
Sample preparation for identification of S-nitrosylated proteins. Each organ was
homogenized in 3 mL of lysis buffer (250 mM Hepes-NaOH, pH 7.7, containing 1 mM
DTPA, 0.1 mM neocuproine, 1% Triton X-100, and protease inhibitors) on ice using a
Teflon pestle and a Jumbo Stirrer (Fisher Scientific). The homogenates were then
centrifuged at 13,000 × g for 30 min at 4 °C. The soluble protein fraction was collected
and the protein concentration was determined by the Bradford assay. Each sample
consisted of 21 mg of protein in 42 mL of lysis buffer (0.5 mg/mL). Liver protein lysates
were supplemented with 100 mM mannitol and 5 mM MMTS and split into 1- 28 mL
aliquot (untreated protein and peptide capture) and 1 – 14 mL aliquot (UV-illuminated).
The 14 mL aliquot was illuminated under a conventional UV transilluminator for 7 min
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on ice and the other aliquot was left untreated on ice. Liver and thymus lysates were then
further prepared for capture as previously described (Doulias et al. 2010).
Capture of S-nitrosylated proteins and peptides via organomercury resin capture
(MRC). Wildtype and GSNOR-/- SNO-proteomes of mouse thymus and liver were
resolved using a previously described mercury-based mass spectrometric approach
known as organomercury resin capture (MRC) (Doulias et al. 2010). An organomercurial
derivative of Affi-Gel-10 N-hydroxysuccinimide-activated agarose gel for capture of Snitrosylated cysteines was synthesized as first described (McDonagh et al. 1976) and
utilized/prepared as previously described. Protein samples were prepared as described
above and loaded onto their respective MRC columns either for protein capture or oncolumn digestion thereby yielding peptides.
Detection of S-nitrosylated cysteines by mass spectrometric analysis. The protein
fractions obtained from the MRC capture method were analyzed by gel electrophoresis
liquid chromatography/tandem MS analysis (GeLC-MS/MS) as previously described
(Doulias et al. 2010). Protein samples were mixed with 6× Laemmli sample buffer and
equal volumes (20 μL) were loaded on NuPAGE 10% Bis-Tris gels (Invitrogen). Proteins
were electrophoresed in Mops running buffer for approximately 1 cm and visualized by
colloidal blue stain (Invitrogen). Stained gels were immediately processed by in gel
trypsin digestion after each lane was cut into three slices and individually. Tryptic peptide
digests were analyzed by a hybrid LTQ-Orbitrap mass spectrometer (Thermo Electron)
coupled to a 2D LC system (Eksigent) and autosampler. Generation and Evaluation of
SEQUEST Peptide Assignments. Peptide assignments were generated, evaluated, and
analyzed as was previously described (Doulias et al. 2010). Briefly, DTA files were
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generated from MS/MS spectra extracted from the RAW data file with previously
described threshold criteria (Doulias et al. 2010) and submitted to Sorcerer-SEQUEST
(version 4.0.3, revision 11; Sagen Research). Database searching was performed against a
Uniprot database containing Mus musculus sequences from Swiss-Prot plus common
contaminants, which were then reversed and appended to the forward sequences. The
database was indexed with previously described parameters including static
modifications of cysteine by carboxyamidomethylation (+57 amu) for in-gel digestion or
by sulfonic acid (+48 amu) and methionine sulfone (+32 amu) for peptide affinity
capture. After generation of potential sequence-to-spectrum peptide assignments by
Sorcerer-SEQUEST, Scaffold (version 2.2; Proteome Software) was used to validate
protein identifications and perform manual inspection of MS/MS spectra as well as to
compare protein identifications across experimental conditions. Threshold criteria for
acceptance of protein identification were applied as previously described (Doulias et al.
2010). In-gel digestion experiments required a threshold of at least 99% protein
confidence with at least two unique peptides and at least 90% confidence with an
estimated protein false discovery rate of no greater than 5%. Xcorr thresholds were
applied to sulfonic acid-containing and non-modified peptides independently, so peptide
false discovery rate was no greater than 5%. Because one unique peptide per protein was
permitted, manual inspection of all MS/MS spectra was performed as previously
described.
Generation of GSNOR-/- unique SNO-proteome. Sulfonic acid-containing peptides
identified for each biological condition (wildtype or GSNOR null) for both organs
(thymus and liver) were pooled into 2-separate lists according to their experimental
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condition (untreated or UV-illuminated) (n=2 thymus, n=3 liver). Any peptides found
present in both the untreated and UV-illuminated lists were removed from the untreated
list. The remaining sulfonic acid-containing peptides were then matched to proteins
identified via the MRC protein capture method. The GSNOR-/- unique population was
derived by removing any sites of S-nitrosylation which were shared between the wildtype
and GSNOR-/- SNO-proteomes.
Gene ontology analysis. Subcellular localization was determined using UniProt
Knowledgebase protein database (www.uniprot.org) and statistics were calculated using
Babelomics 4.2 (http://babelomics.bioinfo.cipf.es). Ingenuity Pathway Analysis was used
to categorize molecular and cellular functions of proteins and calculate statistical
significance as compared to the entire mouse proteome.
Calculation of Hydropathy Indices. Kyte-Doolittle hydropathy indices for S-nitrosylated
cysteines were calculated in a 13 amino acid window using the ExPASy ProtScale tool.
Linear motif. Linear motifs surrounding all S-nitrosylated cysteines were calculated
using the Motif-X program (Schwartz et al. 2005). Sequences of identified SNO-peptides
are used as input and compared to the entire mouse proteome to determine if any amino
acids are overrepresented. Motifs were also calculated within a 13 amino acid window.
Distribution of secondary structure. Proteins identified as S-nitrosylated were
coordinated with their respective three dimensional structures in the RCSB Protein Data
Bank (PDB). Matched structures required the conservation of the cysteine residue
identified as S-nitrosylated and ≥ 50% sequence homology to target protein. Secondary
structure of SNO-cysteine and surrounding residues was obtained when structures were
viewed in the PyMOL molecular visualization software.
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Predicted pKa values. The program Propka 2.0 (Li et al. 2005) was used to calculate the
predicted pKa values of S-nitrosylated cysteines using their corresponding three
dimensional protein structures.
Calculated surface exposure. The relative residue surface accessibility (RSA) for all
cysteines within the S-nitrosoproteome was calculated with Naccess 2.1.1 using the
radius of a water molecule (1.4 Å2) as a probe (Lee & Richards et al. 1971). Cysteines
with a relative RSA less than 10% were designated as buried whereas a relative RSA
greater than 10% meant that the cysteine residue was solvent accessible.
Molecular dynamics simulations. The structure of 2DGV was obtained as previously
described above. Molecular dynamics simulations were performed using Amber package
with Amber99SB force field. Explicit solvent model was used with a TIP3P water in
truncated octahedron periodic box with a spacing distance of 9.0 Å around the molecule.
For modeling of the trans-S-nitrosation intermediate, an artificial residue named CYG
was defined in place of target cysteine (Figure 3.1). CYG contains two fragments (glutamic acid and nitroxyl disulfide) which are undefined in the standard force field.
Therefore, previously defined parameters were used to describe -glutamic acid (Rigsby
et al. 2007) and parameters for nitroxyl disulfide were calculated using generalized
Amber force field (GAFF) combined with B3LYP/6-31G(d) charges fitted by Restrained
Electrostatic Potential (RESP) ESP charge Derive (R.E.D.) software (Dupradeau et al.
2010).
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Figure 3.1: CYG intermediate used in molecular dynamics simulations. Dotted line
indicates intermediate which replaces cysteine residue and is attached to the protein.

The protocol for MD simulations includes the following steps: waters were minimized,
while the protein remains static using an initial 500 steps of the steepest descent (SD)
algorithm with an additional 500 conjugate gradient (CG) algorithm steps to ensure
complete minimization. The entire system was then minimized with 1000 steps of the SD
algorithm and an additional 2500 steps of CG minimization. With the complex again held
static, the solvent was then equilibrated to 300 K over the course of 20 picoseconds. For
the simulation, time steps of 2 ps were used, periodic boundary conditions were
employed, the SHAKE algorithm was applied, and a non-bonded cutoff of 10.0 Å was
employed.
For simulated annealing calculations, the same preliminary calculations were used to
obtain an equilibrated system at 300 K. A series of MD simulations were run with the
protein initially restrained (heating to 600 K for 60 ps, equilibrating at 600 K for 10 ps,
cooling back to 300 K in 60 ps) and then unrestrained (heating to 600 K for 60 ps,
constant temperature for 10, 30 or 50 ps followed by cooling down to 300 K). Instead of
2ps, the time step was chosen to be 1 ps. Each simulation time was a total of 8 ns
resulting in a total sampling time for each modified cysteine of 24 ns (trajectories with
different annealing setup were merged). Dynamical Cross-Correlation Matrix (DCCM)
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plots were generated with a function available in the Amber toolkit using MD trajectories
as inputs. Plots were generated only for arrays of distances over simulation time for
charged groups pairs corresponding to DCCM elements greater than 0.75.
Quantum

mechanics/molecular

mechanics

(QM/MM)

calculations.

ONIOM-

PCM/X(ε=4.24)(PBE0/def2-SV(P)+d:Amber95) was used for QM/MM calculations to
further investigate the interaction of close-lying arginine and -SN(O)S- group of Cyg675.

3.4

Results

Identification of the GSNOR-/- Unique SNO-proteome
By employing the MRC method, a total of 170 sites belonging to 150 proteins
were identified as being unique to the GSNOR null liver and thymus (Table 3.1). This
final SNO-proteome was derived by removing 69 sites which were shared between
wildtype and GSNOR null organs. With the previous identification of 2 proteins from
GSNOR null organs (Wei et al, Lima et al.), this corresponds to the discovery of 99%
novel targets of S-nitrosylation in GSNOR null SNO-proteome. Gene ontology analysis
using Babelomics 4.2 (Medina et al. 2010) revealed that the top four primary subcellular
locations of GSNOR-/- unique proteins were cytoplasm (n=25), mitochondria (n=24),
membrane (n=15), and ribosome (n=16) (Figure 3.2A). Those proteins located in
membrane, mitochondria, and ribosome were calculated to be statistically significant as
compared to the entire mouse proteome (p-values=3.80E-04, 1.13E-10, and 6.12E-07,
respectively). The molecular and cellular functions of these proteins were then identified
using Ingenuity Pathway Analysis which calculates enrichment as compared to the entire
mouse proteome. The majority of proteins were determined to be involved in small
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molecule biochemistry (n=52, p-value=1.10E-06) followed by nucleic acid metabolism
(Figure 3.2B). Thirty (30) proteins were found to also have additional sites of Snitrosylation in the wildtype unique population while sixteen (16) proteins were found to
be poly-S-nitrosylated (i.e. having more than one cysteine residue modified).

Figure 3.2: Gene ontology analysis of GSNOR null unique proteome. (A) Top four
cellular localization of GSNOR-/- unique S-nitrosylated cysteines. (B) Top four
statistically significant cellular functions of GSNOR-/- unique S-nitrosylated cysteines.
GSNOR-/- cysteines display large distribution of hydropathy indices
To characterize our GSNOR-/- unique S-nitrosated cysteines further, biochemical
and bioinformatic tools were used to interrogate their individual microenvironments. It
has been previously suggested that cysteines endogenously targeted for S-nitrosylation lie
in areas of increased hydrophobicity (Nedaspov et al. 2000). To further investigate this
hypothesis, Kyte-Doolittle hydropathy indices were calculated for GSNOR-/- unique
population of cysteine residues within a 13-residue window using the primary amino acid
sequence. With an average hydropathy index of -0.158±0.616 (n=154), GSNOR-/- unique
cysteines were determined to be slightly hydrophilic. Kernel density approximation was
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used to investigate the existence of subpopulations of hydropathy indices. The density of
indices peaked near the average value with nearly 60% (n=91) corresponding to cysteines
within hydrophilic regions of the protein with the remaining values corresponding to
cysteines in hydrophobic regions of the protein (Figure 3.3). GSNOR-/- unique cysteines
did not show a predisposition to lie in hydrophobic regions of the protein. This does not
differ significantly from what has been previously observed when examining the
wildtype liver SNO-proteome (Doulias et al. 2010) and the NO-Cys data set curated by
Marino and coworkers (Marino et al. 2010). With such a large amount of variation
between hydropathy values, it is difficult to conclude that hydropathy is an indicator of
endogenous S-nitrosation via S-nitrosoglutathione.

Hydrophobic

Density

Hydrophilic

Figure 3.3: Kernel density plot of S-nitrosylated cysteines from GSNOR-/- unique
SNO-proteome. Hydrophilic cysteines correspond to hydropathy indices values <0
(n=91) whereas hydrophobic values correspond to values ≥0 (n=63).
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Accessibility of S-nitrosoglutathione to targeted cysteines
To learn more about the influence of structure on GSNO-mediated mechanisms of
transnitrosation, a total of 111 GSNOR-/- unique S-nitrosated cysteines were coordinated
with their corresponding three dimensional structures as previously described (Table 3.2).
Biological assemblies were downloaded from the Protein Data Bank (PDB) in place of
the asymmetric unit to ensure that the protein was in its most physiologically relevant
state. To first investigate the accessibility of modified cysteines to small molecules such
as the tripeptide S-nitrosoglutathione, the surrounding secondary structures within a 21
amino acid window were characterized. The flanking secondary structure was examined
10 residues upstream and 10 residues downstream of the S-nitrosated cysteine which was
denoted by position 0. GSNOR-/- unique S-nitrosated cysteines were present most
frequently in coils (38%) closely followed by β-sheets (36%) and found least frequently
in α-helices (25%) (Figure 3.4). Modified cysteines were positioned near the end of a
short β-strand region (positions -3 to -1) and at the beginning of an extended stretch of
coils (position 1 to 10). With the exception of positions -3 to -1, coils were surprisingly
the predominant secondary structure surrounding S-nitrosated cysteines (positions -10 to
-4). The presence of these cysteines in more flexible regions of the proteins suggests that
these proteins may be more adept at accommodating molecules like the tripeptide GSNO.

Percentage of Residues
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Position

Figure 3.4: Distribution of secondary structure flanking S-nitrosylated GSNOR-/unique cysteine residue. Position 0 denotes S-nitrosylated cysteine of interest whereas
positions -10 to -1 denote residues upstream of cysteine and 1 to 10 denote residues
downstream of cysteine (n=91).
To further investigate the mechanism by which GSNO can transnitrosate cysteine
residues, the relative residue surface accessibility (RSA) of each GSNOR-/- unique
cysteine was calculated. Using the program NAccess, a 1.4Å probe representing the
radius of a water molecule was used to calculate RSA values for 65 GSNOR-/- unique
cysteines. With a value > 10% indicating solvent exposure, seventy-four percent of
cysteines were found to be buried (N = 48) while the remaining 17 were solvent exposed
(Figure 3.5). With an average relative RSA
value of 1.38±2.3, buried cysteines remained tightly distributed while solvent accessible
cysteines were much more broadly distributed (27.4±22.7). While these data are
comparable to what was previously found regarding the wildtype liver (Doulias et al.
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2010), it is a surprising result regarding potential mechanisms of GSNO-mediated Snitrosation. With > 50% of cysteines calculated as not being on the surface of the protein,
this alludes to a mechanism which must allow the tripeptide GSNO access to these
cysteines. This latter hypothesis is additionally supported by the above described data
showing that coils exist as the predominant secondary structure surrounding Snitrosylated cysteines.

Figure 3.5: Relative residue surface accessibility of GSNOR-/- unique S-nitrosated
cysteines (n=48 buried, n=17 exposed)

Predicted reactivity of GSNOR null cysteines

Using the program Propka 2.0, predicted pKa values were calculated for cysteines
within the GSNOR-/- unique SNO-proteome using their corresponding three dimensional
structures. Ninety-two (92) cysteines had an average predicted pKa = 9.12±2.45 (Figure
3.6). This is lower than the previously reported average pKa value of 10.0±2.10 (n=142)
predicted for the wildtype liver SNO-proteome (Doulias et al. 2010). These data suggest
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that the GSNOR-/- unique SNO-proteome may be enriched for a subpopulation of more

S-nitrosylated cysteines

reactive cysteines.

Predicted pKa value

Figure 3.6: Predicted pKa values for each S-nitrosylated GSNOR-/- unique cysteine
calculated using the program Propka 2.0 (n=92)

Role of three-dimensional environment on transnitrosation via GSNO
Molecular dynamics simulations were performed using the CYG intermediate in
place of the cysteine residue (see Materials and Methods) to investigate the mechanism
by which GSNO may transnitrosate cysteines endogenously (Houk et al. 2003). With the
intermediate weakly bound between the protein and glutathione, it can effectively
represent the influence of the protein environment on the formation of a specific reaction
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product (i.e. GSNO or SNO-cysteine). The RNA binding domain of heterogeneous
nuclear ribonucleoprotein M (PDB code 2DGV) was selected as the model protein.
2DGV has a small size (92 amino acids) which proves to be fairly stable during
molecular dynamic simulations (RMSD 1.14 Å after 2 ns simulation). Although C675 is
the only cysteine identified as being S-nitrosylated, 2DGV contains a total of 4 cysteines
(C652, C675, C693, & C708). All four cysteines contain charged residues in their
respective proximal environments making 2DGV a challenging system for identifying
true sites of transnitrosation via GSNO.
To analyze the influence of the protein environment on the intermediate CYG,
correlated motions between CYG and other residues were investigated across MD
simulations. Interactions of charged and polar groups of His, Arg, Lys, Asp, Glu, Gln,
and Asn with S, N, and O atoms of the CYG intermediate were specifically scrutinized.
Dynamical Cross-Correlation Matrices (DCCM) were used to visualize these interactions.
A single pixel corresponds to the correlation between two specific atoms. Atoms
displaying any correlated motions are given a positive cross-correlation coefficient with a
value of 1 (white) being the most correlated. Blue pixels correspond to atoms which are
the least correlated and therefore completely independent of onanother. DCCM plots
were generated for all four cysteines in 2DGV. When compared to unmodified cysteines
within the same protein, Cys675 displayed the largest region of atoms responsive to the
CYG intermediate (cross-correlation coefficient > 0.75) (Figure 3.7, top right).
Probability plots depicting the distances between highly correlated motions were
generated for Cyg675 (Figure 3.8) using trajectories of the MD simulations. Statistically
significant interactions between both sulfurs of nitroxyl disulfide and a close-lying
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arginine, Arg706, were observed. Both Sγ (sulfur belonging to GSNO) and S1 (sulfur
belonging to protein-cysteine residue) displayed maximum probability distances of
slightly less than 4 Angstroms. However, S1 was equally likely to be either 6 or 8 Å
(cumulative probability ~ 0.5) from Arg706 (Figure 3.8a) whereas Sγ showed a much
greater likelihood to be 4 Å from Arg706 (Figure 3.8b). Observed distances between Sγ
and Arg706 were calculated to be as large as 10 Å, but these states were far less
populated and pronounced than the 4 Å distance. The remaining 3 cysteines were also
examined to ascertain the influence of each microenvironment on the stabilization of the
CYG intermediate (data not shown). Probability plots for Cys693 point to an interaction
between Sγ and Lys684 but show that it occurs at a distance of nearly 7 Å. In fact, this
same lysine residue was more closely coordinated to the OE atom of CYG. A similar
finding of O-coordination was also observed between Cys708 and Arg709.
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Probability

Probability

Figure 3.7: DCCM plots of all four cysteines in 2DGV. Cyg652 (top left), Cys675 (top
right), Cyg693 (bottom left), & Cyg708 (bottom right). Cyg675 displays the largest
region of correlation as evidenced by large rectangular near bottom left of Cyg675 map.

Distance (in Angstroms)

Distance (in Angstroms)

Figure 3.8: Distance probability plots of CYG675 intermediate interaction with
neighboring basic residue. (A) Analysis of molecular dynamics trajectories shows
interaction between S1 of CYG675 intermediate and Arg706 occurs most frequently at a
4 Angstrom distance but also exists across a broad range of distances. (B) Sγ of CYG675
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also interacts with Arg706 but displays a higher probability of being within a 4 Å
distance.

A novel mechanism of S-nitrosation catalysis
A series of hybrid Quantum Mechanics/Molecular Mechanics (QM/MM)
calculations were performed to interrogate the interaction between Arg706 and the SN(O)S- group of Cyg675 and to also determine the final products of the transnitrosation
reaction. Coordination of Arg706 at Sγ led to the elongation of the corresponding Sγ-N
bond of GSNO (r(S-N) = 1.931 Å)), whereas the S1-N bond became shorter, suggesting
an increase in double bond character (Figure 3.9). Coordination to Sγ promotes the
formation of protein S-nitrosocysteine whereas coordination to S1 would lead back to the
reactants (GSNO and Protein-SH). These data are additionally supported by our
previously published data regarding the chemical reactivity of RSNOs based upon their
interactions with Lewis acids (Timerghazin et al. 2007).
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Figure 3.9: QM/MM calculations demonstrating S-coordination of Arg706 to
CYG675 in 2DGV

With a total of 111 S-nitrosocysteines coordinated to three dimensional structures,
QM/MM and molecular dynamics calculations for the entire GSNOR-/- unique proteome
would prove to be computationally expensive. Therefore, after the identification of this
novel GSNO-mediated mechanism in the model system 2DGV, the GSNOR-/- unique
proteome was then investigated to determine if any other cysteines might be subject to
this particular mechanism. Of the 111 cysteines coordinated to structures, 109 had at least
one charged residue within 6 Angstroms. Four cysteines had only acidic residues nearby
while twenty-two had only basic residues nearby. A total of 83 cysteines had both a basic
and acidic residue within 6 Angstroms.
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3.5

Discussion
To date, global investigations into the specificity of S-nitrosylation have revealed

a diversity of data, suggestive of multiple mechanisms taking place in vivo (Marino et al.
2009; Doulias et al. 2010). Therefore, the best approach for investigating a specific
mechanism would be to isolate those cysteines specifically targeted by that mechanism.
By perturbing the endogenous metabolism of GSNO, the GSNOR-/- mouse was used to
characterize those cysteines endogenously targeted for transnitrosation via GSNO. By
removing any S-nitrosocysteine residues also identified in the wildtype proteomes, a
novel GSNOR-/- unique proteome was derived. The biochemical and biophysical
properties of these cysteines did not differ significantly from those previously reported
for the wildtype proteome (Doulias et al. 2010). This suggests that there must be another
mechanism by which these cysteines are targeted for transnitrosation.
The chemical reactivity and stability of S-nitrosothiols has long been of interest to
the scientific community (Aruslamy et al. 1999; Wang et al. 2002, Baciu et al. 2003,
Timerghazin et al. 2007). As more recent data reveal the importance of RSNOs in health
and disease, it becomes even more critical to understand their reactivity in the
intracellular environment. GSNO is frequently used as an exogenous source of nitric
oxide for S-nitrosylation studies yet the mechanism by which it transnitrosates proteins in
vivo is not very well understood. Many studies have suggested a role of charged residues
in S-nitrosylation. Initially, charged residues were investigated to determine their
influence on cysteine nucleophilicity. Perez-Mato et al. further extended the role of
charged residues in the reactivity of GSNO during transnitrosation reactions. They
proposed a “push-pull” mechanism in the protein methionine adenosyltransferase
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whereby which a basic residue would deprotonate cysteine residue (“pull”) and an acidic
residue would promote donation of a NO+ from GSNO (“push”). Mutational analysis of
the acidic residue resulted in decreased nitrosation, suggesting its role in transnitrosation.
Herein, we describe a novel mechanism of transnitrosation which requires the
coordination of a basic residue to S-nitrosoglutathione to promote S-nitrosocysteine
formation. Utilizing the CYG intermediate allowed for a novel approach to monitoring
reaction intermediates as a function of the surrounding protein environment. Our
investigations demonstrate that positively charged residues coordinated to the sulfur atom
promote the formation of a nitrosonium ion. In the case of S-Coordination, the bond
length between the coordinated sulfur and nitrogen atom may increase, thereby
promoting transnitrosation to the alternate sulfur atom. Coordination of arginine to other
atoms in CYG such as oxygen CYG may alternatively help to stabilize the intermediate
and decrease the likelihood of a transnitrosation reaction taking place. These data suggest
that the surrounding protein environment can play both the dual role of catalyzing the
formation of protein S-nitrosocysteine as well as stabilizing the S-nitrosocysteine residue
once it is formed.
While the overwhelming presence of charged residues suggests that a mechanism
similar to 2DGV may occur in vivo for other GSNOR-/- unique proteins, further
experiments are needed to test this hypothesis. Although the majority of GSNOR-/unique cysteines were buried, the presence of charged residues on the surface of the
protein may also help to stabilize GSNO such that transnitrosation events can occur. This
is what Marino et al. characterized as an extended acid base motif. Understanding the
relationship between GSNO docking and base catalyzed-transnitrosation might help to

118

further distinguish populations of SNO-cysteines modified by GSNO. Those cysteines
which have both favorable GSNO docking and base-catalyzed mechanisms of
transnitrosation may refer to a population of cysteines which are most readily modified
by GSNO. Alternatively, GSNO docking may be favorable near the site of
transnitrosation yet no basic residues may be involved in catalysis. Transnitrosation via
GSNO is one of several proposed mechanisms for forming SNO-proteins; still, GSNOmediated transnitrosation may itself contain multiple mechanisms involving protein
electrostatics. Therefore, it is becoming increasingly important to design experiments that
distinguish the contributions of differing protein electrostatics. Present studies are
underway to investigate the influence of favorable GSNO docking on base catalyzed
transnitrosation reactions.

Table 3.1: Endogenously S-nitrosylated GSNOR-/- unique proteins in liver and thymus

Organ
Liver

Protein name
10-formyltetrahydrofolate dehydrogenase

Uniprot
Accession
Q8R0Y6

Protein
molecular
weight
(kDa)
99

Thymus

26S proteasome non-ATPase regulatory
subunit 1

Q3TXS7

106

C437VAYAESHDQALVGDK

Liver

2-oxo-4-hydroxy-4-carboxy-5ureidoimidazoline decarboxylase

Q283N4

20

RLQC141QPESELR

Liver

2-oxoisovalerate dehydrogenase subunit
alpha, mitochondrial

P50136

50

QMPVHYGC194K

Liver

3-hydroxyisobutyryl-CoA hydrolase,
mitochondrial

Q8QZS1

43

Thymus

40S ribosomal protein S11

P62281

18

Thymus
Liver
Thymus
Liver

40S ribosomal protein S17
40S ribosomal protein S2
40S ribosomal protein S26
40S ribosomal protein S27

P63276
P25444
P62855
Q6ZWU9

16
31
13
9

RGC44GGVITLNRPK
DVQIGDIVTVGEC131RPLSK
KC60PFTGNVSIR
NMSVHLSPC116FR
VC35EEIAIIPSKK
KLLMMAGIDDC222YTSAR
LHYC74VSCAIHSK
ARLTEGC77SFR

P61922

56

TMGC224LATTHSK
NKGVVLGGC467GDKSIR
AGAPPGLFNVVQGGAATGQFLC220HHREVAK
VLC164LAVAVGHVK
SRFC23RGVPDAK
IC71ANKYMVK
INKMLSC105AGADRLQTGMR
RLIPDGC195GVK

Liver

4-aminobutyrate aminotransferase,
mitochondrial
4-trimethylaminobutyraldehyde
dehydrogenase
60S ribosomal protein L10a

Q9JLJ2
P53026

56
25

Liver

60S ribosomal protein L10-like

P86048

25

119

Liver
Thymus

Peptide sequence
AVQMGMSSVFFNKGENC707IAAGR

Thymus
Liver
Liver
Liver
Liver
Liver
Liver
Thymus
Thymus
Liver
Thymus
Thymus
Liver
Thymus
Liver

60S ribosomal protein L13a
60S ribosomal protein L14
60S ribosomal protein L23
60S ribosomal protein L24
60S ribosomal protein L36a
60S ribosomal protein L4
60S ribosomal protein L6
60S ribosomal protein L7
60S ribosomal protein L8
7-dehydrocholesterol reductase
Actin, cytoplasmic 1
Actin-related protein 2
Adenylate kinase 2, mitochondrial
Adenylyl cyclase-associated protein 1
Aldehyde dehydrogenase X, mitochondrial

Thymus
Liver
Liver

Caspase-6
Catalase
Choline dehydrogenase, mitochondrial

23
24
15
18
12
47
33
31
28
54
42
45
26
52
58

C38EGINISGNFYR
C54MQLTDFILKFPHSAR
ISLGLPVGAVINC28ADNTGAK
MKVELC6SFSGYK
C88KHFELGGDKK
SGQGAFGNMC96RGGR
AKPHC51SRNPVLVR
FGIIC208MEDLIHEIYTVGKR
TELFIAAEGIHTGQFVYC90GKK
AIEC376SYTSADGLKHHSK
C285DVDIRKDLYANTVLSGGTTMYPGIADR
LC221YVGYNIEQEQK
LAENFC40VC42HLATGDMLR
C355VNTTLQIK
LGQKEGAKLLC388GGER

Q99K67
Q91XE4
Q922B2
O70133
Q8VDW0
Q8CGC7
Q922D8

103
35
57
149
49
170
101

SSPC776EKLKEVVFTK
VAVTGGTHGNEMC26GVYLAR
LQSGIC203HLFR
VRPGFCFHLC779SR
NC164PHVVVGTPGR
SC1377QFVAVRR
SC326KPKLIGNLAR

P97742

88

O08738
P24270
Q8BJ64

32
60
66

C394RQTYFAR
IFIIQAC146R
KLHFC271PKPSK
LVNADGEAVYC232KFHYKTDQGIK
AKADSAYHPSC516TC518K

120

Liver

Alpha-aminoadipic semialdehyde synthase,
mitochondrial
Aspartoacylase-2
Aspartyl-tRNA synthetase, cytoplasmic
ATP-dependent RNA helicase A
ATP-dependent RNA helicase DDX39
Bifunctional aminoacyl-tRNA synthetase
C-1-tetrahydrofolate synthase, cytoplasmic
Carnitine O-palmitoyltransferase 1, liver
isoform

Liver
Liver
Liver
Thymus
Thymus
Liver
Liver

P19253
Q9CR57
P62830
Q8BP67
P83882
Q9D8E6
P47911
P14148
P62918
O88455
P60710
P61161
Q9WTP6
P40124
Q9CZS1

Liver
Thymus
Thymus

WSTAC244AYLHPVLSRPNLR
FRGYSIPEC101QK
YSC359QREFALK
LTGIKHELQANC139YEEVKDR
DGALICTSC195R

Q9CZU6
P18760
O89053

52
19
51

Thymus
Thymus
Liver
Both
Liver
Liver
Thymus
Thymus

Citrate synthase, mitochondrial
Cofilin-1
Coronin-1A
Cullin-associated NEDD8-dissociated
protein 1
Cysteine and glycine-rich protein 1
Cysteine-rich protein 2
Cysteine-rich protein 2
Cytochrome P450 2D10
Cytochrome P450 3A11
Cytoplasmic FMR1-interacting protein 2
Cytosolic non-specific dipeptidase

Q6ZQ38
P97315
Q9DCT8
Q9DCT8
P24456
Q64459
Q5SQX6
Q9D1A2

136
21
23
23
57
58
146
53

Thymus

D-3-phosphoglycerate dehydrogenase

Q61753

57

C356LDAVVSTRHEMLPEFYK
NLDSTTVAVHGEEIYC58K
C129NKRVYFAEK
C8DKTVYFAEK
NLGVFPFPVAPYPYQLC496AVMREQGH
VC378KKDVELNGVYIPK
C98NEQPNRVEIYEK
DVGAETLLHSC300K
VLISDSLDPC18C19RK
NAGTC369LSPAVIVGLLR

Liver

D-beta-hydroxybutyrate dehydrogenase,
mitochondrial

Q80XN0

38

SPYC209ITK

Q8CHT0
Q9R0P5
O08553

62
19
62

SAFEYGGQKC347SAC350SR
AVIFC39LSADKK
THNSALEYNIFEGMEC439R

Q8CHR6

112

RGLPLAVKPVC1025

Liver

Dimethylaniline monooxygenase [N-oxideforming] 3

P97501

60

VVSKVQKSC509SHFYSR
ILC294GMVTIKPNVK

Liver
Thymus

Dimethylaniline monooxygenase [N-oxideforming] 5
DNA replication licensing factor MCM7

P97872
Q61881

60
81

LLLGPC468TPVQYR
GNIHIC378LMGDPGVAK

121

Liver

Delta-1-pyrroline-5-carboxylate
dehydrogenase, mitochondrial
Destrin
Dihydropyrimidinase-related protein 2
Dihydropyrimidine dehydrogenase
[NADP+]

Liver
Thymus
Thymus

Thymus
Thymus
Liver
Liver

Thymus
Liver
Liver

DNA-directed RNA polymerase II subunit
RPB9
ES1 protein homolog, mitochondrial
precursor
Fatty acid synthase
Fructose-bisphosphate aldolase B

Galectin-9
GDH/6PGL endoplasmic bifunctional
protein
Gephyrin

P60898

15

C89GHKEAVFFQSHSAR

Q9D172
P19096
Q91Y97

28
272
40

O08573

40

ALGAKHC219VKGVTEAHVDQK
VGDPQELNGITRSLC313AFRQAPLLIGSTK
ALNDHHVYLEGTLLKPNMVTAGHAC240TK
C258GGDIAFHLNPR
FEEGGYVVC73NTK
GMPFELC101FLVQR

Q8CFX1
Q8BUV3

89
83

C390LPQQIIFYIGHGELGHPAILVSR
C326SSKENILR

Q9Z2Z9
P15105
Q9CQM9

33
42
38

C2GIFAYLNYHVPR
ETDC461GVHINAGPEIGVASTK
KPAETNLRHIC117K
LTHAAPC148MLFMK

P47791

54

GVYAVGDVC355GK

Thymus

Glucosamine-fructose-6phosphateaminotransferase [isomerizing] 1
Glutamine synthetase
Glutaredoxin-3
Glutathione reductase, mitochondrial
precursor

Liver

Glycerol-3-phosphate dehydrogenase
[NAD+], cytoplasmic

P13707

38

IC102DQLKGHLK

Thymus

Guanine nucleotide-binding protein
G(I)/G(S)/G(T) subunit beta-1

P62874

37

ELAGHTGYLSC148C149R

Thymus

Guanine nucleotide-binding protein subunit
beta-2-like 1

P68040

35

TNHIGHTGYLNTVTVSPDGSLC207ASGGK

P14483
P11499
Q9Z2X1

30
83
46

TRAELDTVC106RHNYEGPETHTSLR
C412LELFSELAEDKENYKK
DLSYC267LSGMYDHR

Q9D0E1

78

DKFNEC675GHVLYADIK

Thymus
Liver
Thymus

Thymus
Thymus
Thymus
Thymus

H-2 class II histocompatibility antigen, A
beta chain precursor
Heat shock protein HSP 90-beta
Heterogeneous nuclear ribonucleoprotein F
Heterogeneous nuclear ribonucleoprotein
M

122

Thymus
Thymus

Heterogeneous nuclear ribonucleoproteins
C1/C2
Histidine triad nucleotide-binding protein 1

Q9Z204
P70349

34
14

Thymus

Histone-binding protein RBBP7

Q60973

48

IVGC46SVHKGFAFVQYVNER
IIFEDDRC38LAFHDISPQAPTHFLVIPK
TPSSDVLVFDYTKHPAKPDPSGEC166NPDLR
VHIPNDDAQFDASHC97DSDKGEFGGFGSVTGK

Liver

Hydroxymethylglutaryl-CoA lyase,
mitochondrial

P38060

34

TSSKVAQATC323KL

Thymus
Liver
Liver
Thymus

Hypoxanthine-guanine
phosphoribosyltransferase
Importin-5
Indolethylamine N-methyltransferase
Inositol monophosphatase

P00493
Q8BKC5
P40936
O55023

25
124
29
30

DLNHVC206VISETGK
TKENVNATENC972ISAVGK
VLRC142DVTK
EKYPC64HSFIGEESVAAGEK

Thymus

Isocitrate dehydrogenase [NAD] subunit
alpha, mitochondrial precursor

Q9D6R2

40

Q9CXF0
Q91WN4
P14733
P58710
Q60767
P34884
P14152

52
55
67
50
197
13
37

C351SDFTEEIC359R
GVVC425DKREPDGIR
NC45FYIPK
VAVIGGGLVGALNAC25FLAK
C199QSLTEDLEFRK
FTRGDDILLSPC354FQR
C83LGLDITK
LLC81GLLSDRLHISPDR
SAPSIPKENFSC154LTR

P08249

36

EGVVEC275SFVQSK

Liver
Liver
Thymus
Liver
Thymus
Thymus
Thymus

Liver
Thymus

Methylcrotonoyl-CoA carboxylase subunit
alpha, mitochondrial
Myosin light polypeptide 6

Q99MR8
Q60605

79
17

YC450LHQYNIVGLR
ILYSQC32GDVMR

Thymus

NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 10, mitochondrial
precursor

Q99LC3

41

VITVDGNIC67SGK

123

Thymus

Kynureninase
Kynurenine 3-monooxygenase
Lamin B1
L-gulonolactone oxidase
Lymphocyte antigen 75 precursor
Macrophage migration inhibitory factor
Malate dehydrogenase, cytoplasmic
Malate dehydrogenase, mitochondrial
precursor

NADH dehydrogenase [ubiquinone] ironsulfur protein 6, mitochondrial

P52503

13

TGTC104GYC107GLQFKQHHH

Thymus

NADH-ubiquinone oxidoreductase 75 kDa
subunit, mitochondrial precursor

Q91VD9

80

Thymus
Liver

NADPH--cytochrome P450 reductase
Nitrilase homolog 1

P37040
Q8VDK1

77
36

FC64YHERLSVAGNC75R
LIHEGGAHIYVC630GDAR
VHPNSVHIC472AVAVEYEAK
THLC161DVEIPGQGPMR

Thymus
Thymus
Thymus
Liver

Non-POU domain-containing octamerbinding protein
PDZ and LIM domain protein 1
Peptidyl-prolyl cis-trans isomerase A
Peroxisomal 2,4-dienoyl-CoA reductase

Q99K48
O70400
P17742
Q9WV68

55
36
18
31

Q9R0H0

75

FAC147HSASLTVR
GHFFVEDQIYC305EKHAR
HTGPGILSMANAGPNTNGSQFFIC115TAK
HGC53HTVIVGR
NLC559LLYSLYGISQK
ASEAHC531HYVTVK

Q9DC50
P16331
Q9EPE9
Q8VC12
P62962
P17918
P50580
O35955
Q921K8
Q3UPL0
Q05920

70
52
132
75
15
29
44
29
102
134
130

LHGRPGC437C438YETAMTR
VFHC265TQYIR
AVVGNAVPC10GARPGGAR
AYPIDQYPC95R
C71SVIRDSLLQDGEFTMDLR
C62DRNLAMGVNLTSMSK
KADVIKAAHLC149AEAALR
ATNDSVVADKSC70EKIHFIAPK
VVLAAHEAMLC279APK
C1140LSSATDPQTKR
INGCAIQC376R

Q9D051
P47199
Q91V41

39
35
24

PVGHC249LEAAAVLSK
VHAC45GVNPVETYIR
FMADC40PHTIGVEFGTR

Liver
Liver
Liver
Liver
Liver
Thymus
Thymus
Thymus
Thymus
Thymus
Liver
Liver

Peroxisomal acyl-coenzyme A oxidase 1
Peroxisomal carnitine Ooctanoyltransferase
Phenylalanine-4-hydroxylase
Probable cation-transporting ATPase 13A1
Probable urocanate hydratase
Profilin-1
Proliferating cell nuclear antigen
Proliferation-associated protein 2G4
Proteasome subunit beta type-10 precursor
Protein FAM115C
Protein transport protein Sec31A
Pyruvate carboxylase, mitochondrial

Thymus
Liver
Thymus

Pyruvate dehydrogenase E1 component
subunit beta, mitochondrial precursor
Quinone oxidoreductase
Ras-related protein Rab-14

124

Liver

Regucalcin
RNA-binding protein Raly

Q64374
Q64012

33
33

VEC8VLRENYR
VAGC51SVHKGYAFVQYANER

Liver
Liver
Thymus

Sarcoplasmic/endoplasmic reticulum
calcium ATPase 2
Sepiapterin reductase
Serine protease inhibitor A3K

O55143
Q64105
P07759

115
28
47

SMSVYC498TPNKPSR
LKSDGALVDC235GTSAQK
HFRDEELSC259SVLELK

Thymus

Serine/threonine-protein phosphatase 2A 56
kDa regulatory subunit gamma isoform

Q60996

55

C334VSSPHFQVAER

Thymus
Liver

Serine/threonine-protein phosphatase 6
regulatory ankyrin repeat subunit B
S-formylglutathione hydrolase

B2RXR6
Q9R0P3

107
31

Q64213

70

TC408LHAAAAGGNVEC420IK
AYDATC206LVK
C282GGAGHIASDC292KFQRPGDPQSAQDK
SITNTTVC279TK

Q8K2B3

73

GC357GPEKDHVYLQLHHLPPEQLATR

Q9WUM5
Q9R1T2
P42932
Q8VBW8
Q62264
O55201

36
39
60
20
17
121

IIC60QGFTGK
DVIIKVDQIC150HR
NIQAC36KELAQTTR
RQLVLLNPYAALC168NR
SIC67VEVDHGLLPR
VELHSTC734QTISVDR

Q01853
P40142

89
68

LADDVDLEQVANETHGHVGADLAALC415SEAALQAIR
TVPFC386STFAAFFTR

Q99JY0
P99024
Q02053
O70475

51
50
118
55

KDGGQYALVAAC459AAGGQGHAMIVEAYPK
REIVHIQAGQC12GNQIGAK
C588VYYRKPLLESGTLGTK
AADLKYIEAC112ARR

Liver

Thymus

Splicing factor 1
Succinate dehydrogenase [ubiquinone]
flavoprotein subunit, mitochondrial
precursor

Thymus
Thymus

Succinyl-CoA ligase [GDP-forming] subunit
alpha, mitochondrial
SUMO-activating enzyme subunit 1
T-complex protein 1 subunit theta
Tetratricopeptide repeat protein 36
Thyroid hormone-inducible hepatic protein
Transcription elongation factor SPT5
Transitional endoplasmic reticulum
ATPase
Transketolase

Thymus
Thymus
Both
Liver

Trifunctional enzyme subunit beta,
mitochondrial precursor
Tubulin beta-5 chain
Ubiquitin-like modifier-activating enzyme 1
UDP-glucose 6-dehydrogenase

Liver
Thymus
Liver
Liver
Thymus
Thymus
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Liver
Thymus

Liver

Uncharacterized protein KIAA0564
homolog

Q8CC88

213

HNNC1415VTLTHTNQVVR

Liver
Liver
Thymus

UPF0317 protein C14orf159 homolog,
mitochondrial
Uricase
Valyl-tRNA synthetase

Q8BH86
P25688
Q9Z1Q9

66
35
140

AFLC419KDGDPKSPR
C188FATQVYC195K
C1184SIHLQLQGLVDPAR

Thymus

Voltage-dependent anion-selective channel
protein 1

Q60932

32

EHINLGC140DVDFDIAGPSIR
YQVDPDAC245FSAK

Thymus
Thymus

Voltage-dependent anion-selective channel
protein 3
WD repeat-containing protein 1

Q60931
O88342

31
66

YKVC65NYGLTFTQK
C438FSIDNPGYEPEVVAVHPGGDTVAVGGTDGNVR

126

Table 3.2: GSNOR-/- unique proteins coordinated to PDB structures
Protein name
10-formyltetrahydrofolate
dehydrogenase

UNIPROT
Accession

Peptide sequence

Structure

Q8R0Y6

AVQMGMSSVFFNKGENC707IAAGR

2o2p (98%) 405-902

2-oxoisovalerate dehydrogenase
subunit alpha, mitochondrial

P50136

QMPVHYGC194/152K

2bff (93%) 48-442

3-hydroxyisobutyryl-CoA hydrolase,
mitochondrial
40S ribosomal protein S11
40S ribosomal protein S11
40S ribosomal protein S11

Q8QZS1
P62281
P62281
P62281

RGC44/45GGVITLNRPK
KC60/59PFTGNVSIR
NMSVHLSPC116/115FR
DVQIGDIVTVGEC131/128RPLSK

3bpt (83%) 34-385
3iz6 (68%) 41-126/chain P
3iz6 (68%) 41-126/chain P
3jyv (74%)69-149/chain Q

40S ribosomal protein S14
40S ribosomal protein S2
40S ribosomal protein S27

P62264
P25444
Q6ZWU9

C85KELGITALHIK
KLLMMAGIDDC222/130YTSAR
ARLTEGC77/79SFR

2zkq (100%) 23-147/chain k
2zkq (96%) 101-249/chain e
3iz6 (84%) 31-80

P61922

TMGC224/196LATTHSK

1ohv (93%) 39-499

4-aminobutyrate aminotransferase,
mitochondrial

P61922

NKGVVLGGC467/439GDKSIR

1ohv (93%) 39-499

4-trimethylaminobutyraldehyde
dehydrogenase
60S ribosomal protein L10a
60S ribosomal protein L10-like
60S ribosomal protein L10-like
60S ribosomal protein L10-like
60S ribosomal protein L13a
60S ribosomal protein L23
60S ribosomal protein L24
60S ribosomal protein L36a
60S ribosomal protein L4

Q9JLJ2
P53026
P86048
P86048
P86048
P19253
P62830
Q8BP67
P83882
Q9D8E6

AGAPPGLFNVVQGGAATGQFLC220/229HHREVAK
VLC164/163LAVAVGHVK
SRFC23/22RGVPDAK
INKMLSC105/104AGADRLQTGMR
IC71/70ANKYMVK
C38/37EGINISGNFYR
ISLGLPVGAVINC28ADNTGAK
MKVELC6SFSGYK
C88KHFELGGDKK
SGQGAFGNMC96/95RGGR

1a4s (69%) 2-494
3izr (63%)3-217
2zkr (99%) 4-169 (chain h)
2zkr (99%) 4-169 (chain h)
2zkr (99%) 4-169 (chain h)
2zkr (97%)7-142 (chain j)
2zkr (100%) 16-139/chain k
2zkr(100%)4-56/chain u
2zkr(100%)2-93/chain 4
2zkr (97%) 7-263/chain c
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4-aminobutyrate aminotransferase,
mitochondrial

P14148
P62918

FGIIC208MEDLIHEIYTVGKR
TELFIAAEGIHTGQFVYC90GKK

2zkr (98%)111-270/chain w
2zkr (99%)2-246/chain a

Actin, cytoplasmic 1

P60710

C285DVDIRKDLYANTVLSGGTTMYPGIADR

2btf(100%)2-375

Actin-related protein 2
Actin-related protein 2
Adenylyl cyclase-associated protein 1
Aldehyde dehydrogenase X,
mitochondrial
Aspartoacylase-2
Aspartyl-tRNA synthetase,
cytoplasmic
ATP-dependent RNA helicase A
ATP-dependent RNA helicase DDX39
ATP-dependent RNA helicase
DDX3X

P61161
P61161
P40124

C20GYAGSNFPEHIFPALVGRPIIR
LC221YVGYNIEQEQK
C355/356VNTTLQIK

2p9i (76%)9-362
1tyq(100%)143-350/chain B
1k8f (98%)318-474

Q9CZS1
Q91XE4

LGQKEGAKLLC388/369GGER
VAVTGGTHGNEMC26GVYLAR

3inj (75%) 26-519
3nh4

Q922B2
O70133
Q8VDW0

LQSGIC203/255HLFR
VRPGFCFHLC779/440SR
NC164/165PHVVVGTPGR

1asy (56%) 22-501
3kx2(25%)374-1115
1xti(93%)45-425

Q62167

VRPC298VVYGGAEIGQQIR

2i4i(97%)168-5880

Carbonyl reductase [NADPH] 1
Caspase-6
Catalase
Citrate synthase, mitochondrial
Citrate synthase, mitochondrial
Cofilin-1
Coronin-1A
Cysteine and glycine-rich protein 1
Cysteine-rich protein 2
Cysteine-rich protein 2

P48758
O08738
P24270
Q9CZU6
Q9CZU6
P18760
O89053
P97315
Q9DCT8
Q9DCT8

ALKNC150/149RLELQQK
IFIIQAC146/163R
LVNADGEAVYC232/231KFHYKTDQGIK
FRGYSIPEC101/74QK
YSC359/332QREFALK
LTGIKHELQANC139YEEVKDR
DGALICTSC195R
NLDSTTVAVHGEEIYC58K
C129/15NKRVYFAEK
C8/15DKTVYFAEK

1wma(88%)7-277
3od5 (86%)14-273
4blc (92%)4-501
3enj (96%) 28-464
3enj (96%) 28-464
1q8g (98%)1-166
2aq5
1b8t(89%)1-193
2cu8 (81%) 126-184
2cu8 (98%) 1-63

Cytochrome P450 2D10
Cytochrome P450 3A11
Cytosolic non-specific dipeptidase

P24456
Q64459
Q9D1A2

NLGVFPFPVAPYPYQLC496/493AVMREQGH
VC378/377KKDVELNGVYIPK
DVGAETLLHSC300K

2f9q (69%) 37-500
1tqn (73%) 30-499
2zog
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60S ribosomal protein L7
60S ribosomal protein L8

Destrin
Dihydrolipoyl dehydrogenase,
mitochondrial
Dihydropyrimidinase-related protein
2

Q9R0P5

AVIFC39LSADKK

1ak6 (95%)2-165

O08749

VC484/449HAHPTLSEAFR

1zmd(95%)37-509

O08553

THNSALEYNIFEGMEC439R

2vm8 (98%)14-490

P60898

C89/78GHKEAVFFQSHSAR

3h0g (48%)14-125/chain I

Q921G7

VTVFAEGC247/215HGHLAK

2gmh(93%)38-616

Fatty acid synthase

P19096

VGDPQELNGITRSLC313AFRQAPLLIGSTK

3hhd (87%) 2-853

Fructose-bisphosphate aldolase B
Galectin-9
Galectin-9
Glucosamine-fructose-6phosphateaminotransferase
[isomerizing] 1
Glucosamine-fructose-6phosphateaminotransferase
[isomerizing] 1
Glutamine synthetase

Q91Y97
O08573
O08573

ALNDHHVYLEGTLLKPNMVTAGHAC240/239TK
FEEGGYVVC73NTK
GMPFELC101FLVQR

1qo5 (96%) 2-349
2d6n
2d6n

Q9Z2Z9

C2/1GIFAYLNYHVPR

2bpl (37%)2-682

Q9Z2Z9
P15105

ETDC461/459GVHINAGPEIGVASTK
KPAETNLRHIC117K

2zj3 (83%) 316-682
2qc8 (94%) 10-365

Glutathione reductase, mitochondrial
precursor

P47791

GVYAVGDVC355/333GK

3dk9 (88%)41-500

Glycerol-3-phosphate dehydrogenase
[NAD+], cytoplasmic

P13707

IC102DQLKGHLK

1x0v (93%) 1-349

Guanine nucleotide-binding protein
subunit beta-2-like 1

P68040

TNHIGHTGYLNTVTVSPDGSLC207ASGGK

2zkq (99%)4-311

H-2 class II histocompatibility
antigen, A beta chain precursor
Heat shock protein HSP 90-beta
Heterogeneous nuclear

P14483
P11499
Q9D0E1

TRAELDTVC106/105RHNYEGPETHTSLR
C412LELFSELAEDKENYKK
DKFNEC675GHVLYADIK

1lnu
3pry (95%)284-546
2dgv (100%)651-729
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DNA-directed RNA polymerase II
subunit RPB9
Electron transfer flavoproteinubiquinone oxidoreductase,
mitochondrial

ribonucleoprotein M
Heterogeneous nuclear
ribonucleoproteins C1/C2
Histidine triad nucleotide-binding
protein 1

IVGC46SVHKGFAFVQYVNER

1wf2 (94%)2-92

P70349

IIFEDDRC38LAFHDISPQAPTHFLVIPK

1kpe (94%)14-126

Histone-binding protein RBBP7

Q60973

TPSSDVLVFDYTKHPAKPDPSGEC166NPDLR

3cfv (95%)1-410

Hydroxymethylglutaryl-CoA lyase,
mitochondrial

P38060

TSSKVAQATC323KL

2cw6 (87%) 28-323

DLNHVC206/205VISETGK
VLRC142/141DVTK
GVVC425DKREPDGIR
C83/55LGLDITK

1bzy (97%)5-218
2a14 (57%) 6-262
2hzp (83%) 6-460
1dqg (20%)32-155

P34884
P14152

LLC81/80GLLSDRLHISPDR
SAPSIPKENFSC154/153LTR

2gdg
5mdh (94%)2-334

Malate dehydrogenase, mitochondrial
precursor
Myosin light polypeptide 6
NADPH--cytochrome P450 reductase

P08249
Q60605
P37040

EGVVEC275/251SFVQSK
ILYSQC32/31GDVMR
VHPNSVHIC472AVAVEYEAK

1mld (95%)25-337
1br1 (89%)4-151
1ja1 (98%)63-678

Non-POU domain-containing
octamer-binding protein
PDZ and LIM domain protein 1

Q99K48
O70400

FAC147HSASLTVR
GHFFVEDQIYC305/65EKHAR

2cpj (68-153)
1x62 (91%)249-316

P17742

HTGPGILSMANAGPNTNGSQFFIC115TAK

3k0m (96%)2-164

Q9WV68

HGC53/54HTVIVGR

1g0o (23%)1-273

Q9R0H0

NLC559LLYSLYGISQK

1is2 (89%) 1-655

Q9R0H0

ASEAHC531HYVTVK

1is2 (89%) 1-655

Hypoxanthine-guanine
phosphoribosyltransferase
Indolethylamine N-methyltransferase
Kynureninase
Lymphocyte antigen 75 precursor
Macrophage migration inhibitory
factor
Malate dehydrogenase, cytoplasmic

Peptidyl-prolyl cis-trans isomerase A
Peroxisomal 2,4-dienoyl-CoA
reductase
Peroxisomal acyl-coenzyme A oxidase
1
Peroxisomal acyl-coenzyme A oxidase
1

P00493
P40936
Q9CXF0
Q60767
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Q9Z204

Phenylalanine-4-hydroxylase
Profilin-1
Proliferating cell nuclear antigen
Proliferation-associated protein 2G4

P16331
P62962
P17918
P50580

VFHC265TQYIR
C71/70SVIRDSLLQDGEFTMDLR
C62DRNLAMGVNLTSMSK
KADVIKAAHLC149AEAALR

1phz (96%)19-427
1pne (96%)2-140
1vyj (97%)1-257
2v6c

Proteasome subunit beta type-10

O35955

ATNDSVVADKSC70/31EKIHFIAPK

1iru(57%)40-259, chain I

Protein DJ-1
Pyruvate dehydrogenase E1
component subunit alpha, somatic
form, mitochondrial
Pyruvate dehydrogenase E1
component subunit beta,
mitochondrial
Quinone oxidoreductase
Ras-related protein Rab-14
Regucalcin
RNA-binding protein Raly

Q99LX0

VTVAGLAGKDPVQC46SR

1q2u(91%)1-189

P35486

EATKFAAAYC273/244R

1ni4(98%)29-390

Sarcoplasmic/endoplasmic reticulum
calcium ATPase 2
Sepiapterin reductase
Serine hydroxymethyltransferase,
cytosolic
Serine protease inhibitor A3K
Serine/threonine-protein phosphatase
2A 56 kDa regulatory subunit gamma
isoform
S-formylglutathione hydrolase
Succinate dehydrogenase
[ubiquinone] flavoprotein subunit,
mitochondrial precursor

VHAC45GVNPVETYIR
FMADC40PHTIGVEFGTR
VEC8VLRENYR
VAGC51/58SVHKGYAFVQYANER

2ozl(94%)30-359
1yb5 (80%) 6-331
1z0f (100%)7-173
3g4e (88%) 3-299
1wf1 (94%)3-97

O55143
Q64105

SMSVYC498TPNKPSR
LKSDGALVDC235GTSAQK

3ar4 (84%)1-992
1oaa

P50431
P07759

LIIAGTSC198/204YSR
HFRDEELSC259/258SVLELK

1eji
1yxa (73%)48-418

Q60996

C334/324VSSPHFQVAER

3fga (99%)34-436

Q9R0P3

C11FGGLQK

3fcx(90%)3-281

Q8K2B3

GC357/315GPEKDHVYLQLHHLPPEQLATR

1zoy (96%)52-664

IIC60/20QGFTGK
DVIIKVDQIC150/146HR

1euc (93%) 42-346
3kyd (87%)29-349

Q9WUM5
Q9R1T2
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Succinyl-CoA ligase [GDP-forming]
subunit alpha, mitochondrial
SUMO-activating enzyme subunit 1

Q9D051
P47199
Q91V41
Q64374
Q64012

IERQGTHITVVAHSRPVGHC249/219LEAAAVLS
K

Superoxide dismutase [Cu-Zn]
Transcription elongation factor SPT5

P08228
O55201

Transitional endoplasmic reticulum
ATPase
Transketolase

AVC7VLKGDGPVQGTIHFEQK
VELHSTC734/740QTISVDR

3gtt
2e70 (96%) 696-751

Q01853
P40142

LADDVDLEQVANETHGHVGADLAALC415SEAAL
QAIR
TVPFC386STFAAFFTR

/1e32
3mos (95%) 4-618

Q99JY0
P99024

KDGGQYALVAAC459/386AAGGQGHAMIVEAYPK
REIVHIQAGQC12GNQIGAK

1ulq (32%)53-473
1tvk (97%)2-427

Q02053
O70475

C588/556VYYRKPLLESGTLGTK
AADLKYIEAC112ARR

3cmm(51%)48-1057
3khu (97%) 1-466

Voltage-dependent anion-selective
channel protein 1

Q60932

EHINLGC140/127DVDFDIAGPSIR

3emn

Voltage-dependent anion-selective
channel protein 1

Q60932

YQVDPDAC245/232FSAK

3emn

Trifunctional enzyme subunit beta,
mitochondrial precursor
Tubulin beta-5 chain
Ubiquitin-like modifier-activating
enzyme 1
UDP-glucose 6-dehydrogenase
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4.1

Abstract
Understanding the structural consequences of S-nitrosylation has proved to be

difficult due to a lack of structures for SNO-proteins. A recent study has revealed that Snitrosylation may regulate the function of very long chain acyl-coA dehydrogenase
(VLCAD), a mitochondrial enzyme that catalyzes the first rate-limiting step in the βoxidation of fatty acids. Upon S-nitrosylation, the Km of the enzyme decreases by 5-fold,
suggesting that the protein can bind the substrate more efficiently. Normal mode analysis
was used to investigate this hypothesis and identify protein movements which might be
correlated to enhanced substrate binding upon S-nitrosylation. S-nitrosylation did not
induce global conformational changes in the protein. However, smaller motions were
observed across four different regions in the binding site, with the most apparent
movement near the VLCAD S-nitrosocysteine, Cys238. This work further supports the
hypothesis that S-nitrosylation may induce protein conformational changes that influence
activity.

4.2

Introduction
A global proteomic investigation into the endogenous S-nitrosoproteome of

mouse liver identified 328 sites belonging to 192 proteins (Doulias, et al. 2010). Protein
network mapping revealed that sixteen of the S-nitrosylated proteins were clustered
around the hormone leptin (Figure 4.1). Leptin is a hormone secreted by adipose tissue
which acts on the central nervous system to maintain energy homeostasis. Leptin has also
been shown to play a role in liver metabolism through its repression of stearoyl-CoA
desaturase-1 which is the rate limiting step in monosaturated fat biosynthesis (Cohen et
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al., 2004). Mice lacking leptin (ob/ob) can be nearly triple the size of their wildtype
littermates with increased adipocyte size and number (Halaas et al., 1995; Pelleymounter

Figure 4.1: Ingenuity pathway analysis (IPA) identifies indirect relationship
between leptin and Very long chain acyl-CoA dehydrogenase (A) Protein network
mapping reveals significant clustering of 16 S-nitrosylated liver proteins around the
hormone leptin. Very long chain acyl-CoA dehydrogenase (gene name: ACADVL, red
circle) was revealed as indirect target (dashed line) of leptin. (B) Very long chain acylCoA dehydrogenase (VLCAD) catalyzes the first step in the β-oxidation of fatty acids. It
oxidizes the substrate palmitoyl-CoA, forming a double bond between α and β carbons to
form trans-Δ2-Enoyl-CoA.

et al.,1995; Jackson Laboratories).
A study conducted in 2008 (Oliveira, et al. 2008) investigated the role of nitric
oxide in nonalcoholic fatty liver, a disease that is characterized by an accumulation of fat
deposits in the liver which can then result in impairment of its function. Administration
of the S-nitrosothiol S-nitroso-N-acetylcysteine (SNAC) to ob/ob mice by gavage
inhibited and reversed the phenotype. Interestingly, mice lacking endothelial nitric oxide
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synthase also exhibited accumulation of lipids, further substantiating a role for nitric
oxide in lipid metabolism (Schild et al. 2008).
Very long-chain specific acyl-CoA dehydrogenase (VLCAD), a mitochondrial
enzyme, is one of the sixteen proteins identified as having an indirect link to leptin.
VLCAD catalyzes the rate limiting first step in the β-oxidation of fatty acids in the liver
(Figure 4.1). With a catalytic glutamate as its proton acceptor, VLCAD oxidizes the
substrate palmitoyl-CoA, producing a double bond between its α and β carbons to form
trans-Δ2-Enoyl-CoA. Its recent identification has led to the hypothesis that S-nitrosylation
of VLCAD may function as a molecular link between nitric oxide and liver metabolism.
Therefore, when nitric oxide is unable to S-nitrosylate VLCAD, its function is impaired
leading to the accumulation of fatty acids. Recent work within the lab has confirmed that
Cys238 is S-nitrosated in ob/ob mice after GSNO treatment (Figure 4.2). Upon Snitrosylation, the kinetics of VLCAD are altered such that its Km is decreased by nearly
5-fold (Figure 4.2), suggesting an increased binding efficiency of its substrate palmitoylCoA. However, the molecular mechanism by which S-nitrosylation might alter substrate
binding is largely unknown.
VLCAD consists of a 67 kiloDalton homodimer and is a member of the acyl-CoA
deydrogenase (ACAD) family (McAndrew et al. 2008). Its substrate specificity is derived
from a salt bridge formed between two helices which extends its binding cavity as
compared to other ACADS. It also has an additional 180 residues on its carboxylterminal end shown to be essential in mitochondrial membrane binding (Souri et al.
1998b). Several studies have attempted to correlate VLCAD modifications with its
activity. Mutation of a phosphorylation site resulted in reduced electron transfer activity
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of the enzyme (Kabuyama et al. 2010). Souri et al. demonstrated abnormal Km values for
palmitoyl-CoA after mutation of an alanine to a proline near the carboxyl-terminus (Souri
et al. 1998a). A more comprehensive study investigated the effect of missense mutations
on substrate binding, enzyme-cofactor interaction, dimerization, & folding of the
polypeptide chain (Gobin-Limballe et al. 2010). A glycine-to-alanine mutation

Figure 4.2: Cysteine238 confirmed as S-nitrosation site after GSNO treatment. (A)
Cys238 identified as site of S-nitrosylation in VLCAD peptide sequence:
SSAVPSPC238GKYYTLNGSK. (B) Kinetics of VLCAD altered after GSNO treatment.
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disrupted a hydrophobic pocket lining the substrate binding cavity whereas a R453Q
mutation induced changes in the positioning of its catalytic glutamate.
Herein, we describe attempts to elucidate the structural consequences of Snitrosylation for the enzyme VLCAD. We first began with an interrogation into the
structures of existing S-nitrosylated cysteines to acquire favorable rotamer conformations
for S-nitrosocysteine. Using normal mode analysis, we investigated the influence that
introducing a nitric oxide moiety might have on protein structure in an attempt to explain
our kinetic data.

4.3

Methods

Sequence conservation. Basic local alignment search tool (BLAST) was used to align
the sequences of human (Uniprot Accession Number: P49748) and mouse VLCAD
(Uniprot Accession Number: P50544).
Calculating bond angles and lengths. Bond angles and lengths of existing Snitrosylated proteins were calculated by editing Perl scripts made available by the
Dunbrack laboratory.
Generation of S-nitrosylated cysteine. S-nitrosocysteine was generated using the “Snitrosator”` Python script from Timerghazin laboratory in the Molecular Modeling
Toolkit. “S-nitrosator” utilizes the coordinates of thioredoxin and χ3 values calculated
using from PCM-ONIOM(PBE0/def2-TZVPPD:AmberFF) calculation of an Snitrosocysteine residue in an alpha–helix content.
Normal mode analysis using elNemo. ElNemo (Suhre et al. 2004) was used to observe
the 100 lowest frequency modes and perturbed models were generated for the first five
non-trivial modes of VLCAD. Residue mean square displacement (r2) (as calculated by
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elNemo) was used to identify protein movement. The substrate binding site was separated
into four regions for the purpose of analysis. Region 1: 160Tyr, 163Leu, 164Val, 167Val,
174Val, 176Ile, 178Leu, 179Gly, 180Ala, 182Gln, 183Ser, and 184Ile; Region2: 214Phe,
216Leu, 217Thr, 222Gly, 223Ser, 224Asp, and 225Ala; Region3: 334Met, 337Leu,
340Gly, 341Arg, 343Gly, 344Met, and 347Ala; Region4: 458Phe, 460Ile, 461Phe,
462Glu, 463Gly, and 464Thr.

4.4

Results and Discussion

Use of existing S-nitrosylated protein structures for prediction of Cys238 side chain
conformation
There is currently no published structure of mouse very long chain acyl-CoA
dehydrogenase; however, the PDB contains two structures of human VLCAD. The first
structure (PDB ID: 2UXW) was released in 2007. It is at 1.45 Å resolution, crystallized
with trans-Δ2-Palmitenoyl-CoA and contains residues 72-655. The second structure is at
1.91 Å resolution and contains amino acids 69-655 (PDB ID: 3B96); however, 3B96 is
instead crystallized with myristoyl-CoA, a fatty acid of shorter chain length. The
structure of 2UXW was selected for the purposes of this study (Figure 4.3).
Basic Local Alignment Search Tool (BLAST) was used to identify sequence
homology between mouse and human VLCAD. The sequence alignment of mouse
VLCAD (mVLCAD) and human VLCAD (hVLCAD) showed that the two share more
than 80% sequence homology. More importantly, there was conservation of the Snitrosylated cysteine residue (Cys238 in mouse; Cys237 in human) as well as high
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conservation near the substrate binding site. In addition to being conserved between mice
and humans, Cys238 is conserved across other mammalian species including rat, bovine,
canine, and pig.
To investigate the influence of S-nitrosocysteine on VLCAD dynamics, it was
first necessary to generate an S-nitrosylated form of the protein. The program SCWRL
(Bower et al. 1997) can be used to predict the position of the cysteine side chain using a
χ1-dependent rotamer library; however, because S-nitrosylation is still an emerging
posttranslational modification, the library must be appended to incorporate the Snitrosocysteine residue. The rotamer library is composed of a curated set of residues from
high resolution structures in the PDB with low B-factors (Wang et al. 2008). A search of
the PDB for the ligand S-nitrosocysteine (SNC) resulted in a total of 9 structures of
which 6 were nonredundant: hemoglobin (1BUW), hypoxia inducible factor prolyl
hydroxylase domain 2 (2Y33 and 2Y34), protein tyrosine phosphatase 1B (3EU0),
blackfin tuna myoglobin (2NRM), thioredoxin (2HXK, 2IFQ, and 2IIY) and
dimethylarginine dimethylaminohydrolase (2CI1).
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Figure 4.3: VLCAD structure 2uxw. Cysteine 238 is shown in sphere representation
with coloring based upon elemental composition. Trans-Δ2-Palmitenoyl-CoA is shown in
purple in stick representation. Electron acceptor FAD is shown in blue in sticks
representation. Catalytic glutamate shown in red in sphere representation.

In total, bond lengths and angles were calculated for twelve S-nitrocysteine
residues across 9 different structures. The χ3 (chi3) value measures the bond angle
between CB-SG-ND-OE; therefore, it is a detailed descriptor of the S-nitrosocysteine
rotamer conformation. The chi3 data exhibited some variance but values for all
thioredoxin S-nitrosocysteines remained fairly close to 0 (Table 4.1). Measured bond
lengths of r(N-CA), r(CA-C), r(CA-CB), and r(CB-SG) remained fairly consistent across
all S-nitrosocysteine residues (Table 4.2) with Cα carbon bond lengths being the most
tightly distributed. Bond lengths between SG-ND and ND-OE were the most dispersed.
r(SG-ND) ranged in length from 1.63 to 1.806 Å and r(ND-OE) ranged in length from
1.193 to 1.472 Å (Table 4.2). When comparing structures of hypoxia inducible factor
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prolyl hydroxylase which forms S-nitrosocysteine by two different chemical reactions
(GSNO soaked versus NO exposed), there is a striking difference in bond lengths for
(ND-OE). The GSNO soaked structure (which would form S-nitrosocysteine through a
transnitrosation reaction with a nitrosonium ion) had a measured length of 1.193 Å
compared to the same protein treated with an •NO donor, which had a bond length of 1.46
Å. These data suggest that chemical species other than –Cys-S-N=O may exist. In fact,
QM/MM studies conducted in the English Laboratory at Concordia University show that
geometries for S-nitrosocysteine residues in published crystal structures are oftentimes
more consistent with –C-S-NH-OH (personal communication).
With a total of six independent data points, these data were not incorporated into
the rotamer library for side chain prediction. Additionally, the diversity of data calculated
suggests that all residues classified as an S-nitrosocysteine may not be the same chemical
species as an S-nitrosocysteine residue. Interestingly, that is what Chen and coworkers
proposed when they published the structures of hypoxia inducible factor prolyl
hydroxylase (Chen et al. 2008). They suggest that they were instead observing a reaction
intermediate between nitric oxide and the cysteine residue. This again underscores that 1)
the field of S-nitrosylation is in dire need of three dimensional structures of protein Snitrosocysteine, and 2) exogenous sources of nitric oxide can result in different reaction
products. Additionally, it is unfortunate that the Protein Data Bank still classifies 2Y33
and 2Y34 as containing S-nitrosocysteine residues when the authors themselves doubt its
existence (Chen et al. 2008).
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Table 4.1: Calculated bond angles of existing S-nitrosylated cysteines
PDBid

ResNum Chain

phi

psi

omega

chi1

chi2

chi3

2IFQ

69

A

-88.69

3.06

178.45

-68.42

-71.19

1.22

2IFQ

69

C

-84.94

2.70

178.52

-66.26

-84.91

151.85

1BUW

93

B

-79.99

-60.79

-176.99

-54.71

-99.84

87.55

1BUW

93

D

-81.96

-70.29

-179.79

-54.16

-79.77

-75.65

2CI1

83

A

-139.30

111.23

177.56

175.12

79.42

-69.50

2HXK

62

B

-121.26

66.48

-174.47

-92.66

-156.02

-0.56

2HXK

69

B

-96.58

7.66

178.68

-63.56

-81.45

2.49

2IIY

62

A

-125.61

56.22

-161.63

-65.03

-81.52

1.30

2IIY

69

A

-82.42

-2.56

-173.57

-64.35

-71.75

0.71

2Y33

302

A

-135.82

113.66

-178.52

-168.91

-83.34

-76.06

2Y34

302

A

-128.28

117.37

176.77

178.34

-76.24

-93.49

3EU0
2IFQ:
1BUW:
2CI1:
2HXK:
2IIY:
2Y33:
2Y34:
3EU0:

215
A
-138.14
-132.92
179.22
175.05
-56.03
S-nitroso thioredoxin (only Cys69 modified)
S-nitroso hemoglobin
Dimethylarginine dimethylaminohydrolase in complex with S-nitroso-L-homocysteine
S-nitroso thioredoxin (both 62 and 69 modified)
S-nitroso thioredoxin (both 62 and69 modified)
S-nitrosylated hypoxia inducible factor prolyl hydroxylase domain 2 (GSNO soaked)
S-nitrosylated hypoxia inducible factor prolyl hydroxylase domain 2 (NO exposed)
S-nitrosylated protein tyrosine phosphatase 1B

41.08
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Table 4.2: Calculated bond lengths of existing S-nitrosylated cysteines
PDBid

ResNum Chain

r(N-CA) r(CA-C) r(CA-CB) r(CB-SG) r(SG-ND)

r(ND-OE)

2IFQ

69

A

1.458

1.533

1.532

1.764

1.783

1.196

2IFQ

69

C

1.469

1.506

1.532

1.795

1.797

1.188

1BUW

93

B

1.466

1.514

1.566

1.839

1.757

1.202

1BUW

93

D

1.478

1.522

1.557

1.855

1.762

1.209

2CI1

83

A

1.455

1.526

1.519

1.787

1.646

1.472

2HXK

62

B

1.485

1.523

1.567

1.787

1.806

1.205

2HXK

69

B

1.479

1.525

1.535

1.779

1.804

1.199

2IIY

62

A

1.437

1.509

1.535

1.768

1.759

1.193

2IIY

69

A

1.483

1.538

1.519

1.785

1.803

1.207

2Y33

302

A

1.432

1.512

1.522

1.778

1.788

1.193

2Y34

302

A

1.47

1.53

1.53

1.83

1.63

1.46

3EU0

215

A

1.454

1.524

1.53

1.8

1.665

1.308

Normal mode analysis reveals movement near S-nitrosylated cysteine
QM/MM calculations were used to generate an S-nitrosocysteine residue within
the protein structure of VLCAD (2UXW). VLCAD was modified at Cysteine238 to form
SNO-Cysteine (SNC) using the Python script “S-nitrosator” developed by the
Timerghazin Laboratory. Using the program elNemo: The Elastic Network Model, low
frequency vibrational modes of the protein were calculated (Suhre and Sanejouand, et al.
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2004). The lowest frequency normal modes (modes 7-10) were initially examined to
determine if S-nitrosylation induced large

Mode 8

r2

r2

Mode 7

Mode 10

r2

r2

Mode 9

Figure 4.4: S-nitrosylation does not induce large scale motions in VLCAD. Residue
mean square displacement values were examined for lower frequency normal modes
before and after S-nitrosylation.

conformational changes. Large global or collective motions of a protein are described
using low-frequency modes. Examination of Modes 7, 8, 9, and 10 revealed no global
motions which may have been induced by S-nitrosylation of Cys238. In these modes,
residue mean square displacement (r2) remained consistent between wildtype and SNOVLCAD (Figure 4.4).
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The binding site of palmitoyl-CoA was next examined to determine if Snitrosylation induced any quantifiable structural changes. Although Uniprot identifies the
substrate binding pocket as 338-341 and 462-463, viewing the three dimensional
structure of VLCAD in PyMol

Figure 4.5: Binding site of trans-Δ2-Palmitenoyl-CoA in VLCAD. Binding site is
composed of 35 residues divided into 4 different regions: Region 1 (in black), Region 2
(orange); Region 3 (blue); Region 4 (red). Image generated in PyMol Viewer.

revealed that the substrate is in close proximity of 35 residues when bound (Figure 4.5).
To better characterize the entire substrate binding site, it was grouped into 4 different
regions based upon its neighboring residues (Figure 4.5). Residues comprising each
region are previously described in Materials and Methods section. Region 4 (in red)
included the catalytic glutamate residue 462.
The higher frequency modes 45 through 50 were examined to investigate smaller
local motions which might occur near the binding site. Examination of Modes 49 & 50 in
particular revealed the greatest difference in the movement of atoms in response to S-
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nitrosylation. Region 4 consists of 214Phe, 216Leu, 217Thr, 222Gly, 223Ser, 224Asp,
and 225Ala. Upon S-nitrosylation, these residues within the binding site do not show
much movement (Figure 4.6); however, examination of residues surrounding Cys238
shows a large difference in residue displacement (r2) upon S-nitrosylation. The region
displaying the most movement (Residues 232-240) is composed of the cysteinecontaining loop as well as an adjacent beta sheet. Preservation of the shape upon Snitrosylation also suggests a correlated movement of these flanking amino acids. Region
4 also appears to display movement; however, these motions are an artifact since these
residues are involved in membrane anchoring in the mitochondria and are not contained
within the structure.
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Figure 4.6: Higher frequency mode indicates extensive movement of Cys238 upon Snitrosylation. Mode 49 is examined across the four different regions of the binding site
with Region 1. Mode 49 is also representative of Mode 50.

Collectively, these data suggest that the loop region containing Cys238 may be
involved in enhancing the enzymatic activity of very long chain acyl-CoA
dehydrogenase. Interestingly, Cys238 is measured to be ≥ 30 Angstroms from the
substrate binding site, suggesting that longer range motions can influence the ability of
the enzyme to bind substrate. After S-nitrosylation inhibited the activity of the protein
methionine adenosyltransferase, Perez-Mato et al. concluded that S-nitrosylation of
cysteine in a flexible loop changed its conformation and did not allow access of the
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substrate to its binding site (Perez-Mato et al. 1999). In the case of VLCAD, Snitrosylation instead appears to make the loop even more flexible (Figure 4.6). This is a
particularly intriguing finding since the ligand that VLCAD is crystallized with is the
product and not the substrate. Trans-Δ2-Palmitenoyl-CoA is the product that is formed
upon oxidation of palmitoyl-coA. This suggests that S-nitrosylation may play a role in
helping to release the product once it is formed. However, additional experiments,
possibly molecular dynamics simulations, are necessary to fully elucidate these local
protein motions.
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CHAPTER FIVE: SUMMARY AND GENERAL DISCUSSION

5.1

Summary
S-nitrosylation is an emerging posttranslational modification (PTM) by which

nitric oxide can exert its biological function. However, gaps in knowledge regarding its
mechanism of formation, the specificity of its targets, and the molecular mechanism by
which S-nitrosylation can alter protein function remain resolved. This thesis aimed to
address each one of these questions with the use of a global proteomic method for the
identification of endogenous protein S-nitrosocysteine residues.

5.2 Proteomic techniques are essential for characterization of the
endogenous S-nitrosoproteome
While there are still large gaps in knowledge regarding S-nitrosylation, many
cysteines have been and continue to be identified as being S-nitrosylated in vivo. Initial
investigations into the identification of S-nitrosocysteine protein residues began with
techniques which did not allow for a priori hypotheses regarding the identity of the
protein. Sample preparations mandated that the protein either be in isolation or that an
antibody must be available to validate its identification.

The application of tandem mass spectrometry allowed for proteins to be identified
in complex solutions when coupled to chromatographic separation techniques. The
advent of this technology helped to test hypotheses on a much larger scale. For Snitrosylation, many answers to the gaps in knowledge lie in the identification of its
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targets. While LC-MS/MS is a powerful tool, it is useless without a method upstream that
is sensitive enough to enrich for endogenous protein S-nitrosocysteine. To that end we
developed a complementary mercury-based mass spectrometric approach for the
identification of endogenous S-nitrosoproteomes. Without the development of this global
unbiased enrichment technique, the data would not have as effortlessly revealed a
population of cysteines which has yet to be described.

While cysteine residues are not one of the most frequently occurring amino acids,
they are highly conserved, suggesting an important role in biochemical processes.
Cysteines are known to be highly reactive; therefore it was a surprising finding that
identification of S-nitrosylated cysteines resulted in the characterization of an entirely
unique population of cysteine residues. Cysteines identified using our global proteomic
approach were not predicted or experimentally shown to be redox active, engaged in
disulfide bonds, coordinated to metals, glutathionylated, or alkylated. The identification
of this unique population of cysteine residues underscores their biological importance.

Although our proteomic tool does provide a robust proteomic tool for
interrogating an endogenous S-nitrosoproteome, it does have some limitations. By
applying our stringent criteria (i.e. 2 unique protein peptides as well as 1 cysteic acid
containing peptide), the sites of identification may not always be consistent with those
previously found to be S-nitrosylated by others. In addition, because S-nitrosylation is an
emerging signaling mechanism that has been shown to be regulated, the dynamic nature
of SNO may not always allow for the capture of the protein in its S-nitrosylated state.
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Identification of the wildtype liver SNO-proteome resulted in nearly 50% complementary
between both the MRC and mPEG-biotin approach with 25% being unique to either
method. Consequently, when only a single method is used as with the GSNOR-/proteome, a fraction of the proteome may be unaccounted for. To be consistent, the same
approach should be employed when making comparisons between different proteomes.

5.3 Transnitrosation by GSNO is a precisely controlled and targeted
mechanism
After identifying that multiple mechanisms of S-nitrosocysteine formation could
be taking place in vivo in Chapter 2, Chapter 3 sought to delve further into the
mechanism by which GSNO can modify protein cysteine residues. Using a knockout of
the enzyme responsible for in vivo metabolism of GSNO, we were able to identify a
subset of cysteine residues which may form S-nitrosocysteine using this GSNO-mediated
mechanism of transnitrosation. When biochemically/biophysically characterizing the
cysteine residues, there were two novel findings within the GSNOR-/- unique SNOproteome. The first was that cysteine residues were surrounded by charged residues. Only
2 out of 111 cysteines with structures did not have a single charged residue within 6
Angstroms. This is not a completely surprising finding, since the presence of charged
residues near cysteines in the wildtype liver proteome supported our hypothesis regarding
a GSNO-mediated mechanism. However, there does seem to be enrichment for charged
residues within this population since all but 2% fall into this category.
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The second finding is regarding the presence of cysteines in their surrounding
secondary structure. The data revealed that these GSNOR-/- unique cysteines were more
frequently in coils than cysteine within the previously published wildtype proteome
(Doulias et al.). Our initial hypothesis was that S-nitrosylated cysteines lie in these more
flexible regions of the protein in order to accommodate whatever their mechanism of Snitrosocysteine formation might be. This suggests that cysteines targeted by GSNO may
need to exist in these flexible regions to accommodate the tripeptide. This claim is further
supported when examining the relative residue surface accessibility of the cysteines. With
the majority of cysteines classified as being buried, it only underscores that the protein
needs to be flexible to allow access to the residue.

Chapter 3 also presented a novel mechanism of GSNO mediated transnitrosation.
Previous data has posited the idea that the process of transnitrosation is an acid-base
catalysis. Using mutational analysis, Perez-Mato et al. (Perez-Mato et al. 1999)
demonstrate that an acidic residue is somehow involved in the formation of protein Snitrosocysteine. They propose that the acidic residue promotes the leaving of a
nitrosonium ion from GSNO by promoting GSH formation and that basic residues are
involved in increasing the nucleophilicity of the cysteine residue through its
deprotonation.
However, our data support the idea of a base catalysis mechanism of GSNOmediated transnitrosation. Using a model protein which was identified in the GSNOR-/unique dataset, the data show that coordination of a basic residue (Arg) to the sulfur atom
of the CYG intermediate can promote the formation of S-nitrosocysteine to the opposing
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cysteine residue. Therefore, coordination of a basic residue to the SG of GSNO would
result in formation of protein S-nitrosocysteine. In addition, coordination of this same
basic residue to other atoms such as N or O had the opposite effect and did not form
protein S-nitrosocysteine. These findings illustrate how the protein environment can
tightly regulate the reactivity of the transnitrosating agent (GSNO) and promote the
formation of specific reaction products. Initially these findings seem to conflict with what
was previously suggested for the push/pull or acid-base catalyzed mechanism of GSNO
transnitrosation; however, as the QM/MM calculations illustrate, the coordination of the
residue to a specific atom in the S-nitrosothiol is really what drives its reactivity.
Previous calculations conducted by the Timerghazin Laboratory have illustrated how
coordination of acidic residues to atoms other than S (O, N) can actually promote
nitrosonium formation as well.
Collectively, these findings imply that ex vivo supplementation with GSNO does
not faithfully replicate in vivo transnitrosation. Cellular processes are in place to readily
metabolize GSNO when it is in a cellular environment (i.e. GSNOR, reactivity with other
molecules). However, when samples such as cell lysates are treated with GSNO, it can
result in an uncontrolled and non-specific manner. While this is concentration-dependent,
data within our own lab has shown this to be the case (data not shown).
Another important fact to consider is the population of GSNOR-/- unique cysteines
that are identified by comparison between the GSNOR-/- and wildtype proteomes. Snitrosylated cysteines shared between both proteomes were removed to enrich for the
population of cysteines targeted by GSNO-mediated mechanisms of transnitrosation. By
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deriving this unique population of GSNOR-/- cysteines in this way, the data may be
skewed toward more extreme examples of GSNO-mediation. Because our previous
wildtype data suggested that multiple mechanisms may be occurring in vivo, it is likely
that stable GSNO-targeted cysteines would also exist within this population. However, by
subtracting out those cysteines which belong to both groups, this population is not
included in the bioinformatics analysis.

5.4

Implications of this work
Collectively, this body of work illustrates how a global tool can be used to

generate testable hypotheses leading to more targeted investigations regarding cellular
processes. This thesis begins which a global investigation into the identification of an Snitrosoproteome containing over 300 proteins and ends with an investigation into the Snitrosylation induced structural consequences of a single protein. Existing knowledge in
the field of S-nitrosylation can be broadly divided into 5 categories (in decreasing order
of knowledge): 1) identification of S-nitrosylated proteins, 2) alteration in protein
functionality, 3) dependency of target on a specific NOS isoform, 4) regulation of the
signal by denitrosylation, and 5) structural consequences. The data described herein have
contributed in some form to each one of these five categories.

The identification of many proteins as being S-nitrosylated has resulted in the
development of several predictive tools (Lee et al. 2011; Xue et al. 2010). For Snitrosylation, this still remains a challenge due to the fact that there are not specific
motifs which are required for S-nitrosylation. This is largely due to the fact that unlike
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other posttranslational modifications such as acetylation or phosphorylation, no specific
group of proteins has been identified as mediators in the process of S-nitrosylation.
Therefore, protein-protein interactions which have helped to derive motifs and predictive
tools for other PTMs, do not appear to be essential for all S-nitrosocysteine formation.
While several proteins have been shown to transfer nitrosonium ion to another protein,
there is no general category of ―S-nitrosyl‖-ases. Those tools which do exist often use
data which have been obtained using exogenous sources before. As was described
previously, exogenous forms of nitric oxide can result in a myriad of different chemical
species. Therefore, it does not accurately describe endogenous mechanisms of Snitrosocysteine formation.
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